clopidogrel has been researched along with Acute Coronary Syndrome in 1626 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 232 (14.27) | 29.6817 |
| 2010's | 1070 (65.81) | 24.3611 |
| 2020's | 324 (19.93) | 2.80 |
| Authors | Studies |
|---|---|
| Badorc, A; Barré, G; Besse, A; Boldron, C; Bonnet-Lignon, S; Bono, F; Bordes, MF; Briot, C; Delesque, N; Dol, F; Fossey, V; Gau, B; Hérault, JP; Herbert, JM; Lassalle, G; Meneyrol, J; Millet, L; Nazare, M; Pflieger, AM; Rousseaux, T; Savi, P; Tissandié, S; Yvon, X; Zech, G | 1 |
| Angiolillo, DJ; Baber, U; Beerkens, F; Cao, D; Capodanno, D; Chang, K; Chiarito, M; Dangas, G; Hermanides, RS; Kini, AS; Mehran, R; Nardin, M; Nicolas, J; Pivato, CA; Sartori, S; Sharma, SK; Tavenier, AH; Ten Berg, JM; Valgimigli, M; van 't Hof, AWJ | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Boersma, C; Claassens, DMF; Deneer, VHM; Dewilde, WJM; Hermanides, RS; Herrman, JR; Morisco, C; Mosterd, A; Postma, MJ; Ten Berg, JM; Tjon Joe Gin, RM; van 't Hof, AWJ; van der Harst, P; van Dorst, PWM; Vos, GJA | 1 |
| Adali, MK; Buber, I; Kilic, O; Turkoz, A; Yilmaz, S | 1 |
| Benit, E; Diletti, R; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; Mc Fadden, EP; Odutayo, A; Onuma, Y; Räber, L; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Aronow, HD; Barbour, M; Belviso, N; Don, PK; Kogut, S; Lawal, OD; Wen, X; Wyss, R; Zhan, SY; Zhang, Y | 1 |
| Gasecka, A; Jaguszewski, MJ; Malysz, M; Pruc, M; Rafique, Z; Szarpak, L | 1 |
| Abbas, KS; Abdelazeem, B; Adhikari, G; Baral, N; El-Shahat, NA; Hassan, M; Khan, H; Shehata, J | 1 |
| Jo, S; Jo, YS; Kim, SJ; Moon, H; Park, K | 1 |
| Makhdom, F; Menezes, RG; Motiani, V; Naeem, U; Nizam, MA; Ram, P; Rizwan, T; Shahid, I; Siddiqi, TJ; Usman, MS | 1 |
| Franchi, F; Galli, M | 1 |
| Li, Q; Ye, Y; Zeng, Y; Zhang, Y; Zhao, X | 1 |
| Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV | 1 |
| Han, Y; He, P; Huang, L; Jin, J; Li, J; Li, Y; Luo, X; Wang, X | 1 |
| Andersen, M; Linder, M | 1 |
| Luijkx, J; van 't Hof, A; Winkler, P | 1 |
| Alaamri, S; Dalbhi, SA | 1 |
| Chen, Y; Li, D; Li, L; Sun, Y; Wang, D; Ye, X | 1 |
| Go, YI; Kim, GW | 1 |
| Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A | 1 |
| Mehran, R; Spirito, A | 1 |
| Ferro, A; Passacquale, G; Perera, D; Sharma, P | 1 |
| Abu-Assi, E; Bruno, F; Cerrato, E; Chieffo, A; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; De Filippo, O; Dominguez-Rodriguez, A; Elia, E; Gallone, G; Henriques, JPS; Iannaccone, M; Kinnaird, T; Leonardi, S; Liebetrau, C; Manzano-Fernández, S; Omedè, P; Patti, G; Piroli, F; Raposeiras-Roubin, S; Wańha, W | 1 |
| Chen, S; Han, Y; Li, J; Li, X; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Ahmad, H; Bandyopadhyay, D; Chakraborty, S; Chaturvedi, A; Combs, WG; Gupta, R; Mahajan, P; Malik, AH; Mehta, SS; Patel, NC; Sreenivasan, J; Vyas, AV; Yandrapalli, S; Zaid, S | 1 |
| Dayoub, EJ; Eberly, LA; Eneanya, ND; Fanaroff, AC; Geng, Z; Giri, J; Groeneveld, PW; Khatana, SAM; Kobayashi, TJ; Kolansky, DM; Nathan, AS; Tuteja, S | 1 |
| Biswas, M; Ibrahim, B; Khatun Kali, MS; Sukasem, C | 1 |
| Andreev, D; Baturina, O; Bochkov, P; Fedina, L; Grishina, E; Ivashchenko, D; Mirzaev, K; Ryzhikova, K; Shevchenko, R; Sychev, D | 1 |
| Chen, S; Han, Y; Jiang, Z; Li, J; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Abu-Assi, E; Bianco, M; Bo, M; Breviario, S; Bruno, F; Conrotto, F; D'Ascenzo, F; De Ferrari, GM; de Filippo, O; Elia, E; Iannaccone, M; Manai, R; Patti, G; Raposeiras-Roubin, S; Wańha, W | 1 |
| Schäfer, A | 1 |
| Bai, N; Ma, Y; Niu, Y; Shang, YS; Wang, ZL; Zhong, PY | 2 |
| Cheng, LC; Chu, PH; Huang, CL; Kuo, FY; Lan, WR; Lee, CH; Lee, WL; Lin, WS; Liu, PY; Lo, PH; Lu, TM; Su, CH; Tsukiyama, S; Wang, YC; Yang, WC; Yin, WH | 1 |
| Angiolillo, DJ; Capodanno, D; Farkouh, M; Goodman, SG; Kim, SW; Lennon, RJ; O'Cochlain, F; Pereira, NL; Rihal, CS; So, DY; Sweeney, J | 1 |
| Bergh, N; Myredal, A; Nivedahl, P; Petzold, M; Wallerstedt, SM; Wartenberg, C; Zarin, S | 1 |
| Abbott, JD; Aronow, H; Bavishi, C; Heinl, RE; Hyder, ON; Kadiyala, V; Kah, MO; Kennedy, KF; Lang, WR; Long, S; Mitsuyama, R; Ovide, G; Sharma, E; Wark, T; Williams, MU | 1 |
| Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E | 1 |
| Bainey, KR; Marquis-Gravel, G; Mehta, SR; Robert-Halabi, M; Tanguay, JF | 1 |
| Abe, M; Ando, K; Domei, T; Furukawa, Y; Hibi, K; Ikari, Y; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Mori, H; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Natsuaki, M; Nishikura, T; Obayashi, Y; Ogita, M; Ohya, M; Sakamoto, H; Suwa, S; Suzuki, H; Tada, T; Tanabe, K; Tatsushima, S; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yamaji, K; Yamamoto, K | 1 |
| Fahed, AC; Jaffer, FA; Khera, AV; Maamari, DJ | 1 |
| Ip, A; Lau, KK; Ng, AK; Ng, PY; Siu, CW | 1 |
| Dong, Y; Graham, MM; Koshman, SL; Turgeon, RD | 1 |
| Angelini, F; Baldetti, L; Bocchino, PP; Chieffo, A; Conrotto, F; D'Ascenzo, F; de Ferrari, GM; DE Filippo, O; DE Lio, G; Melillo, F; Montefusco, A; Omedè, P; Piroli, F; Saglietto, A | 1 |
| Baroutidou, A; Daniilidou, A; Farmakis, IΤ; Giannakoulas, G; Graidis, S; Karvounis, H; Konstantas, O; Kourti, O; Psarakis, G; Psathas, T; Spyridaki, K; Touriki, AV; Tsolakidis, C; Vrana, E; Zafeiropoulos, S | 1 |
| Berghold, A; Lindenau, I; Mahla, E; Pregartner, G; Schoerghuber, M; Voetsch, A; Zirlik, A; Zweiker, R | 1 |
| Devine, B; Hendrix, N; Jiang, S; Malone, D; Mathias, PC; Shirts, BH; Tarczy-Hornoch, P; Veenstra, D | 1 |
| French, JK; Juergens, CP; Kadappu, K; Leung, DY; Lo, S; Mussap, CJ; Nguyen, P; Premawardhana, U; Rajaratnam, R; Xu, J | 2 |
| An, HJ; He, YY; Li, S; Sheng, XY; Ye, YF; Zhao, JL | 1 |
| Ding, H; Guo, L; Huang, R; Meng, S; Wang, J; Wu, S; Ye, Z | 1 |
| Doundoulakis, I; Farmakis, IT; Giannakoulas, G; Karagiannidis, E; Karvounis, H; Kassimis, G; Michalis, LK; Moysidis, DV; Pagiantza, A; Stalikas, N; Zafeiropoulos, S | 1 |
| Grisafi, L; Mennuni, M; Patti, G; Rognoni, A; Spinoni, EG | 1 |
| Jin, Y; Liu, H; Ma, J; Wang, G; Wang, Y; Wang, Z; Wu, Y; Ye, P; Yin, T; Zou, Y | 1 |
| Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH | 1 |
| Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y | 1 |
| Amos, D; Brieger, D; Chew, DP; Hou, M; Hyun, K; Kritharides, L | 1 |
| Fang, JY; Gong, W; Nie, SP; Wang, X; Yan, Y | 1 |
| Kamouchi, M; Kimura, K; Kitazono, T; Koyama, N; Matsumaru, Y; Matsuo, H; Nakamura, M; Tsutsumi, J; Umemura, K | 1 |
| Feng, J; Li, H; Shen, H; Sun, L; Wang, T; Wu, J; Xu, L; Yu, L; Zhang, H; Zhao, T; Zhou, L | 1 |
| Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X | 1 |
| Chanfreau-Coffinier, C; Dong, OM; Friede, KA; Voora, D | 1 |
| Ten Berg, JM; van den Broek, WWA | 2 |
| Abbott, JD; Farkouh, ME; Goodman, SG; Lennon, R; MacDougall, AM; Madan, M; McLaughlin, MA; Murthy, V; Pereira, NL; Rihal, C; Saw, J; So, DYF | 1 |
| Lin, J; Qin, Q; Xie, C; Zhu, J | 1 |
| Liu, J; Liu, X; Suo, M; Wang, Y; Wang, Z; Wu, X; Yang, N; Zhang, X; Zhao, D | 1 |
| Deneer, VHM; Gimbel, ME; Ten Berg, JM; van den Broek, WWA; van Paassen, JG; Vreman, RA | 1 |
| Peng, F; Xu, B; Xuan, M; Yan, L; Yu, Z; Zhou, Y | 1 |
| Barioli, A; Capodanno, D; D'Agosta, G; Demola, P; Masiero, G; Occhipinti, G; Pompei, G; Ruggiero, R | 1 |
| Bugnon, S | 1 |
| Adar, A; Akbay, E; Akıncı, S; Çoner, A; Müderrisoğlu, H | 2 |
| Caminiti, G; Muscoli, S; Perrone, MA; Pradhan, A; Salimei, C; Sethi, R; Tiwari, A | 1 |
| Antonicelli, R; Bongioanni, S; Bossi, I; Cacucci, M; Cavallini, C; Cesana, BM; Corrada, E; De Luca, G; De Luca, L; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Murena, E; Ottani, F; Petronio, AS; Piatti, L; Ravera, A; Savonitto, S; Sganzerla, P; Tondi, S; Tortorella, G; Toso, A; Verdoia, M; Vitrella, G | 1 |
| Yagita, Y | 1 |
| Abe, M; Akao, M; Ando, K; Domei, T; Furukawa, Y; Hata, Y; Ikari, Y; Inada, T; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Morimoto, T; Morino, Y; Morishima, I; Nakagawa, Y; Nakao, K; Natsuaki, M; Obayashi, Y; Okayama, H; Sakamoto, H; Suematsu, N; Suwa, S; Suzuki, H; Tamura, T; Tanabe, K; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yagi, M; Yamaji, K; Yamamoto, K; Yoshida, R | 1 |
| Abrahams, T; Brown, A; Pol, D | 1 |
| Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC | 1 |
| Conner, CM; Hashim, SW; Ingrassia, JJ; Loya, DS; Mather, JF; McKay, RG; McMahon, SR; Mosleh, W; Sutton, TS; Takata, ET; Yaffee, DW | 1 |
| Chen, B; Chen, J; Chen, Y; Chen, Z; Liang, J; Liu, X; Tang, L; Tu, S; Xia, J | 1 |
| Al-Sayaghi, KM; Albadrani, MS; Alotaibi, YA; Elhusein, AM; Fadlalmola, HA; Hussein, MK; Mamanao, DM; Masada, HK; Mohamedsalih, WE | 1 |
| Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B | 1 |
| Gao, R; Gao, Y; Guo, T; Li, J; Qiu, H; Qiu, Z; Wang, Y; Xi, Z; Zheng, J | 1 |
| Chen, L; Li, J; Shi, X; Su, J; Yang, J; Yu, Q; Zhu, K | 1 |
| Li, X; Lv, Q; Wang, Z; Xia, L; Xu, Q; Yao, Y; Ye, Y; Zou, Y | 1 |
| Beohar, N; Escolar, E; Gazzhal, A; Gjergjindreaj, M; Ibrahim, M; Lacy, SC; Perez, J; Saint Croix, G; Shehadeh, M; Torres, C; Vedantam, K | 1 |
| Ertürk, M; Gültekin Güner, E; Güner, A; Kahraman, S; Uzun, F | 1 |
| Alfredsson, J; Alpkvist, K; Sederholm Lawesson, S; Skibniewski, M; Träff, E; Venetsanos, D; Zwackman, S | 1 |
| DE Luca, G; Gioscia, R; Kedhi, E; Nardin, M; Rognoni, A; Suryapranata, H; Verdoia, M | 1 |
| Al Kindi, DI; Al-Mashdali, A; Alamin, MA; Elshaikh, EA; Othman, F | 1 |
| Batra, G; Becker, RC; Harrington, RA; Held, C; James, SK; Kempf, T; Lindbäck, J; Lopes, RD; Mahaffey, KW; Siegbahn, A; Steg, PG; Storey, RF; Swahn, E; Wallentin, L; Wollert, KC | 1 |
| Lin, J; Xie, C; Zhang, Y | 1 |
| Angiolillo, DJ; Galli, M; Ortega-Paz, L | 1 |
| Bae, JW; Han, JK; Hur, SH; Hwang, D; Kang, J; Kim, HS; Koo, BK; Lee, H; Lee, NH; Park, KW; Rha, SW; Shin, ES; Yang, HM | 1 |
| Ahn, Y; Chang, K; Choi, IJ; Choo, EH; Hwang, BH; Jeon, DS; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Lim, S; Moon, D; Park, MW; Seok Choi, Y; Yoo, KD | 1 |
| Chyrchel, B; Kruszelnicka, O; Surdacki, A | 1 |
| Farley, JF; Kumar, A; Lutsey, PL; Rajpurohit, A; Schommer, JC; St Peter, WL; Van't Hof, JR | 3 |
| Li, X; Lin, Y; Peng, W; Zhang, Y | 1 |
| Fonarow, GC; Ge, J; Han, Y; Hao, Y; Huo, Y; Liu, J; Ma, C; Morgan, L; Smith, JSC; Yang, N; Zhao, D | 1 |
| Banach, M; Biondi-Zoccai, G; Costabel, JP; De Rosa, S; Fischman, D; Galli, M; Gulati, M; Sabouret, P; Savage, MP; Spadafora, L; Ullah, W; Zeitouni, M | 1 |
| Cavallari, LH; Lee, CR; Thomas, CD; Williams, AK | 1 |
| Endo, S; Fujii, T; Ikari, Y; Kasai, S; Kawamura, Y; Nagamatsu, H; Tsuchiya, R; Yoshimachi, F | 1 |
| Dangas, G; Dasgupta, S; Feng, Y; Giustino, G; Hooda, A; Khera, S; Kini, AS; Koshy, AN; Krishnamoorthy-Melarcode, P; Kumar, KR; Mehran, R; Sartori, S; Serrao, GW; Sharma, R; Sharma, SK; Snyder, C; Sweeny, J | 1 |
| Aldica, M; Anchidin, OI; Blendea, D; Moldovan, H; Molnar, A; Nemes, A; Pop, D; Rosianu, SH | 1 |
| Baron, SJ; Dani, SS; Ganatra, S; Ijaz, SH; Kulbak, G; Levy, M; Resnic, F; Shahnawaz, A | 1 |
| Bae, JW; Bong, JM; Chun, KJ; Han, JK; Hwang, D; Kang, HJ; Kang, J; Kim, HS; Kim, SY; Koo, BK; Lee, BK; Lee, KS; Lee, NH; Lim, HS; Lim, YH; Park, K; Park, KH; Park, KW; Rha, SW; Rhew, JY; Shin, WY; Yang, HM | 1 |
| Gentry, CA; Kliewer, BS; Thind, SK; Whitman, CM; Williams, RJ | 1 |
| Landi, A | 1 |
| Ahn, Y; An, M; Cho, K; Hong, Y; Jeong, MH; Kim, J; Kim, Y | 1 |
| Atar, D; Gurvich, ML; Marciniak, TA; Serebruany, VL; Tanguay, JF | 1 |
| Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL | 1 |
| Kastrati, A; Ndrepepa, G | 1 |
| Aradi, D; Chang, K; Choo, EH; Chung, J; Claassens, DMF; Han, JK; Hwang, D; Kang, HJ; Kang, J; Kim, HS; Koo, BK; Massberg, S; Park, KW; Rizas, KD; Sibbing, D; Ten Berg, JM; van den Broek, W; Yang, HM | 1 |
| Arnous, S; Cusack, R; Kiernan, T; O'Connor, C; Soh, BWT; Waters, M | 1 |
| Cavallari, LH; Franchi, F | 1 |
| Baruś, P; Filipiak, KJ; Grabowski, M; Gumiężna, K; Klimczak-Tomaniak, D; Kochman, J; Kuca-Warnawin, E; Ochijewicz, D; Opolski, G; Pasierb, K; Sygitowicz, G; Tomaniak, M; Wiśniewska, A | 1 |
| Fujii, T | 1 |
| Baralis, G; Bianco, M; Cerrato, E; Cinconze, S; Giordana, F; Mottola, FF; Musumeci, G; Rossini, R; Verra, A | 1 |
| Bektasoglu, G; Dogan, Z; Yurtdas, M | 1 |
| Aradi, D; Gross, L; Hadamitzky, M; Hein-Rothweiler, R; Komócsi, A; Massberg, S; Merkely, B; Rizas, KD; Sibbing, D; Trenk, D | 1 |
| Jia, S; Wu, H | 1 |
| Iijima, R | 1 |
| Han, JK; Jun, EJ; Kang, J; Kim, B; Kim, HS; Koo, BK; Park, KW; Rhee, TM; Shin, ES; Won, KB; Yang, HM | 1 |
| Desai, NR; Dhruva, SS; Essa, M; Faridi, KF; Ross, JS; Yeh, RW | 1 |
| Bae, JH; Bailey, K; Baudhuin, LM; Bell, MR; Farkouh, ME; Fu, YP; Geller, N; Goodman, SG; Hasan, A; Ingraham, BS; Iturriaga, E; Jeong, MH; Lennon, RJ; Lerman, A; Mathew, V; Pereira, NL; Rihal, C; Rosenberg, Y; So, D; Tanguay, JF; Welsh, RC | 1 |
| Ahn, SG; Chang, K; Cho, JR; Choi, KH; Choi, SH; Gwon, HC; Hahn, JY; Her, AY; Hong, D; Jeong, MH; Jeong, YH; Joo, HJ; Kim, BK; Kim, HS; Kim, MH; Lee, JM; Lee, SH; Lee, SY; Lim, DS; Park, TK; Park, Y; Shin, ES; Song, YB; Suh, JW; Yang, JH | 1 |
| Angiolillo, DJ; Galli, M | 1 |
| Brown, JD; Cavallari, LH; Thomas, CD; Wang, Y; Winterstein, AG | 1 |
| He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L | 1 |
| Angiolillo, DJ; Bhatt, DL; Franchi, F; Giordano, S; Ortega-Paz, L; Pollack, CV; Rollini, F | 1 |
| De Caterina, R | 1 |
| Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L | 1 |
| Leon, SJ; Shah, AH; Tangri, N; Whitlock, R; Wiens, EJ | 1 |
| Mantri, N; McNulty, E; Mutyala, R; Sachdeva, A; Solomon, M; Zhu, S | 1 |
| Dávila-Fajardo, CL; Díaz-Villamarín, X; Fragoulakis, V; Karamperis, K; Koufaki, MI; Mitropoulou, C; Patrinos, GP; Swen, JJ; Vasileiou, KZ; Vozikis, A | 1 |
| Gao, A; Gao, R; Gao, Y; Lu, Q; Qiu, H; Wang, Y; Xi, Z | 1 |
| Briasoulis, A; Fujisaki, T; Kuno, T; Latib, A; Misumida, N; Takagi, H | 1 |
| Ghani, A; Haider, J; McKay, R; Nagle, C; Patail, H; Rizvi, A | 1 |
| Goto, H; Kitahara, H; Kobayashi, Y; Matsumoto, T; Saito, Y; Sano, K; Sato, T; Suzuki, S; Wakabayashi, S; Yamashita, D | 1 |
| Alex, AG; Attumalil, TV; Dave, RG; Geevar, T; George, P; Gowri, SM; Joseph, G; Mony, PK; Nair, SC; Perla, HT; Thomson, VS | 1 |
| Chung, J; Han, JK; Hwang, D; Kang, J; Kim, HS; Koo, BK; Lee, H; Park, KW; Shin, ES; Yang, HM | 1 |
| An, L; Hau, WK; Lei, M; Li, Y; Nie, S; Wang, J; Wang, X; Xue, Z; Yang, Y; Zhao, Z; Zhou, H | 1 |
| Han, Y; Li, J; Li, P; Li, Y; Liu, H; Na, K; Qi, Z; Qiu, M; Wang, B; Xu, K; Zhou, H | 1 |
| Aikawa, T; Briasoulis, A; Fujisaki, T; Kampaktsis, PN; Kuno, T; Malik, A; Saito, T; Slipczuk, L; Takagi, H; Wiley, J | 1 |
| Benedetto, U; Doble, B; Harris, J; Hopewell-Kelly, N; Johnson, T; Lasserson, D; Loke, Y; Mahadevan, K; Mumford, A; Pithara, C; Pouwels, KB; Pufulete, M; Redwood, S; Reeves, B; Rogers, C; Sterne, J; Wordsworth, S | 1 |
| Baber, U; Cao, D; Chiarito, M; Dangas, G; DeFranco, A; Effron, MB; Henry, TD; Kapadia, S; Keller, S; Kini, A; Mehran, R; Pocock, S; Rao, SV; Sartori, S; Sharma, S; Smith, KF; Spirito, A; Stefanini, G; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Zhang, Z | 1 |
| Comanici, M; Raja, SG | 1 |
| Al-Roub, NM; Almarzooq, ZI; Kinlay, S | 1 |
| Ge, P; Guo, Y; Li, Z; Xiao, J; Xie, L | 1 |
| Buranakiti, B; Chotayaporn, T; Phrommintikul, A; Ueapornpanith, P; Yoodee, V | 1 |
| Abaci, O; Barman, HA; Bulat, Z; Dogan, O; Kılıçarslan, O; Kocas, C; Mirzayev, K; Yildiz, A; Yumuk, MT | 1 |
| Bangalore, S; Bhatt, DL; Cuisset, T; Deharo, P; Fujisaki, T; Kohsaka, S; Kuno, T; Mehran, R; Shoji, S; Stone, GW; Takagi, H; Ueyama, H; Watanabe, A | 1 |
| Chen, HC; Chen, TY; Fang, CY; Fang, HY; Fang, YN; Hsieh, YY; Lee, WC; Tsai, YH; Wu, PJ | 1 |
| Chen, K; Cheng, H; Hao, J; He, S; Lin, Y; Mao, F; Tan, Q; Yang, J; Yang, M | 1 |
| Chen, W; Fu, K; Li, X; Qiu, X | 1 |
| Gao, ST; Ma, L; Wang, Y | 1 |
| Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ | 1 |
| Ahn, JM; Cha, SJ; Jang, MH; Kang, DY; Kim, AR; Kim, JH; Kim, S; Kim, T; Kim, TO; Lee, J; Lee, JH; Lee, PH; Lee, YJ; Oh, HJ; Park, DW; Park, SJ | 1 |
| Angiolillo, DJ; Ortega-Paz, L; Sabaté, M | 1 |
| Ahmad, FS; Anderson, RD; Benziger, CP; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kripalani, S; Marquis-Gravel, G; Muñoz, D; Polonsky, TS; Roe, MT; Rothman, RL; Stebbins, A; Whittle, J; Wruck, L | 1 |
| Alemneh, TA; Belay, KE; Birhan, YA; Efrem, P; Urge, SB | 1 |
| Liu, C; Ma, L | 1 |
| Cayla, G; Lattuca, B | 1 |
| Lüscher, TF | 1 |
| Budaj, A; Gurbel, PA; Ramotowski, B; Tantry, U | 1 |
| Cao, X; Li, JL; Liu, XJ; Xin, YG | 1 |
| Kafian, S; Mobarrez, F; Samad, BA; Wallén, H | 1 |
| Basu, A; Carlson, JJ; Guzauskas, GF; Veenstra, DL | 1 |
| Ge, JB; Qian, JY; Wang, QB; Wu, HY; Zhang, C; Zhao, X | 1 |
| Al-Lawati, J; Al-Mulla, A; Al-Zakwani, I; Almahmeed, W; Alsheikh-Ali, AA; Rashed, W; Zubaid, M | 1 |
| Li, J; Liu, T; Peng, H; Su, Q; Tang, Z; Xing, G; Yang, S | 1 |
| Açıkel, S; Aker, M; Algül, E; Çimen, T; Dural, M; Erat, M; Felekoğlu, MA; Guliyev, İ; Sunman, H; Tulmaç, M | 1 |
| Goto, S | 1 |
| Cho, YR; Kim, MH; Kim, YD; Park, JS; Park, K; Park, TH | 2 |
| Abdullaev, SP; Andreev, DA; Kitaeva, EJ; Mirzaev, KB; Mumladze, RB; Osipova, DV; Shprakh, VV; Sychev, DA | 1 |
| Bongiovanni, D; Cassese, S; Kastrati, A; Nowak, B; Schunkert, H; Stritzke, J; Tebbe, U; von Scheidt, M; Zhao, Q; Zhu, Y | 1 |
| Wang, P; Wang, XZ; Yao, Y; Zhang, L; Zhao, W; Zhao, X; Zhou, TN | 1 |
| Jiang, J; Li, C; Shen, X; Sun, Y; Tao, M; Wang, DW; Wang, Y; Yan, J; Ye, H; Yu, B; Yu, T; Zeng, H; Zhang, L | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Blanco, PF; Boccuzzi, G; Cequier, A; Correia, L; D'Amico, M; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Grossomarra, W; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Lopez-Cuenca, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Paz, RC; Peyracchia, M; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Saglietto, A; Taha, S; Usmiani, T; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Akita, K; Amano, T; Inohara, T; Ishii, H; Kadota, K; Kohsaka, S; Maekawa, Y; Nakamura, M; Numasawa, Y; Yamaji, K | 1 |
| Chen, X; Huangfu, N; Li, Z; Mei, L; Su, J; Xu, X; Zhang, L; Zheng, N | 1 |
| Gimbel, ME; Kelder, JC; Nguyen, TA; Ten Berg, JM; Vos, GJA | 1 |
| Buryachkovskaya, LI; Gabbasov, ZA; Gerasimov, AN; Lomakin, NV; Sumarokov, AB | 1 |
| Jirungda, S; Komanasin, N; Leuangwatthananon, W; Pussadhamma, B; Senthong, V | 1 |
| Gibson, CM; Ohman, EM; Povsic, TJ | 1 |
| Lee, CR; Stouffer, GA | 1 |
| Aw, JWX; Goh, LL; Ho, HK; Liu, J; Ong, HY; Tan, DS; Wee, E; Winther, M | 1 |
| Doukas, D; Schimmer, H; Zehtabchi, S | 1 |
| Bestari, MB; Joewono, IR | 1 |
| Chen, BL; Dai, W; Mo, ZZ; Wang, G; Xiao, FY; Zhang, W; Zhou, G; Zhou, WL | 1 |
| Pinto, DS; Sharma, RK | 1 |
| Lin, Y; Peng, W; Shi, X; Xu, X | 1 |
| Airaksinen, J; Hasvold, P; Khanfir, H; Kytö, V; Prami, T; Reissell, E | 1 |
| Charif, F; El Zein, A; Hamdan, R; Issa, M; Jassar, Y; Saab, M; Younes, M; Youness, G | 1 |
| Gamian, A; Jonkisz, A; Kuliczkowski, W; Lebioda, A; Mysiak, A; Protasiewicz, M; Ściborski, K; Szymkiewicz, P; Wiśniewski, J; Wójcik, T | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Biolè, C; Biondi-Zoccai, G; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; Conrotto, F; Correia, L; D'Ascenzo, F; De Ferrari, GM; Dominguez-Rodriguez, A; Durante, A; Fabrizio, U; Fernández, MC; Fujii, T; Gaido, F; Gallo, D; Garay, A; Gili, S; González-Juanatey, JR; Grosso, A; Henriques, JPS; Huczek, Z; Iñiguez-Romo, A; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Nie, SP; Nuñez-Gil, I; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rettegno, S; Rognoni, A; Song, X; Stone, GW; Taha, S; Templin, C; Valdés, M; Velicki, L; Wilton, SB; Xanthopoulou, I | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Caballero-Jambrina, I; Diarte-de Miguel, JA; Fuertes-Ferre, G; Jimeno-Sánchez, J; Ortas-Nadal, MR; Ruiz-Aranjuelo, A | 1 |
| Crimi, G; De Servi, S; Montalto, C; Savonitto, S | 1 |
| Bannon, SF; da Costa Lino, DO; de Alcantara Lima, N; de Castro, RL | 1 |
| Gorog, DA; Gue, YX; Kanji, R; Srinivasan, M; Wellsted, DM; Wyatt, S | 1 |
| Du, R; Liu, J; Peng, L; Qin, L; Wang, X; Wang, Z; Wu, Y; Yin, T; Zou, Y | 1 |
| Daiber, A; Gori, T; Jurk, K; Koenig, J; Lackner, KJ; Münzel, T; Schnorbus, B; Warnke, S | 1 |
| Ben-Yehuda, O; Claessen, BE; Crowley, A; Faggioni, M; Farhan, S; Généreux, P; Kirtane, AJ; Maehara, A; Mastoris, I; Mehran, R; Redfors, B; Stone, GW; Weisz, G; Witzenbichler, B | 1 |
| Kastrati, A; Schüpke, S | 1 |
| Graham, MM; Har, B; James, MT; Koshman, SL; Turgeon, RD; Wilton, SB; Youngson, E | 1 |
| Colombo, A; Gallo, F; Giannini, F; Khokhar, AA; Laricchia, A; Mangieri, A; Sticchi, A | 1 |
| Furtado, RHM; Giugliano, RP; Guo, J; Im, K; Newby, LK; Nicolau, JC; Sabatine, MS; White, JA | 1 |
| Parker, WAE; Storey, RF | 1 |
| Bliden, K; Gurbel, PA; Rout, A; Tantry, US; Timilsina, S | 1 |
| Han, Y; Jiang, Z; Li, Y; Li, Z; Ma, S; Song, H; Yu, P | 1 |
| Bozina, N; Bozina, T; Cikes, M; Ganoci, L; Krpan, M; Milicic, D; Pasalic, M; Pavasovic, S; Petricevic, M; Samardzic, J; Skoric, B | 1 |
| Al-Badriyeh, D; AlMukdad, S; Elewa, H | 1 |
| Jeong, YJ; Kim, YD; Park, K | 1 |
| Ann, SH; Cho, YR; Guo, LZ; Jin, C; Jin, E; Kim, MH; Kim, SJ; Lee, MS; Park, JS; Shin, ES | 1 |
| Beitelshees, AL; Cavallari, LH; Diaby, V; Dillon, C; Duarte, JD; Empey, PE; Garbett, S; Gong, Y; Graves, J; Hillegass, WB; Holmes, AM; Johnson, JA; Lee, CR; Limdi, NA; Peterson, JF; Pisu, M; Skaar, TC; Zhou, Z | 1 |
| Dingemanse, J; Schilling, U; Ufer, M | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Ayton, S; Flather, M | 1 |
| Ferlini, M; Galvani, M; Visconti, LO | 1 |
| Antonicelli, R; Bongioanni, S; Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Luca, G; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Grosseto, D; Mariani, M; Morici, N; Murena, E; Petronio, AS; Piatti, L; Ravera, A; Rogacka, R; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A; Verdoia, M; Vitrella, G | 1 |
| Antman, EM; Bergmark, BA; Bonaca, MP; Braunwald, E; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM; Wiviott, SD | 1 |
| den Uil, CA; Mandigers, L; Rietdijk, WJR | 1 |
| Fukuta, H; Hagiwara, H; Ishizawa, K; Kamiya, T; Kimura, K; Niimura, T; Ohte, N; Zamami, Y | 1 |
| Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K | 1 |
| Jeong, MH; Johnson, TW; Kim, Y | 1 |
| Chen, F; Chen, ZQ; Li, L | 1 |
| Park, DW; Park, SJ | 1 |
| He, M; Kong, Y; Li, Y; Liu, G; Shi, J; Sun, D; Yan, W; Yuan, Y; Zhang, Y | 1 |
| Baldetti, L; Beneduce, A; Calvo, F; Capodanno, D; Cappelletti, AM; D'Ascenzo, F; De Ferrari, GM; Gallone, G; Godino, C; Gramegna, M; Melillo, F; Moroni, F; Pagnesi, M; Venuti, A | 1 |
| Ai, G; Gu, C; Han, Y; Hao, Y; Liu, Y; Qiu, M; Wang, X; Xu, P; Yang, X; Zhang, J; Zhang, L; Zhao, D; Zhao, X; Zhou, M | 1 |
| Gwak, HS; Lee, N; Seong, JM; Yoon, HY | 1 |
| Gevaert, SA; Sinnaeve, PR | 1 |
| Bergmeijer, T; de Vrey, E; den Hartog, F; Deneer, V; Gimbel, M; Heestermans, T; Hermanides, R; Hofma, S; Jukema, W; Kelder, J; Qaderdan, K; Ten Berg, J; Tjon Joe Gin, M; von Birgelen, C; Voskuil, M; Waalewijn, R; Willemsen, L | 1 |
| Allou, N; Allyn, J; Brulliard, C; Caron, M; Charpentier, T; Cordier, C; Emery, M; Ferdynus, C; Lair, T; Valance, D | 1 |
| Hsieh, MH; Hsieh, YC; Huang, CY; Lin, YK; Liu, JC; Wang, CA; Yeh, JS | 1 |
| Athanasiou, A; Iliopoulos, DC; Paschou, SA; Siasos, G; Spartalis, E; Spartalis, M; Tzatzaki, E; Voudris, V | 1 |
| Altayev, VD; Apartsin, KA; Donirova, OS; Lifshits, GI; Nikolaev, KY; Protasov, KV; Sychev, DA; Voronina, EN; Zelenskaya, EM | 1 |
| Huynh, K | 1 |
| Di, Y; Guo, T; Hou, J; Kong, F; Li, Y; Ming, JE; Ping, C; Wang, L; Xie, F; Yang, N; Yin, H; Zhang, L | 1 |
| Chen, S; Qu, J; Rao, C; Zhang, D; Zhang, H; Zhao, Y; Zheng, Z | 1 |
| Chen, X; Gong, S; Hu, C; Hu, X; Li, L; Pei, T; Yang, J; Zhang, L | 1 |
| Ayoub, F; Sengupta, N | 1 |
| Bonello, L; Burtey, S; Canault, M; Cayla, G; Laine, M; Lemesle, G; Paganelli, F; Pankert, M; Puymirat, E; Quaino, G; Range, G | 1 |
| Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP | 1 |
| Cimino, S; Cirillo, P; Coscioni, E; Esposito, G; Ferrone, M; Gargiulo, G; Giugliano, G; Ilardi, F; Morisco, C; Paolillo, R; Perrino, C; Schiattarella, GG; Stabile, E; Verde, N | 1 |
| Che, JJ; Chen, KY; Liu, T; Rha, SW; Tao, HY; Wang, JR; Wang, P; Wang, WD; Wang, XW; Xu, LX; Xue, ZK; Zhang, YR | 1 |
| Kwan, YH; Lin, YY; Png, WY; Tan, DS; Wee, HL; Wee, JW; Wong, XY | 1 |
| Li, D; Li, X; Shen, S; Wu, H; Xiang, X | 1 |
| Murphy, SA; O'Donoghue, ML; Sabatine, MS | 1 |
| Antonucci, E; Calabrò, P; Cavallari, I; Cesaro, A; Cirillo, P; Gaudio, C; Gragnano, F; Gresele, P; Ielasi, A; Marcucci, R; Moscarella, E; Pafundi, PC; Palareti, G; Patti, G; Pelliccia, F; Pengo, V; Pignatelli, P; Sasso, FC | 1 |
| Chen, Q; Li, D; Lu, C; Wang, C; Wang, S; Wang, Y; Wang, Z; Xu, T; Xuan, H; Zhang, H; Zhang, Y | 1 |
| Cheung, BMY; Fei, Y; Feng, Q; Li, HL; Tsoi, MF | 1 |
| Chen, R; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P | 1 |
| Choi, YH; Deppe, AC; Gerfer, S; Liakopoulos, O; Schlachtenberger, G; Wahlers, TCW; Zeriouh, M | 1 |
| Clopton, P; Giang, K; Penny, WF; Stallings, HE; Stubbs, MK | 1 |
| Hu, Z; Jing, Y; Li, X; Lv, Q; Seybert, A; Wang, J; Wu, H; Xie, X; Xue, Y | 1 |
| Abraham, NS; Herrin, J; Inselman, J; Ngufor, C; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yang, EH; Yao, X | 1 |
| Bergmark, BA | 1 |
| Albertsson, P; Angerås, O; Dworeck, C; Haraldsson, I; Hirlekar, G; Ioanes, D; Myredal, A; Odenstedt, J; Omerovic, E; Petursson, P; Råmunddal, T; Redfors, B; Völz, S | 1 |
| Darius, H | 1 |
| AbdElghany, M; El-Abhar, HS; Mohareb, MW; Zaki, HF | 1 |
| Banai, S; Hershkoviz, R; Isakov, O; Lupu, L; Shepshelovich, D | 1 |
| Ahn, Y; Chang, K; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Kim, CJ; Kim, HY; Kim, MC; Park, CS; Park, MW; Seung, KB; Yoo, KD | 1 |
| Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X | 1 |
| Ai, H; Liu, R; Zhang, YJ; Zhao, XD; Zheng, W | 1 |
| De Servi, S; Landi, A; Savonitto, S | 1 |
| Åkerblom, A; Aukrust, P; Becker, RC; Gregersen, I; Halvorsen, B; Himmelmann, A; James, SK; Johansen, HT; Kontny, F; Lakic, TG; Lindbäck, J; Lunde, NN; Michelsen, AE; Ryeng Skagen, K; Siegbahn, A; Skjelland, M; Solberg, R; Storey, RF; Ueland, T; Wallentin, L | 1 |
| Graham, MM; Turgeon, RD; Youngson, E | 1 |
| Abbott, JD; Bae, JH; Bailey, K; Baudhuin, L; Bell, M; Cagin, C; Chavez, I; Farkouh, ME; Fu, YP; Geller, N; Goodman, SG; Gordon, P; Hasan, A; Iturriaga, E; Jeong, MH; Lennon, R; Lerman, A; Mathew, V; Pereira, NL; Rihal, C; Rosenberg, Y; Sidhu, M; So, D; Tanguay, JF; Wang, L; Weinshilboum, R; Welsh, R | 1 |
| Gremmel, T; Hoberstorfer, T; Kopp, CW; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Disney, BR; McFarlane, M | 1 |
| Bartoli, L; Ferracane, E; Messori, A; Trippoli, S | 1 |
| Alfredsson, J; Erlinge, D; Hofmann, R; Jernberg, T; Lindahl, B; Montez-Rath, ME; Ravn-Fischer, A; Svensson, P; Szummer, K | 1 |
| Canonico, ME; Corda, G; De Vito, E; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Paniccia, R; Parodi, G; Sanna, GD; Scudiero, F; Valenti, R; Vitale, R; Zirolia, D | 1 |
| Eshak, N; Nguyen, J; Tarbox, M; Walterscheid, B | 1 |
| De Luca, G; Fierro, N; Gioscia, R; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Sagazio, E; Tonon, F; Verdoia, M | 1 |
| Elgendy, IY | 1 |
| Kelsey, MD; Newby, LK | 1 |
| Bangalore, S; Bhalla, N; Bhandary, DD; DeRita, R; Diercks, DB; Frost, A; Heitner, JF; Johnson, C; Khan, ND; Peacock, WF; Pollack, CV; Rao, SV; Silber, SH | 1 |
| Adamson, PD; Loganath, K; Moss, AJ | 1 |
| Fu, ML; Li, YY; Luo, LM; Pang, ZQ; Tu, L; Xu, XZ | 1 |
| Zhao, J | 1 |
| Li, Q; Tu, C; Ye, Y; Zeng, Y; Zhao, X | 1 |
| Biswas, M; Biswas, TK; Ibrahim, B; Rahaman, S | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y | 1 |
| Granger, CB; Nanna, MG | 1 |
| Ahmed, SH; Benitez, RM; Hartzell, SA; Kalich, BA; Lusk, KA | 1 |
| Bates, ER | 1 |
| Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC | 1 |
| Gao, M; Hou, YL; Jia, XM; Ma, LP; Ren, MY; Wang, JR; Zhang, M; Zhang, P; Zhang, Y | 1 |
| Lee, CH; Lee, NY; Li, YH; Lin, HW; Lin, SH | 1 |
| Bensenor, IM; Goulart, AC; Lotufo, PA; Santos, IS; Santos, RCO | 1 |
| Eichelberger, B; Gremmel, T; Panzer, S; Pultar, J; Tscharre, M; Wadowski, PP; Weikert, C | 1 |
| Corbett, SJ; Ftouh, S; Lewis, S; Lovibond, K | 1 |
| Cave, BE; Khouzam, RN; Lukas, JG; Moore, CH | 1 |
| Costantini, A; Romagnoli, A; Santoleri, F | 1 |
| Chan, MYY; Kim, JH; Tan, DS | 1 |
| Al-Badriyeh, D; AlMukdad, S; Arafa, S; Elewa, H | 1 |
| James, S; Khan, SU; Navarese, EP | 1 |
| Han, Y; Li, J; Li, X; Li, Y; Ma, S; Na, K; Qi, Z; Qiu, M | 1 |
| Jeong, YH; Kim, HK; Kubica, J | 1 |
| Gupta, A; Krumholz, HM; You, SC | 1 |
| Beasley, M; Brown, TM; Cai, A; Clarkson, SA; Dillon, C; Heindl, B; Limdi, N | 1 |
| Ahmad, M; Choudhry, M; Parmar, D; Yazdouni, S | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Claassens, DMF; Deneer, VHM; Dewilde, WJM; Hermanides, RS; Herrman, JR; Janssen, PWA; Kelder, JC; Mahmoodi, BK; Morisco, C; Mosterd, A; Ten Berg, JM; Tjon Joe Gin, RM; van 't Hof, AWJ; van der Harst, P; Vos, GJA | 1 |
| Fajar, JK; Heriansyah, T; Ilmawan, M; Mahdi, BA; Mahendra, AI; Mazen, M; Pikir, BS; Purnamasari, Y; Rohman, MS; Tamara, F; Yamin, M | 1 |
| Ando, T; Bangalore, S; Briasoulis, A; Fujisaki, T; Kuno, T; Takagi, H | 1 |
| Chen, L; Devi Shamloll, Y; Jiang, Z; Jin, J; Xiao, M; Zhuo, X | 1 |
| Kakouros, N; Kassas, I; Rade, J; Soueid, AE | 1 |
| Cheng, LC; Chu, PH; Huang, CL; Kuo, FY; Lan, WR; Lee, CH; Lee, WL; Lin, WS; Liu, PY; Lo, PH; Lu, TM; Nikolajsen, C; Rafael, V; Su, CH; Tsukiyama, S; Wang, YC; Yang, WC; Yin, WH | 1 |
| Dong, Z; Pan, L; Zhai, H; Zhang, B | 1 |
| Aggarwal, S; Ali, T; Ding, WY; Elamin, A; Fisher, M; Grainger, R; Hasara, J; Heseltine, T; Kasolo, Y; Khand, A; Kirmani, BH; Meah, MN; Mullen, L; Obeidat, M; Patel, B; Rashid, M; Shahzad, A; Shaw, M; Thatchil, J | 1 |
| Borrelli, C; Emdin, M; Gentile, F; Giannoni, A; Mirizzi, G; Passino, C | 1 |
| Jneid, H; Kamran, H; Kayani, WT; Khalid, U; Levine, GN; Nambi, V; Virani, SS | 1 |
| Asselbergs, FW; Barbato, E; Bergmeijer, TO; Claassens, DMF; de Vrey, EA; den Hartog, FR; Deneer, VHM; Dewilde, W; Gimbel, ME; Heestermans, TACM; Hermanides, RS; Herrman, JR; Hofma, SH; Jukema, JW; Mahmoodi, BK; Morisco, C; Mosterd, A; Ten Berg, JM; Tjon Joe Gin, RM; van der Harst, P; Van't Hof, AWJ; von Birgelen, C; Vos, GJA; Voskuil, M; Waalewijn, RA | 1 |
| Che, J; Chen, K; Dou, S; Liu, H; Liu, X; Wang, W; Wang, X; Zhang, X; Zhou, X | 1 |
| Barbieri, L; De Luca, G; Verdoia, M | 1 |
| Alkattan, A; Alsalameen, E | 1 |
| Figatowski, T; Gasecka, A; Jaguszewski, MJ; Pruc, M; Ruetzler, K; Szarpak, L | 1 |
| Bae, JW; Cho, DK; Choi, SH; Gwon, HC; Hahn, JY; Jeong, JO; Oh, JH; Park, YH; Rha, SW; Song, PS; Song, YB | 1 |
| Bierer, J; Bisleri, G; Cartier, A; Dagher, O; Dhingra, NK; Eikelboom, R; Forgie, K; Kirubaharan, A; Luc, J; Makhdoum, A; Vaillancourt, O; Verma, S; Vo, TX; Yanagawa, B; Yau, TM | 1 |
| Lam, ASM; Lee, VWY; Yan, BPY | 1 |
| Gaudino, M; Sandner, S | 1 |
| Fukuta, H; Hagiwara, H; Hashimoto, H; Ishizawa, K; Kamiya, T; Niimura, T; Ohte, N; Zamami, Y | 1 |
| Hsieh, KP; Hwang, SJ; Li, YS; Wang, SH; Yang, YH | 1 |
| Cong Luu, T; Le Phuong, T; Manh Pham, H; Mellstrom, C; Quang Nguyen, T; Thi Thu Nguyen, T; Van Do, D; Van Hoang, S | 1 |
| De Luca, L | 1 |
| Chen, J; Geng, Q; Jia, H; Ling, F; Liu, X; Mak, WH; Su, Z; Wang, J; Xu, H; Xu, X; Yang, F; Yang, H; Zhang, T; Zhang, X; Zhang, Z; Zhong, S | 1 |
| Kengkla, K; Kumtep, W; Saokaew, S; Senthong, V; Ungsriwong, S; Wongsalap, Y | 1 |
| Becker, RC; Chan, MY; Grenier, JC; Hussin, JG; Jolicœur, EM; Lopes, RD; Lordkipanidzé, M; Mehanna, P; Neely, ML; Newby, LK; Ruiz, M; Samman, KN; Takla, E; Wang, TY | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solè, A; Bianco, M; Biolè, CA; Boccuzzi, G; Careggio, A; Cerrato, E; Correia, L; D'Ascenzo, F; De Ferrari, GM; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fujii, T; Gonzàlez Juanatey, JR; Henriques, JPS; Huczek, Z; Kawaji, T; Kawashiri, MA; Kinnaird, T; Liebetrau, C; Luciano, A; Manzano-Fernàndez, S; Montagna, L; Morbiducci, U; Nie, SP; Nunez-Gil, I; Quadri, G; Quiros, A; Raposeiras-Roubin, S; Rognoni, A; Song, X; Spirito, A; Templin, C; Ugo, F; Varbella, F; Velicki, L; Wilton, SB | 1 |
| Arévalos, V; Brugaletta, S; Caballero-Borrego, J; Gil-Jimenez, T; Gomez-Hospital, JA; Gomez-Lara, J; Moreno-Terribas, G; Ortega-Paz, L; Oyarzabal, L; Rodriguez-Arias, JJ; Romaguera, R; Sabate, M; Teruel, L | 1 |
| Ten Berg, JM; van den Broek, WW | 1 |
| Briasoulis, A; Cuisset, T; Deharo, P; Fujisaki, T; Kohsaka, S; Kuno, T; Latib, A; Shoji, S; Takagi, H | 1 |
| Bálint, A; Eitmann, S; Garami, A; Hanák, L; Hegyi, P; Komócsi, A; Márta, K; Rumbus, Z; Solymár, M; Szakács, Z | 1 |
| Bai, H; Li, H; Li, Y; Liu, W; Sun, L; Wang, T; Wu, J; Yu, A; Yu, L; Zhu, W | 1 |
| Abusnina, W; Al-Abdouh, A; Alshebani, Y; Bizanti, A; Dahal, K; Gill, G; Houssien, A; Kanmanthareddy, A | 1 |
| Guo, L; Man, F; Pan, Q; Wang, W; Wang, X; Zhang, J; Zhang, L | 1 |
| Han, J; Li, W; Lin, B; Lin, Y; Peng, W; Shi, X; Wang, Y; Yan, J; Zhang, Y; Zheng, Z | 1 |
| Antoniucci, D; Bellandi, B; Gori, AM; Marchionni, N; Marcucci, R; Migliorini, A; Parodi, G; Scudiero, F; Tarantini, G; Valenti, R; Zocchi, C | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Chen, XP; Li, MP; Tang, J; Zhang, YJ | 1 |
| Buscema, M; Calabrò, P; Capodanno, D; Cattaneo, M; De Carlo, M; de Servi, S; Della Riva, D; Femia, EA; Genereux, P; Grossi, E; Maffeo, D; Palmerini, T; Palmieri, C; Piscione, F; Podda, GM; Toso, A | 1 |
| Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y | 1 |
| Berti, S; Bolognese, L; D'Ascenzo, F; De Luca, L; De Servi, S; Marchese, A; Musumeci, G; Parodi, G; Saia, F; Varbella, F | 1 |
| Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A | 1 |
| Cao, Y; Cui, W; Cui, Y; Guo, X; Li, C; Li, J; Li, S; Shen, X; Sun, Y; Wang, D; Wang, DW; Wang, H; Wang, Y; Yan, J; Yang, J; You, L; Zeng, H; Zhang, L; Zhang, Y | 1 |
| Kanic, V; Kanic, Z; Kompara, G; Markota, A; Penko, M; Vollrath, M | 1 |
| Alfredsson, J; Armstrong, PW; Bhatt, DL; Cornel, JH; Fox, KA; Goodman, SG; Mahaffey, KW; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Tricoci, P; White, HD; Winters, KJ | 1 |
| Huang, Y; Li, M; Shi, X; Wang, H; Xuan, L; Zhang, N; Zhou, T | 1 |
| Cho, JY; Choi, YJ; Jang, IJ; Jo, HJ; Jung, HC; Kim, N; Lee, DH; Nam, RH; Park, JH; Park, YS; Shin, CM; Yoon, H | 1 |
| Brown, EB; Cyr, DD; Goldstein, SA; Hamm, CW; Lüscher, TF; Neely, M; Newby, LK; Ohman, EM; Roe, MT; White, HD | 1 |
| Becker, RC; Cannon, CP; Hagström, E; Himmelmann, A; James, SK; Katus, HA; Lindholm, D; López-Sendón, JL; Maurer, G; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bellomo, G; Carriero, A; Daffara, V; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Verdoia, M | 1 |
| Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K | 1 |
| Cao, S; Chen, BL; Fan, L; Liu, M; Liu, ZQ; Xiao, FY; Zhang, W; Zhou, G; Zhou, HH | 1 |
| Choi, CW; Jeong, DI; Kang, DH; Kim, HW; Kim, WC; Lim, TW; Ryu, DG; Shin, JG | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V | 1 |
| Sinnaeve, PR; Van de Werf, F | 1 |
| Chiswell, K; Doll, JA; Kosiborod, M; Li, S; Roe, MT; Scirica, BM; Wang, TY | 1 |
| Ardati, AK; DiDomenico, RJ; Kim, K; Lee, TA; Touchette, DR; Walton, SM | 3 |
| Kochubiei, O; Ovrakh, T; Serik, S | 1 |
| Armstrong, PW; Bhatt, DL; Cyr, DD; Dalby, AJ; Fox, KAA; Gottlieb, S; Magnus Ohman, E; McGuire, DK; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Winters, KJ; Wiviott, SD | 1 |
| Aquino, M; Baber, U; Baker, BA; Bansilal, S; Chandrasekhar, J; DeFranco, A; Effron, M; Henry, TD; Kapadia, S; Keller, S; Kini, A; Marrett, E; Mehran, R; Muhlestein, JB; Pocock, S; Poddar, KL; Rao, SV; Sartori, S; Strauss, C; Toma, C; Weintraub, W; Weiss, S | 1 |
| Bognetti, P; Cardile, A; De Servi, S; Demarchi, A; Ferlini, M; Frattini, S; Grieco, N; Ielasi, A; Lettieri, C; Mafrici, A; Musumeci, G; Rossini, R; Russo, A; Sponzilli, C; Vecchiato, C; Visconti, LO | 1 |
| Becker, RC; Cannon, CP; Davoudi, F; Diercks, DB; Himmelmann, A; James, SK; Lim, ST; Pollack, CV; Schulte, PJ; Spinar, J; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L | 1 |
| Ariyoshi, N; Fujimoto, Y; Kitahara, H; Kobayashi, Y; Nakayama, T; Nishi, T; Sugimoto, K; Wakabayashi, S | 1 |
| Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W | 1 |
| Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R | 1 |
| Ako, J; Ando, K; Anzai, H; Hamasaki, T; Iijima, R; Inoue, K; Ishiwata, S; Ito, Y; Kadotani, M; Kawaguchi, K; Morita, T; Nakamura, M; Niinuma, H; Nishida, Y; Ochiai, M; Ohira, H; Okada, H; Omiya, K; Shinke, T; Takiuchi, S; Tanaka, H; Ueda, Y; Yasaka, Y; Yokoi, H; Zen, K | 1 |
| Christoph, M; Ende, G; Ibrahim, K; Jellinghaus, S; Loehn, T; Mierke, J; Pfluecke, C; Poitz, DM; Quick, S; Richter, B; Schoener, L; Speiser, U; Strasser, RH | 1 |
| Kosar, L; Koziol, K; Martens, B; Schellenberg, A; Shmyr, D | 1 |
| Ebisawa, S; Ikeda, U; Koyama, J; Miura, T; Mochidome, T; Motoki, H; Nishimura, H; Saigusa, T; Senda, K; Ueki, Y | 1 |
| Jiang, M; You, JHS | 1 |
| Furuse, E; Hosokawa, Y; Kitamura, M; Kubota, Y; Miyachi, H; Shimizu, W; Takano, H; Yamamoto, T; Yoshizane, T | 1 |
| Liu, J; Lu, C; Peng, L; Qin, L; Xi, S; Yin, T | 1 |
| Borse, MS; Dong, OM; Farley, JF; Lee, CR; Polasek, MJ; Stouffer, GA | 1 |
| Cao, S; Chen, BL; Liu, M; Liu, ZQ; Luo, JQ; Xiao, FY; Zhang, W; Zhou, G; Zhou, HH | 1 |
| Gurm, HS | 1 |
| Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Faggioni, M; Farhan, S; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Candela Sánchez, E; Carrillo Alemán, L; Esteve-Pastor, MA; Lozano, T; MacíasVillanego, MJ; Marín, F; Orenes-Piñero, E; PerniasEscrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruíz-Nodar, JM; Sandín Rollán, M; Tello-Montoliu, A; Valdés, M; Véliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Cremer, J; Giannitsis, E; Goss, F; Koscielny, J; Labenz, J; Spannagl, M; von Heymann, C; Zeymer, U | 1 |
| Ji, JZ; Jia, YM; Tai, T; Xie, HG | 1 |
| Coslovsky, M; Galatius, S; Jabbari, R; Kaiser, C; Pfisterer, M; Wein, B | 1 |
| Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J | 1 |
| Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I | 1 |
| Godschalk, TC; Kelder, JC; Ten Berg, JM; Zwart, B | 1 |
| Angiolillo, DJ; Barozzi, C; Bartorelli, A; Bellandi, F; Calabrò, P; Capodanno, D; Cattaneo, M; De Carlo, M; De Servi, S; Della Riva, D; Genereux, P; Leoncini, M; Maffeo, D; Palmerini, T; Palmieri, C; Piscione, F; Tomasi, L; Toso, A | 1 |
| Bash, LD; Patel, MD; Simpson, RJ; Vyas, A | 1 |
| Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D | 1 |
| Fairley, S; Harding, SA; Holley, A; Larsen, PD; Simmonds, M; Wilkins, B | 1 |
| Hernández, D; Jover, E; Marín, F; Orenes-Piñero, E; Quintana, M; Rivera, J; Rivera-Caravaca, JM; Rodriguez, AI; Romero, A; Silvente, A; Tello-Montoliu, A; Valdés, M; Veliz, A | 1 |
| Athanasiou, A; Spartalis, E; Spartalis, M; Tzatzaki, E | 1 |
| Han, Y; Li, C; Li, J; Li, Y; Qi, J; Tang, Y; Wang, H | 1 |
| Lowenstern, A; Newby, LK | 1 |
| Adamson, PD; Anand, A; Dias, S; Lee, KK; McAllister, DA; Mills, NL; Newby, DE; Shah, AS; Welton, N | 1 |
| Cattabiani, MA; De Palma, R; Guastaroba, P; Marino, M; Menozzi, A; Rasia, M; Solinas, E; Tadonio, I; Vignali, L | 1 |
| Bauersachs, J; Schäfer, A | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| He, B; Lin, H; Tobe, RG; Wu, B; Zhang, L | 1 |
| Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S | 1 |
| Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E | 1 |
| Carugo, S; Castini, D; Cazzaniga, S; Centola, M; Ferrante, G; Lucreziotti, S; Persampieri, S; Salerno-Uriarte, D; Sponzilli, C | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Bonello, L; Burtey, S; Laine, M; Lemesle, G; Puymirat, E | 1 |
| Becher, PM; Blankenberg, S; Fluschnik, N; Schnabel, R; Westermann, D | 1 |
| Nikiteas, NI; Spartalis, E; Spartalis, M; Tzatzaki, E | 1 |
| Kaiser, C; Wein, B | 1 |
| Angiolillo, DJ; Cattaneo, M; Crimi, G; De Servi, S; Palmerini, T; Piscione, F; Somaschini, A | 1 |
| Landmesser, U; Stähli, BE | 1 |
| He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z | 1 |
| Chan, R; Ip, P; Kwok, J; Kwong, KM; Lee, SWL; Tam, CC | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Deharo, P; Fernandez, M; Fourcade, L; Ibrahim, M; Johnson, TW; Morange, PE; Quilici, J; Suchon, P; Verdier, V | 1 |
| Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N | 1 |
| Hirono, S; Ikegami, R; Minamino, T; Ozaki, K; Ozawa, T; Suda, M; Takano, T; Tanaka, K; Wakasugi, T; Yanagawa, T | 1 |
| Ascarrunz, SD; Cho, MY; Peralta-Bazan, F; Rodriguez, AE; Rodriguez-Granillo, AM | 1 |
| Assanelli, EM; Camisasca, P; Chizzola, G; Corrada, E; De Servi, S; Demarchi, A; Farina, A; Ferlini, M; Grieco, N; Lettieri, C; Mafrici, A; Musumeci, G; Oltrona Visconti, L; Pedrinazzi, C; Rossini, R; Sponzilli, C | 1 |
| Boland, P; Bourke, M; Chan, V; Chong, AY; Dupuis, JY; Goubran, D; Hibbert, B; James, TE; Lordkipanidzé, M; Malhotra, N; Perrault, L; Rubens, F; Ruel, M; Russo, JJ; Singh, K; So, DY; Tanguay, JF; Tran, DT; Wells, GA | 1 |
| Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L | 2 |
| Attanasio, C; Caravita, L; Cattaneo, M; Femia, EA; Galvani, M; Ottani, F | 1 |
| Akoudad, H; Habbal, R; Hassani Idrissi, H; Hmimech, W; Khorb, NE; Nadifi, S | 1 |
| de Belder, MA; Freeman, P; Johnson, T; Kontopantelis, E; Kwok, CS; Ludman, P; Mamas, MA; Sirker, A; Zaman, A | 1 |
| Berthe, A; Diaby, V; Ezendu, K; Okere, AN | 1 |
| Ajjan, RA; Bertilsson, M; Gabrysch, K; Himmelmann, A; James, SK; Siegbahn, A; Storey, RF; Sumaya, W; Wallentin, L | 1 |
| Altiparmak, İH; Besli, F; Gungoren, F; Tanriverdi, Z | 1 |
| Lozano, I; Rondan, J; Segovia, E; Vegas, JM | 1 |
| Hess, S; Jesel, L; Kibler, M; Marchandot, B; Messas, N; Meyer, N; Morel, O; Ohlmann, P; Ristorto, J; Schaeffer, M; Tuzin, N | 1 |
| Abdel-Latif, A; Aoi, S; Kim, SM; Misumida, N; Ziada, KM | 1 |
| Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Ge, ML; Han, YL; Jing, QM; Li, L; Li, Y; Liu, HW; Ma, YY; Wang, B; Wang, G; Wang, XZ; Xu, K; Yang, BS; Zhang, L; Zhao, X | 1 |
| Antoni, D; Hitzke, E; Hoffmann, E; Ott, A; Rieber, J; Schmidtler, F; Selhorst, G; Tomelden, J | 1 |
| Berti, S; Bolognese, L; D'Ascenzo, F; De Luca, L; De Servi, S; Gallo, P; Granatelli, A; Gulizia, MM; Musumeci, G; Pennacchi, M; Rigattieri, S | 1 |
| Austin, PC; Chong, A; de Melo, JF; Jackevicius, CA; Ko, DT; Koh, M; Krumholz, HM; Stukel, TA; Tu, JV | 1 |
| Akkerhuis, KM; Ariotti, S; Brugaletta, S; Gianni, U; Janssens, GN; Karagiannis, A; Leonardi, S; Ortega-Paz, L; Rimoldi, SF; Valgimigli, M; van den Berge, JC; van Leeuwen, M; Windecker, S | 1 |
| Bae, JH; Cho, DK; Cho, JH; Choi, JH; Choi, KH; Choi, SH; Choi, WG; Doh, JH; Gwon, HC; Hahn, JY; Jeong, JO; Kim, BO; Kim, DI; Kim, J; Kim, SH; Lee, JB; Lee, JM; Lee, WS; Oh, JH; Park, HK; Park, JS; Park, TK; Song, YB; Suh, IW; Yang, JH | 1 |
| Onwordi, ENC; Parker, WA; Storey, RF | 1 |
| Bella, J; Krim, N; Zeb, I | 1 |
| Fonarow, GC; Ge, J; Han, Y; Hao, Y; Huo, Y; Liu, J; Ma, C; Morgan, L; Nie, S; Smith, SC; Taubert, KA; Wang, X; Zhao, D; Zhao, G; Zhou, M | 1 |
| Abu-Assi, E; Alegre, O; Alexopoulos, D; Alfonso, E; Ariza-Solé, A; Cequier, A; Chen, Y; Correia, L; D'Ascenzo, F; Fan, JY; Filipiak, K; Formiga, F; Fujii, T; Gaita, F; Garay, A; García-Acuña, JM; Giordana, F; González-Juanatey, JR; Henriques, JPS; Huczek, Z; Ikari, Y; Kalpak, O; Kawaji, T; Kawashiri, MA; Kedev, S; Kikkert, WJ; Kowara, M; Liebetrau, C; Lorente, V; Möllmann, H; Moretti, C; Nakahashi, T; Nie, SP; Nuñez-Gil, I; Osman, N; Raposeiras-Roubín, S; Sakata, K; Sánchez-Salado, JC; Saucedo, J; Shiomi, H; Song, X; Southern, D; Terol, B; Wang, X; Wilton, SB; Xanthopoulou, I; Yamagishi, M; Yan, Y; Zhang, D | 1 |
| Ahn, JM; Jang, S; Kang, DY; Lee, CH; Lee, PH; Lim, HS; Park, DW; Park, SJ; Park, SW; Yun, SC | 1 |
| Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E | 1 |
| Fang, S; He, L; Li, H; Niu, J; Qin, S; Shen, L; Wang, L; Zhang, S; Zhu, B; Zhu, J | 1 |
| Armstrong, PW; Cyr, DD; Fox, KAA; Goodman, SG; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; White, H; Yan, AT | 1 |
| Alexopoulos, D; Altman, RB; Aradi, D; Bergmeijer, TO; Bliden, K; Campo, G; Chang, K; Cleator, JH; Déry, JP; Dridi, NP; Fernandez-Cadenas, I; Fontana, P; Gawaz, M; Geisler, T; Gensini, GF; Giusti, B; Gong, L; Gurbel, PA; Hochholzer, W; Holmvang, L; Horenstein, RB; Hulot, JS; Kim, EY; Kim, HS; Klein, TE; Kubo, M; Lee, MTM; Lewis, JP; Marcucci, R; Mitchell, BD; Montaner, J; Pakyz, RE; Reny, JL; Ritchie, MD; Roden, DM; Schaeffeler, E; Schwab, M; Shin, JG; Shuldiner, AR; Siller-Matula, JM; Simon, T; Ten Berg, JM; Trenk, D; Valgimigli, M; Wen, MS; Whaley, RM; Winter, S | 1 |
| Ashby, A; Curzen, N; Dalton, RT; Harris, S; Khanna, V; Mahmoudi, M; Mariathas, M; Nicholas, Z; Olechowski, B; Vavyla, M | 1 |
| He, B; Liu, Y; Tobe, RG; Wu, B | 1 |
| Garay-Sánchez, P; Martínez-Quintana, E; Medina-Gil, JM; Riaño, M; Rodríguez-González, F; Saavedra, P; Tugores, A | 1 |
| Hirata, KI; Kijima, Y; Kozuki, A; Masano, T; Nagoshi, R; Otake, H; Shibata, H; Shinke, T; Shite, J; Takeshige, R; Tsukiyama, Y; Yanaka, KI | 1 |
| Chertovskih, JV; Fedorinov, DS; Ivashchenko, DV; Maksimova, NR; Mirzaev, KB; Popova, NV; Rudykh, ZA; Sychev, DA; Tayurskaya, KS; Temirbulatov, II | 1 |
| Billinger, M; Blöchlinger, S; Heg, D; Hunziker, L; Karagiannis, A; Koskinas, KC; Moro, C; Moschovitis, A; Pilgrim, T; Praz, F; Räber, L; Räsänen, M; Seiler, C; Stortecky, S; Temperli, F; Valgimigli, M; Windecker, S; Zanchin, C; Zanchin, T | 1 |
| Alexander, JH; Lopes, RD; Newby, LK; Newman, MF; Smith, PK; Wang, A; Wojdyla, D; Wu, A | 1 |
| Basiri, H; Firouzi, A; Hoseinimoghaddam, M; Mahdieh, N; Maleki, M; Noohi, F; Rabbani, A; Rabbani, B; Saedi, S; Sanati, H; Zahedmehr, A | 1 |
| An, GD; Han, JY; Kim, JM; Kim, KH; Kim, MH; Li, S; Lim, HH; Woo, KS | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JHW; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Giri, J; Nathan, A | 1 |
| Akkerhuis, KM; Ariotti, S; Brugaletta, S; Gianni, U; Janssens, G; Karagiannis, A; Leonardi, S; Ortega-Paz, L; Rimoldi, SF; Valgimigli, M; van den Berge, JC; van Leeuwen, M; Windecker, S | 1 |
| Åkerblom, A; Becker, RC; Eriksson, N; Himmelmann, A; James, SK; Parker, WAE; Storey, RF; Voora, D; Wallentin, L | 1 |
| Armstrong, PW; Bansilal, S; Becker, RC; Cannon, CP; Clare, RM; Davoudi, F; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Pieper, KS; Schulte, PJ; Scirica, BM; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bangalore, S | 1 |
| Egger, F; Freynhofer, MK; Gruber, SC; Huber, K; Hübl, W; Weiss, TW; Willheim, M | 1 |
| Aradi, D; Baylacher, M; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Hausleiter, J; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Parma, R; Sibbing, D; Trenk, D | 1 |
| Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L | 1 |
| Velázquez de Campos, O | 1 |
| Klein, MD; Lee, CR; Stouffer, GA | 1 |
| Bliden, KP; Gurbel, PA; Navarese, EP; Tantry, US | 1 |
| Li, X; Lv, Q; Wang, Q; Wang, Z; Xu, Q | 1 |
| Aradi, D; Baylacher, M; Gawaz, M; Geisler, T; Gross, L; Hadamitzky, M; Hromek, J; Jacobshagen, C; Krieg, A; Massberg, S; Sibbing, D; Stimpfle, F; Trenk, D; Vogelgesang, A | 1 |
| Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM | 1 |
| Chen, J; Fan, Y; Ji, Y; Kong, D; Li, C; Li, J; Meng, H; Xu, K; Ye, S; Zhang, J; Zhu, T | 1 |
| Aylward, PE; Bhatt, DL; Fox, KAA; Gurbel, PA; Hamm, C; Hinohara, TT; Huber, K; Neely, ML; Ohman, EM; Roe, MT; White, HD; Wiviott, SD | 1 |
| Calnan, MW; Crawford, AN | 1 |
| Andreev, DA; Belyakova, GA; Fedorinov, DS; Giliarov, MI; Grishina, EA; Konova, OD; Mirzaev, KB; Rytkin, E; Ryzhikova, KA; Sozaeva, ZA; Sychev, DA | 1 |
| Balanescu, DV; Cilingiroglu, M; Donisan, T; Durand, JB; Giza, DE; Iliescu, C; Kim, PY; Lopez-Mattei, JC; Marmagkiolis, K; Mouhayar, EN; Mukerji, SS; Muñoz Gonzalez, ED; Palaskas, N; Song, J | 1 |
| Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH | 1 |
| Carrillo-Alemán, L; Esteve-Pastor, MA; Lozano, T; Macías-Villanego, MJ; Marín, F; Martínez-Martínez, JG; Orenes-Piñero, E; Pernias-Escrig, V; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Tello-Montoliu, A; Véliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Calabria, S; Cimminiello, C; Dondi, L; Maggioni, AP; Martini, N; Pedrini, A; Ronconi, G | 1 |
| Ahn, J; Cha, KS; Choe, JC; Choi, JH; Hong, TJ; Jeong, MH; Lee, HC; Lee, HW; Oh, JH; Park, JS | 1 |
| Aradi, D; Bonello, L; Burtey, S; Dabry, T; Frere, C; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Puymirat, E; Sibbing, D; Thuny, F | 1 |
| Colivicchi, F; Falaschi, G; Tubaro, M | 1 |
| Frelinger, AL; Gachet, C; Gresele, P; Harrison, P; Mezzano, D; Mumford, AD; Noris, P | 1 |
| Birkett, N; Crispo, J; Farhat, N; Haddad, N; Krewski, D; Mattison, DR; McNair, D; Momoli, F; Wen, SW | 1 |
| Chae, IH; Cho, YS; Lee, W; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ | 1 |
| Apostolovic, S; Konstantinovic, SS; Lilic, J; Marinkovic, V; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB | 1 |
| Fan, J; Gong, W; Nie, S; Wang, X; Wei, Y | 1 |
| Desai, RJ; Gagne, JJ; Lewey, JJ; Patorno, E; Schneeweiss, S; Spoendlin, J | 1 |
| Aquino, M; Baber, U; Baker, B; Chandrasekhar, J; Claessen, BE; Defranco, A; Effron, MB; Faggioni, M; Farhan, S; Henry, T; Kapadia, S; Keller, S; Kini, A; Mehran, R; Muhlestein, JB; Pocock, S; Poddar, K; Rao, SV; Sartori, S; Snyder, C; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Lin, Z; Liu, J; Xuan, J; Yin, H; Zhang, L | 1 |
| Cui, XR; Jia, M; Li, RB; Wang, D; Yang, XH; Zhang, JD | 1 |
| Liao, H; Liu, L; Liu, Y; Xiao, C; Zhong, S | 1 |
| Duconge, J; Gonzalez, S; Hernandez-Suarez, DF; Hua, S; Kaplan, RC; Melin, K; Moon, JY; Qi, Q; Zeng, D | 1 |
| Brodie, BR; Généreux, P; Gohs, FX; Kirtane, AJ; Maehara, A; McAndrew, T; Mehran, R; Metzger, DC; Neumann, FJ; Redfors, B; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Bizzozero, C; Blum, S; Bolliger, D; Buser, A; Gebhard, C; Glauser, S; Grapow, MTR; Siegemund, M; Vuilliomenet, T | 1 |
| Angiolillo, DJ | 4 |
| Armstrong, PW; Bakal, J; Cyr, D; Fanaroff, AC; Fox, KAA; Lopes, RD; Neely, ML; Ohman, EM; Roe, MT; White, HD | 1 |
| Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Henry, TD; Kini, A; Krucoff, M; Leisman, DE; Mehran, R; Moliterno, D; Pocock, SJ; Sartori, S; Steg, PG; Witzenbichler, B | 1 |
| Body, R; Jarman, H; Morris, N; Moss, P; Reynard, C | 1 |
| Candela-Sanchez, E; Carrillo-Aleman, L; Esteve-Pastor, MA; Lozano, T; Macías, M; Marín, F; Martínez-Martínez, JG; Orenes-Piñero, E; Pernias-Escrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Sandín-Rollan, M; Veliz, A; Vicente-Ibarra, N | 1 |
| Kinnaird, T | 1 |
| Bolognese, L; Bovenzi, FM; Cacucci, M; Crimi, G; De Carlo, M; De Luca, G; De Servi, S; Elia, LR; Ferrario, M; Ferri, LA; Grosseto, D; Mandurino Mirizzi, A; Morici, N; Piatti, L; Piscione, F; Savonitto, S; Toso, A; Trimarco, B | 1 |
| Chen, TJ; Chen, XA; Guo, W; Shen, ZJ; Wang, XL; Wang, YJ | 1 |
| Aquino, M; Baber, U; Baker, B; Bansilal, S; Chandrasekhar, J; Claessen, B; Defranco, A; Effron, M; Faggioni, M; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, A; Mehran, R; Muhlestein, B; Pocock, S; Poddar, KL; Rao, SV; Sartori, S; Snyder, C; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S | 1 |
| Benichou, J; Blin, P; Bonello, L; Dallongeville, J; Danchin, N; Droz, C; Dureau-Pournin, C; Falissard, B; Jové, J; Lassalle, R; Moore, N; Thomas-Delecourt, F | 1 |
| Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D | 1 |
| Chen, XH; Zhao, HL | 1 |
| Aradi, D; Filipiak, KJ; Gori, T; Gross, L; Hadamitzky, M; Huber, K; Huczek, Z; Jacobshagen, C; Klopotowski, M; Koltowski, L; Komosa, A; Kowara, M; Lesiak, M; Massberg, S; Opolski, G; Parma, R; Rymuza, B; Sibbing, D; Tomaniak, M; Witkowski, A | 1 |
| Klein, MD; Lee, CR; Stouffer, GA; Williams, AK | 1 |
| Klein, MD; Lee, CR; Martin, J; Rossi, JS; Stouffer, GA; Weck, KE; Williams, AK | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Angiolillo, DJ; Budaj, AJ; Cornel, JH; Franchi, F; Ghukasyan Lakic, T; Himmelmann, A; James, SK; Katus, HA; Keltai, M; Kontny, F; Lewis, BS; Storey, RF; Wallentin, L | 1 |
| Fan, ZG; He, SH; Ji, J; Tian, NL; Xu, B; Zhang, WL | 1 |
| Bilotta, F; Campo, G; Parodi, G; Pavasini, R; Serenelli, M; Tonet, E; Vitali, F | 1 |
| Bianco, M; Biscaglia, S; Campo, G; Cerrato, E; Corleto, A; Destefanis, P; Giolitto, S; Gravinese, C; Lo Savio, L; Luciano, A; Nuñez-Gil, I; Pozzi, R; Quadri, G; Tizzani, E; Varbella, F | 1 |
| Chen, S; Cui, Y; Gong, Y; Hu, K; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhou, S | 1 |
| Araszkiewicz, A; Grajek, S; Grygier, M; Hengstenberg, C; Komosa, A; Krasiński, Z; Lesiak, M; Mitkowski, P; Mularek-Kubzdela, T; Olasińska-Wiśniewska, A; Pyda, M; Siller-Matula, JM; Siniawski, A; Skorupski, W | 1 |
| Baber, U; Baker, BA; Chandiramani, R; Chandrasekhar, J; Claessen, BE; Dangas, G; DeFranco, A; Effron, MB; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Li, SX; Mehran, R; Muhlestein, B; Pocock, S; Rao, SV; Sartori, S; Strauss, C; Toma, C; Weiss, S | 1 |
| Aggarwal, D; Bishnoi, A; Daroach, M; Panda, P; Parsad, D; Radotra, BD | 1 |
| Alexander, KP; Armstrong, PW; Clemmensen, P; Fox, KA; Goodman, SG; Hochman, JS; Kaul, P; Ohman, EM; Prabhakaran, D; Roe, MT; Savu, A; White, HD | 1 |
| Cao, X; Chen, X; Hu, W; Li, J; Liu, Z; Sun, Y; Xin, Y; Zhao, Y | 1 |
| Angiolillo, DJ; Kalkman, DN; Mehran, R | 1 |
| Akutsu, N; Fukamachi, D; Hirayama, A; Hiro, T; Kitano, D; Kojima, K; Migita, S; Mineki, T; Morikawa, T; Murata, N; Okumura, Y; Sudo, M; Takayama, T; Tamaki, T | 1 |
| Angiolillo, DJ; Chan, KT; Del Aguila, M; Girotra, S; Han, Y; Huang, WC; Paek, D; Patti, G; Sibbing, D; Yakovlev, A | 1 |
| Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D | 1 |
| Chan, NC; Chen, J; Fan, Y; Hu, X; Kong, D; Li, C; Li, J; Wang, F; Xu, K; Xu, L; Yang, L; Yang, M; Ye, S; Ying, L; Zhang, J; Zhang, S; Zhang, X; Zhu, H; Zhu, T | 1 |
| Chang, K; Choi, IJ; Choo, EH; Chung, WS; Hwang, BH; Kim, CJ; Lee, JM; Lee, KY; Lim, S | 1 |
| Liu, R; Nie, S; Qin, X; Shaqdan, A; Wang, C; Wang, X; Yuan, L; Zhao, X; Zheng, W | 1 |
| Chen, CP; Chen, JH; Cheng, JJ; Chiang, FT; Chiu, YW; Hsieh, IC; Kuo, JY; Lai, WT; Lee, WL; Lei, MH; Li, YH; Lo, PH; Sung, SH; Ueng, KC | 1 |
| Carriero, A; De Luca, G; Kedhi, E; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Tonon, F; Verdoia, M | 1 |
| Carrillo-Alemán, L; Esteve-Pastor, MA; Lozano, T; Macías-Villanego, MJ; Marín, F; Martínez, J; Orenes-Piñero, E; Pernías-Escrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruiz-Nodar, JM; Sandín-Rollán, M; Tello-Montoliú, A; Veliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Bo, WL; Feng, W; He, MJ; Li, S; Li, Y; Liu, GZ; Liu, YY; Shi, J; Sun, DH; Wang, WN; Wang, ZH; Zhang, CY; Zhang, S; Zheng, LQ | 1 |
| Andreev, DA; Grishina, EA; Mirzaev, KB; Potapov, PP; Ryzhikova, KA; Samsonova, KI; Sychev, DA | 1 |
| Åkerblom, A; Becker, RC; Cannon, CP; de Souza Brito, F; Himmelmann, A; James, SK; Katus, HA; Lopes, RD; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Abe, S; Inoue, T; Kanaya, T; Koyabu, Y; Nakajima, T; Obi, S; Sakuma, M; Toyoda, S; Yoneda, S | 1 |
| Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J | 1 |
| Benedetto, U; Doble, B; Harris, J; Johnson, TW; Lasserson, D; Loke, Y; Mumford, A; Pithara, C; Pufulete, M; Redwood, S; Reeves, BC; Rogers, CA; Sterne, JAC; Wordsworth, S | 1 |
| Carriero, A; De Luca, G; Kedhi, E; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Gual Capllonch, F; Sancho Cía, JM; Triguero Moreno, A | 1 |
| Hao, Z; Xiang, L; Yang, C; Zheng, L | 1 |
| Koroleva, LY; Korotaeva, ES; Kovaleva, GV; Kuzmenko, EA; Nosov, VP | 1 |
| Aradi, D; Dézsi, CA; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Kiss, RG; Koltowski, L; Komócsi, A; Massberg, S; May, AE; Merkely, B; Mügge, A; Neumann, FJ; Rizas, KD; Ruzsa, Z; Sibbing, D; Trenk, D; Ungi, I; Zeiher, AM | 1 |
| Aradi, D; Baylacher, M; Beuthner, BE; Geisler, T; Gross, L; Hadamitzky, M; Hein-Rothweiler, R; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Kupka, D; Löw, A; Massberg, S; Merkely, B; Orban, M; Rizas, K; Sibbing, D; Trenk, D | 1 |
| Chunhacha, P; Fujise, K; Halim, H; Pinkaew, D; Sinthujaroen, P; Thiagarajan, P | 1 |
| Cai, JJ; Lu, Y; Sun, X; Wang, B; Wu, JR; Wu, QY; Xu, P; Yin, SH; Yuan, H; Zhou, ML | 1 |
| Alapati, V; Benson, MM; Brener, SJ; Chan, D; Cunn, G; Khan, S; Kutkut, I; Narayanan, CA; O'Laughlin, JP; Sacchi, TJ | 1 |
| Cho, MS; Kim, S; Kim, YJ; Nam, GB; Park, DW; Park, JJ; Park, K; Yun, JE | 1 |
| Lee, VW; Nichol, MB; Tomlinson, B; Wang, Y; Wu, J; Yan, BP | 1 |
| Bruno, V; Egger, F; Farhan, S; Freynhofer, MK; Geppert, A; Huber, K; Hübl, W; Rohla, M; Tscharre, M; Weiss, TW; Willheim, M; Wojta, J | 1 |
| Cavallari, LH; Lee, CR | 1 |
| Ding, LY; Li, XZ; Liu, Y | 1 |
| Dinicolantonio, JJ; Serebruany, VL | 2 |
| Angiolillo, DJ; Rollini, F | 1 |
| Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB | 1 |
| Bhatt, DL; Dauerman, HL; Gibson, CM; Goodman, SG; Gruberg, L; Herrmann, HC; Leonardi, S; Lincoff, AM; Lokhnygina, Y; Lopes, RD; Mahaffey, KW; McLaurin, BT; Parikh, KH; Stebbins, A; Stone, GW; Todd, M; White, HD | 1 |
| Finkel, JB; Marhefka, GD; Weitz, HH | 1 |
| Asseburg, C; Giannitsis, E; Katus, H; Theidel, U | 1 |
| Hauge, J; Kragh, R; Poulsen, BK | 1 |
| Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I | 1 |
| Chen, J; Chen, JL; Gao, RL; Han, YL; Qiao, SB; Tang, XF; Wang, J; Wu, Y; Wu, YJ; Xu, B; Yang, YJ; Yuan, JQ; Zhang, JH | 1 |
| Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ | 1 |
| Cannatà, A; Cavallari, I; D'Ambrosio, A; Di Sciascio, G; Dicuonzo, G; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V | 1 |
| Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C | 1 |
| Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S | 1 |
| Homan, DJ; Price, MJ | 1 |
| Becker, RC; Cannon, CP; Harrington, RA; James, SK; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Wang, H; Wang, WE; Wang, X; Zeng, C | 1 |
| Bliden, KP; Gurbel, PA; Swiger, KJ; Tantry, US; Yousuf, O | 1 |
| Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
| Ballesteros Ortega, D; Blancas Gómez-Casero, R; Castro Gallego, O; Chana García, M; Estébanez Montiel, B; López Matamala, B; Marina Martínez, L; Martín Parra, C; Martínez González, O; Prieto Valderrey, F; Quintana Díaz, M; Vigil Escribano, D | 1 |
| Barbato, E; Colonna, G; D'Ambrosio, A; Di Sciascio, G; Mangiacapra, F; Montinaro, A; Pasceri, V; Patti, G; Ricottini, E; Vizzi, V; Wijns, W | 1 |
| Coleman, CI; Limone, BL | 1 |
| Enar, R | 1 |
| Khachikyan, MV; Khaspekova, SG; Mazurov, AV; Ruda, MY; Yakushkin, VV; Zyuryaev, IT | 1 |
| Göddertz, R | 1 |
| Duan, Z; Hu, K; Jiang, Z; Wang, Z; Wu, H; Ye, F; Zhang, Z | 1 |
| Fischer, MJ; Ho, PM; Lowy, E; McDermott, K; Parikh, CR | 1 |
| Chen, Y; Jin, Y; Li, J; Li, X; Li, Y; Lu, C; Ma, C; Qu, F; Wang, H; Xu, B; Yang, J; Yin, T; Zhang, L; Zhang, Y | 1 |
| Huber, K; Lip, GY | 1 |
| Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E | 1 |
| Wheatcroft, S | 1 |
| Abd Elhamid, S; Abulata, N; El Sobky, M; Khafagy, D; Mostafa, A; Zoheir, N | 1 |
| Berger, JS | 1 |
| Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M | 2 |
| Christ, G; Francesconi, M; Grohs, K; Hafner, T; Podczeck-Schweighofer, A; Siller-Matula, JM; Wilhelm, E | 1 |
| Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Andersson, D; Bergström, G; Bernfort, L; Janzon, M; Kaul, P; Lamm, CJ; Levin, LÅ; Storey, RF; Wallentin, L | 1 |
| Cano, P; Conesa, P; Consuegra-Sánchez, L; Dau, D; Jaulent, L; Picó, F; Torres-Moreno, D; Villegas, M | 1 |
| Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ | 1 |
| Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
| Aronow, WS | 2 |
| Gurbel, PA; Tantry, US | 4 |
| Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C | 1 |
| Huo, Y; Li, J | 1 |
| Keßler, M; Koenig, W; Rottbauer, W | 1 |
| Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL | 1 |
| Avanzas, P; Callejo, F; Hernández-Vaquero, D; Llosa, JC; López, J; Morales, C | 1 |
| Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Nagashima, Z; Sugano, T; Tsukahara, K; Umemura, S | 1 |
| Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D | 1 |
| Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Cattaneo, M; Ottani, F | 1 |
| Ahmed, JM; Badar, A; Bagnall, AJ; Edwards, RJ; Egred, M; Keavney, BD; Purcell, IF; Robinson, SD; Scaife, J; Spyridopoulos, I; Yan, AT; Zaman, AG | 1 |
| Alessi, MC; Beguin, S; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Pons, C; Quilici, J | 1 |
| Kreutz, RP; Lu, D; Owens, J | 1 |
| Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Collet, JP; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB | 1 |
| Dinicolantonio, JJ; Norgard, NB | 1 |
| Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD | 1 |
| Bednar, F; Kocka, V; Linkova, H; Sulzenko, J; Tousek, P; Widimsky, P | 1 |
| Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J | 1 |
| Gross, L; Massberg, S; Orban, M; Sibbing, D | 1 |
| Aylward, PE; Sinhal, AR | 1 |
| Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL | 1 |
| D'Ugo, E; De Caterina, R; Rossi, S | 1 |
| Behera, V; Choudhary, G; Gaddam, S; Kim, J; Sharma, S; Wu, WC | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Giugliano, RP; Mogabgab, O; Sabatine, MS; Sloan, S; Wiviott, SD | 1 |
| Angiolillo, DJ; Cardillo, TE; Diodati, JG; Effron, MB; Fisher, HN; French, JK; Fung, AY; Henneges, C; Saucedo, JF | 1 |
| Aradi, D; Bonello, L; Collet, JP; Gulba, D; Huber, K; Husted, S; Kiss, RG; Komócsi, A; Sibbing, D; Storey, RF; Trenk, D | 1 |
| Bauters, A; Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Landel, JB; Lemesle, G; Sudre, A; Susen, S | 1 |
| Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ | 1 |
| Gasche, D; Greiner, RA; Meier, B; Ulle, T | 1 |
| Bangalore, S; Dinicolantonio, JJ; Lavie, CJ; Meier, P; Niazi, AK; O'Keefe, JH | 1 |
| Ecob, R; Hossain, R; Joshi, RR; Judge, HM; Karunakaran, A; Morton, AC; Storey, RF; Wales, C; Walker, JV | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C | 1 |
| Adsett, G; Jayasinghe, R; Markham, R | 1 |
| Lip, G; Marìn, F; Oldgren, J; Rubboli, A | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD | 1 |
| Bansilal, S; Bonaca, MP; Sabatine, MS | 1 |
| Damman, P; Eriksson, P; Erlinge, D; James, SK; Koul, S; Lagerqvist, B; Varenhorst, C | 1 |
| Becker, RC; Cannon, CP; Cornel, JH; Giannitsis, E; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lindholm, D; Mahaffey, KW; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L; Wernroth, L | 1 |
| Campbell, CL; Moliterno, DJ | 1 |
| Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R | 1 |
| Brennan, T; Canestaro, WJ; Chaplin, D; Choudhry, NK; Desai, NR; Kyrychenko, P; Martell, LA; Matlin, OS | 1 |
| Ji, WJ; Jiang, TM; Li, JL; Li, YM; Lu, RY; Luo, T; Shi, R; Yang, GH; Zhang, JQ; Zhang, YY; Zhao, JH; Zhou, X | 1 |
| Bakirci, EM; Borekci, A; Kalkan, K; Karakoyun, S; Sevimli, S; Topcu, S; Vançelik, S | 1 |
| Bakhai, A; Belger, M; Berkenboom, G; Coufal, Z; Norrbacka, K; Sartral, M; Zeymer, U | 1 |
| Verheugt, FW | 2 |
| Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD | 1 |
| Biasucci, LM; Camaioni, C; Cialdella, P; Gustapane, M | 1 |
| Gurbel, PA; Mahla, E; Tantry, US | 1 |
| Horowitz, JD; Karnon, JD; Pekarsky, B; Sorich, MJ; Sorich, W; Wiese, MD | 1 |
| Gau, CS; Hsiao, FY; Lin, CF; Shen, LJ; Wu, FL | 1 |
| Bonello, L; Camoin-Jau, L; Condo, J; Dignat-George, F; Frere, C; Fromonot, J; Gariboldi, V; Guieu, R; Helal, O; Kipson, N; Laine, M; Mancini, J; Paganelli, F; Thuny, F | 1 |
| Ako, J; Kobayashi, M; Morino, Y; Nakamura, M | 1 |
| Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I | 1 |
| Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M | 1 |
| Barrios Alonso, V; del Castillo-Carnevali, H; Zamorano Gómez, JL | 1 |
| Bontardelli, F; Merlini, PA; Notarangelo, MF | 1 |
| Cattaneo, M | 3 |
| Golino, P | 1 |
| Valgimigli, M | 2 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R | 1 |
| Fox, SC; Heptinstall, S; Johnson, A; May, JA; Thomas, MR; Wijeyeratne, YD | 1 |
| Good, RI; Goodall, AH; James, TE; McConnachie, A; McGarrity, A; Miller, H; Oldroyd, KG; Sheehan, R; Stephens, J; Watkins, S | 1 |
| Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Morange, P; Pankert, M; Quilici, J; Verdier, V | 1 |
| Chen, PA; Lei, XM; Li, GL; Li, SN; Liu, Z; Luo, Y | 1 |
| Dalén, M; Holm, M; Ivert, T; Lindvall, G; van der Linden, J | 1 |
| Caiazzo, G; De Rosa, S; Giampà, S; Gulletta, E; Indolfi, C; Micieli, M; Mongiardo, A; Palella, E; Spaccarotella, C; Torella, D | 1 |
| Akdeniz, B; Aytemiz, F; Badak, O; Barış, N; Göldeli, O; Ozpelit, E; Uzel, H | 1 |
| Serebruany, VL | 13 |
| Alexopoulos, D | 1 |
| Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK | 1 |
| Hirschl, MM | 1 |
| Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H | 1 |
| Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Antignano, A; De Amicis, V; Di Tommaso, L; Mannacio, V; Meier, P; Vosa, C | 2 |
| Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA | 1 |
| Chen, SC; Gau, CS; Hsiao, FY; Hsu, WW; Lee, CM | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Juurlink, D | 1 |
| Coons, JC; Harris, J; Schwier, N; Seybert, AL | 1 |
| Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H | 1 |
| Badimon, JJ; Balasubramaniam, K; Marshall, SM; Viswanathan, GN; Zaman, AG | 1 |
| Choi, JL; Han, JY; Kim, BR; Kim, JE; Kim, JM; Kim, KH; Kim, MH; Woo, KS | 1 |
| Beigel, R; Fefer, P; Gannot, S; Hod, H; Matetzky, S; Rosenberg, N; Savion, N; Shechter, M; Varon, D | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Fiedler, KA; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Ott, I; Schlichting, A; Schulz, S; Schunkert, H; Sibbing, D | 1 |
| Henriksson, M; Janzon, M; Nikolic, E; Ohna, A; Wallentin, L | 1 |
| Delzor, F; Nanau, RM; Neuman, MG | 1 |
| Antoniucci, D; De Luca, G; Marino, P; Parodi, G; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Jeong, YH | 1 |
| De Servi, S; Fabiszak, T; Kasprzak, M; Koziński, M; Kubica, J; Navarese, EP; Obońska, K; Rość, D; Siller-Matula, JM; Stankowska, K; Stolarek, W | 1 |
| Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Angiolillo, DJ; Cardillo, TE; Diodati, JG; Duvvuru, S; Effron, MB; Fisher, HN; Henneges, C; Jakubowski, JA; Lipkin, FR; Saucedo, JF; Sundseth, SS; Walker, JR | 1 |
| Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Doktorova, M; Motovska, Z; Ondrakova, M; Widimsky, P | 1 |
| Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Elosua, R; Marrugat, J; Vila, J | 1 |
| Blinc, A; Bozic-Mijovski, M; Kranjec, I; Melkic, E; Noc, M; Steblovnik, K | 1 |
| Daiber, A; Gori, T; Jurk, K; König, J; Krahn, U; Lackner, K; Munzel, T; Schnorbus, B; Warnke, S | 1 |
| Fortmann, SD; Serebruany, VL | 2 |
| Massberg, S; Sibbing, D | 1 |
| Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S | 1 |
| Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Baber, U; Christodoulidis, G; Mehran, R | 1 |
| Budaj, A; Macioch, T; Niewada, M; Pawęska, J; Perkowski, P | 1 |
| Krpan, M; Milicic, D; Pasalic, M; Petricevic, M; Samardzic, J; Skoric, B | 1 |
| Gurbel, PA; Rafeedheen, R; Tantry, US | 1 |
| Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B | 1 |
| Maggioni, AP | 1 |
| Baek, YS; Kim, DH; Kim, SH; Kwan, J; Park, KS; Park, SD; Shin, SH; Woo, SI | 1 |
| Drucker, AG; Januzzi, JL; Manchette, AM | 1 |
| Schühlen, H | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI | 1 |
| Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Gurbel, PA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Sritara, P; White, HD; Zamoryakhin, D | 1 |
| Ang, SC; Bannon, PG; Cao, C; Indraratna, P; Manganas, C; Park, J; Yan, TD | 1 |
| Alström, U; Bertilsson, M; Braun, OÖ; Cannon, CP; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Scirica, BM; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Delle Karth, G; Siller-Matula, JM | 1 |
| Duraj, L; Fedor, M; Fedorová, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Škorňová, I; Staško, J | 1 |
| Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R | 1 |
| Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z | 2 |
| Chen, F; Drenning, D; Lhermusier, T; Lipinski, MJ; Marso, S; Torguson, R; Waksman, R | 1 |
| Bernardo, E; De Agustín, JA; Escaned, J; Feltes, G; Fernández-Ortiz, A; Jiménez-Quevedo, P; Macaya, C; Mejía-Rentería, HD; Nombela-Franco, L; Núñez-Gil, IJ; Vivas, D | 1 |
| Gaglia, MA | 1 |
| Ding, J; Ding, Z; Kunapuli, SP; Li, J; Liu, L; Luo, X; Wen, Z; Ye, J; Zhang, S; Zhang, Y | 1 |
| Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P | 1 |
| Akasaka, T; Arima, Y; Hokimoto, S; Kaikita, K; Mizobe, K; Nakagawa, K; Ogawa, H; Oniki, K | 1 |
| Nishikawa, M | 1 |
| Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Kollslid, R; Lønborg, JT; Paarup Dridi, N; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K | 1 |
| Van de Werf, F | 2 |
| Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Choi, BJ; Choi, SY; Choi, YW; Hwang, GS; Jin, XJ; Lee, YH; Lim, HS; Park, JS; Park, SJ; Seo, KW; Shin, JH; Shin, JS; Tahk, SJ; Yang, HM; Yoon, MH | 1 |
| Cannon, CP; Henriksson, M; James, S; Janzon, M; Mellström, C; Nicolau, JC; Storey, RF; Wallentin, L | 1 |
| Angiolillo, DJ; Barozzi, C; Bartorelli, A; Bianchi, R; Calabrò, P; Capodanno, D; Cattaneo, M; De Carlo, M; De Rosa, R; De Servi, S; Della Riva, D; Généreux, P; Maffeo, D; Mariani, A; Mariani, M; Palmerini, T; Palmieri, C; Piscione, F; Podda, G; Reggiani, LB; Stone, GW; Taglieri, N; Tomasi, L; Toso, A | 1 |
| Crivera, C; Dea, K; Fields, LE; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, JR | 1 |
| Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Vengoechea, F | 1 |
| Biocina, B; Bulum, J; Burcar, I; Petricevic, M | 1 |
| Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Leibowitz, D; Nachmias, B | 1 |
| Judkins, C; Thompson, AG; Thompson, PL | 1 |
| Bagai, A; Chua, D; Cohen, EA; Fitchett, D; Saw, J; Verma, S; Vijayaraghavan, R; Welsh, R | 1 |
| Badia, T; Bellandi, F; Leoncini, M; Maioli, M; Toso, A; Tropeano, F; Villani, S | 1 |
| Anderson, RA; Bundhoo, S; James, PE | 1 |
| Wan, S | 1 |
| Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD | 1 |
| Guo, W; Li, X; Lu, C; Peng, L; Wang, X; Xu, Q; Yang, J; Yin, T; Zhang, L; Zhang, Y | 1 |
| Geersing, GJ; Kappelle, LJ; Verheugt, FW | 1 |
| Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H | 1 |
| Bakheet, MF; Hart, RG; Pearce, LA | 1 |
| González-Pérez, A; Johansson, S; Nagy, P; Rodríguez, LA; Sáez, ME | 1 |
| Abbate, R; Antoniucci, D; Cantini, G; Capodanno, D; Carrabba, N; De Luca, G; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Paniccia, R; Parodi, G; Valenti, R | 1 |
| Iakushkin, VV; Khaspekova, SG; Mazurov, AV; Ruda, MIa; Sirotkina, OV; Ziuriaev, IT | 1 |
| Hu, ZL; Huang, XH; Li, J; Shen, CL; Wang, BN; Wang, XQ | 1 |
| Jiang, XL; Lesko, LJ; Samant, S; Schmidt, S | 1 |
| Ding, XL; Gao, J; Hang, YF; Jiang, B; Miao, LY; Xie, C; Xue, L | 1 |
| Cavallini, C; De Servi, S; Ferlini, M; Leonardi, S | 1 |
| Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K | 1 |
| Qin, J; Sun, Z; Tang, N; Xu, X; Yin, S | 1 |
| Bernheim, AM; Eberli, FR; Erne, P; Kurz, DJ; Pedrazzini, G; Radovanovic, D; Roffi, M; Seifert, B; Windecker, S | 1 |
| Liu, J; Qi, Y; Sun, J; Wang, W; Wang, Y; Zhao, D | 1 |
| Lhermusier, T; Waksman, R | 1 |
| Cohen, DJ; Galper, BZ; Garg, P; Mauri, L; Yeh, RW | 1 |
| Jiang, M; You, JH | 3 |
| Roffman, DS | 1 |
| Anstrom, KJ; Cannon, CP; Cowper, PA; Davidson-Ray, L; Harrington, RA; Janzon, M; Kaul, P; Levin, LÅ; Mark, DB; Nikolic, E; Pan, W; Wallentin, L | 1 |
| Hlatky, MA; Kazi, DS | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Nakamura, M; Nanto, S; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
| Bultas, J | 1 |
| Ando, G; Calabro, P; Costa, F; Leonardi, S; Moscarella, E; Oreto, G; Valgimigli, M; Vranckx, P; Zijlstra, F | 1 |
| Almendro-Delia, M; Arboleda Sánchez, JA; García Rubira, JC; Garcia-Alcantara, Á; Gonzalez-Torres, L; Hidalgo-Urbano, R; Reina-Toral, A; Rodríguez Yañez, JC | 1 |
| Steg, PG; Wiviott, SD | 1 |
| Bozina, N; Ganoci, L; Krpan, M; Milicic, D; Pasalic, M; Petricevic, M; Samardzic, J; Skoric, B | 1 |
| Arnaud, L; Bonello, L; Cointe, S; Dignat-George, F; Frere, C; Guieu, R; Kerbaul, F; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Sabatier, F; Thuny, F | 1 |
| Abbate, R; Caruso, R; Cecchettini, A; Citti, L; Cozzi, L; Giusti, B; Gori, AM; Marcucci, R; Parodi, G; Parodi, O; Parolini, M; Rocchiccioli, S; Romagnuolo, I | 1 |
| Chen, K; Chu, H; Jia, M; Li, L; Li, Z | 1 |
| Alexander, KP; Armstrong, PW; Cyr, DD; Fox, KA; Hochman, JS; Ohman, EM; Prabhakaran, D; Roe, MT; Westerhout, CM; White, HD; Winters, KJ | 1 |
| Chen, Y; Li, X; Liu, J; Lu, C; Peng, L; Wang, X; Xu, Q; Yang, J; Yin, T; Zhang, L; Zhang, Y | 1 |
| Bainey, KR; Ferguson, C; Sharma, A | 1 |
| Bednar, F; Knot, J; Maly, M; Motovska, Z; Ondrakova, M; Ulman, J | 1 |
| Bomb, R; Khouzam, RN; Oliphant, CS | 1 |
| Abbate, R; Calabretta, R; Cecchi, E; Chiostri, M; Cordisco, A; Gensini, GF; Giglioli, C; Innocenti, L; Marcucci, R; Mecarocci, V; Romano, SM; Spini, V | 1 |
| Baan, J; Barbanti, M; Blanchard, D; Delewi, R; Durand, E; Eltchaninoff, H; Hassell, ME; Hildick-Smith, D; Kikkert, WJ; Piek, JJ; Poliacikova, P; Rubino, P; Sharma, S; Stabile, E; Tamburino, C; Ussia, GP; Wiegerinck, EM | 1 |
| Aires, D; Deibert, B; Fischer, R; Fraga, G; Gillihan, R; Gollub, S; Laarman, R; Maybrook, RJ | 1 |
| Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M | 1 |
| Cui, C; Qiao, R; Zhang, J | 2 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Reid, C; Yudi, MB | 1 |
| Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM | 1 |
| Alfredsson, J; Gustafsson, KM; Janzon, M; Jonasson, L; Lindahl, TL; Logander, E; Nilsson, L; Swahn, E | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 4 |
| Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ | 1 |
| Chua, T; Gruntowicz, D; Johnson, SG; Morlock, RJ | 1 |
| Ahsan, CH; Ali, ML; Amin, MN; Chowdhury, MZ; Haq, MM; Karim, MR; Khan, SR; Mansur, M; Millat, MH; Rashid, MA | 1 |
| Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S | 1 |
| Bin, H; Liping, Z; Qiming, F | 1 |
| Cao, H; Wang, DG; Wei, YQ; Yang, H | 1 |
| Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Hur, SH; Jeong, JO; Kim, DI; Kim, HS; Park, HS; Ryu, DR; Song, PS; Song, YB | 1 |
| An, L; Du, D; Lai, X; Li, Y; Wang, F; Zhang, Z | 1 |
| Elis, A; Lishner, M; Pereg, D; Yahia, DH | 1 |
| Li, J; Lin, G; Wang, L; Xie, J; Yi, L; Zhang, K; Zhang, R | 1 |
| Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Hafley, G; Melloni, C; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Zamoryakhin, D | 1 |
| Ford, NF | 2 |
| Chong, AY; Qutub, MA; So, DY | 1 |
| Hizoh, I; Horvath, Z; Kiss, N; Kiss, RG; Kovacs, A; Lee, S; Toth-Zsamboki, E | 1 |
| Azevedo, A; Bennett, K; Dias, P; Laszczynska, O; Lopes-Conceição, L; Lunet, N; Pereira, M | 1 |
| Liu, J; Lu, Y; Nie, XY; Shi, LW; Wang, WM; Zhang, Y | 1 |
| Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL | 1 |
| Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M | 1 |
| Chen, CY; Chiang, YT; Hsieh, CF; Huang, WF | 1 |
| Banya, W; Booth, J; Dalby, M; Davidson, SJ; Droppa, M; Flather, M; Gawaz, M; Geisler, T; Karathanos, A; Müller, K; Stables, RH; Tavlaki, E; Yanez-Lopez, M; Zaman, A | 1 |
| Di Pasquale, G; Rubboli, A | 1 |
| Chen, Y; Cong, H; Dong, W; Hong, T; Li, Z; Wan, Z; Yin, T | 1 |
| Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M | 1 |
| Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J | 1 |
| Berman, E; Boccara, F; Carrie, D; Cattan, S; Cayla, G; Diallo, A; Douard, H; Dreyfus, X; Eltchaninoff, H; Falquier, JF; Furber, A; Georges, JL; Hammoudi, N; Helft, G; Henry, P; Komajda, M; Le Feuvre, C; Leclercq, F; Metzger, JP; Michel, PL; Sebagh, L; Steg, PG; Tuambilangana, A; Vicaut, E | 1 |
| Akdeniz, B; Alpaslan, E; Edem, E; Kınay, AO; Kirdök, AH; Pabuccu, MT; Taş, S; Tekin, Üİ | 1 |
| Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ | 1 |
| Li-Sha, G; Peng, C; Yue-Chun, L | 1 |
| Armstrong, PW; Bhatt, DL; Corbalán, R; Fox, KA; Goodman, SG; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; Neely, B; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; Verheugt, FW; White, HD; Winters, KJ | 1 |
| Armstrong, PW; Clemmensen, P; Cornel, JH; Cyr, DD; Fox, KA; Hochman, JS; Huber, K; McGuire, DK; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Zamoryakhin, D | 1 |
| Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ | 1 |
| Crivera, C; Dea, K; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, J | 1 |
| Brodie, BR; Garg, A; Kirtane, AJ; Maehara, A; Mehran, R; Metzger, DC; Neumann, FJ; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B | 1 |
| Abtan, J; Barthélémy, O; Brugier, D; Collet, JP; Hulot, JS; Kerneis, M; Mansencal, N; Montalescot, G; O'Connor, SA; Payot, L; Rousseau, H; Silvain, J; Vicaut, E; Vignalou, JB | 1 |
| Anderson, RA; Freeman, PM; Hinz, C; James, PE; Kinnaird, TD; Moschonas, KE; O'Donnell, VB | 1 |
| Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D | 1 |
| Ako, J; Morino, Y; Nakamura, M; Okuizumi, K; Usami, M | 1 |
| Bundhun, PK; Chen, MH; Qin, T | 1 |
| Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Ardissino, D; Bianchessi, M; Boffetti, F; Caporale, V; Casu, G; Cereda, M; Cocci, A; Coppini, L; Crocamo, A; del Giudice, F; Demola, MA; Guidorossi, A; Manzalini, C; Marziliano, N; Merlini, PA; Notarangelo, MF; Orsini, F; Pigazzani, F; Pirola, D | 1 |
| O'Donoghue, ML; Sarma, A | 1 |
| Bonnet, JL; Cuisset, T; Pankert, M; Salaun, E | 1 |
| Kim, MH; Pokov, AN; Serebruany, VL; Tomek, A | 1 |
| Giusti, B; Grifoni, E; Marcucci, R | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H | 1 |
| Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X | 1 |
| Bergmeijer, TO; de Boer, MJ; de Vrey, E; Deneer, VH; Groenemeijer, BE; Heestermans, AA; Ishak, M; Janssen, PW; Jukema, JW; Kelder, JC; Qaderdan, K; ten Berg, JM; van't Hof, AW; Vos, GJ; Voskuil, M | 1 |
| Abtan, J; Amour, J; Barthélémy, O; Brugier, D; Collet, JP; Kerneis, M; Leprince, P; Martin, R; Mercadier, A; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Antman, EM; Close, SL; Collet, JP; Delaney, JT; Duvvuru, S; Hulot, JS; Man, M; Mega, JL; Murphy, SA; Paré, G; Price, MJ; Sabatine, MS; Sibbing, D; Simon, T; Sundseth, SS; Trenk, D; Walker, JR; Wiviott, SD | 1 |
| Al Meman, AA; Khalaf, H; Rasool, S | 1 |
| Beltrame, F; Benati, M; Calabria, S; Cattaneo, M; Danese, E; Fava, C; Gelati, M; Gottardo, R; Guidi, GC; Minuz, P; Tagliaro, F; Tavella, D | 1 |
| Sachdeva, A | 1 |
| Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D | 1 |
| Brodie, BR; Clemmensen, P; Cox, DA; Dangas, GD; Duffy, PL; Henry, TD; Kirtane, AJ; Litherland, C; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Schoos, MM; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Yu, J | 1 |
| Cai, JX; Deng, SB; Du, J; Du, JL; Liu, YJ; Qu, GS; She, Q; Wang, DQ; Zhang, JR | 1 |
| Bayon, J; Carrillo, P; CruzGonzalez, I; de la Torre Hernandez, JM; de Leiras, SR; Fernandez-Fernandez, J; Fernandez-Portales, J; Gomez-Jaume, A; Gopar-Gopar, S; Hernandez, F; Lasa, G; Lozano, I; Mañas, P; Pérez-Serradilla, A; Pinar, E; Ruiz-Quevedo, V; Sanchez-Insa, E | 1 |
| Acosta Martínez, J; Cubero Gómez, JM; Díaz De La Llera, LS; Fernández-Quero, M; Guisado Rasco, A; Mendias Benítez, C; Sánchez González, Á; Villa Gil-Ortega, M | 1 |
| Chava, S; Schneider, DJ | 1 |
| Abbate, R; Antoniucci, D; Gensini, GF; Giusti, B; Gori, AM; Grifoni, E; Marcucci, R; Migliorini, A; Paniccia, R; Parodi, G; Valenti, R | 1 |
| Friedman, HS; Heithoff, K; Navaratnam, P; Reed Chase, M; Simpson, RJ | 1 |
| Bui, AH; Cannon, CP; Guo, J; Held, C; Himmelmann, A; Husted, S; Im, K; James, SK; Michelson, EL; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Aisu, H; Hamada, M; Higashi, H; Hitsumoto, T; Ikeda, S; Inaba, S; Morofuji, T; Ohshima, K; Saito, M; Sumimoto, T; Takahashi, K | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; Luca, GD; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Angiolillo, DJ; Carlson, G; Franchi, F; Khan, N; Mehran, R; Raveendran, G; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y | 1 |
| Bălaşa, R; Bănescu, C; Dobreanu, M; Maier, S; Mărginean, A; Mărginean, M; Moldovan, V; Scridon, A; Ţăruşi, M | 1 |
| Armstrong, PW; Chin, CT; Corbalán, R; Fox, KA; Magnus Ohman, E; Neely, B; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB | 1 |
| Armstrong, PW; Bhatt, DL; Doll, JA; Duvvuru, S; Fox, KAA; Gurbel, PA; Jakubowski, JA; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Sundseth, SS; White, HD; Winters, KJ | 1 |
| Fleck, E; Graf, K; Kaufmann, J; Schroeder, T; Stawowy, P; Stockmann, H; Storm, C; Wellnhofer, E | 1 |
| Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX | 1 |
| Angiolillo, DJ; Capodanno, D | 2 |
| Ebina, T; Hibi, K; Imoto, K; Karube, N; Kimura, K; Nagashima, Z; Tsukahara, K; Uchida, K; Umemura, S | 1 |
| Ardissino, D; Armstrong, PW; Bhatt, DL; Fox, KA; Goodman, SG; Hamm, CW; Leonardi, S; Lopes, RD; Martinez, F; Neely, B; Neely, ML; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ | 1 |
| Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hahalis, G; Hamilos, M; Kanakakis, I; Pentara, I; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I | 1 |
| Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R | 1 |
| Baruzzi, AC; da Silva, EE; de Barros e Silva, PG; Ribeiro, HB | 1 |
| Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ | 1 |
| Ruiz-Nodar, JM | 1 |
| Biscaglia, S; Campo, G; Ferrari, R; Pavasini, R; Tebaldi, M; Tumscitz, C | 1 |
| Geraldine, P; Jayakumar, T; Sheu, JR; Yang, CH; Yen, TL | 1 |
| Jain, N; Reilly, RF | 1 |
| Behl, S; Ganah, H; Jarrar, M; Manyam, G; Moustafa, K; Nasab, R; Nazir, M | 1 |
| Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B | 1 |
| Bonello, L; Dignat-Georges, F; Fromonot, J; Guieu, R; Kipson, N; Mottola, G; Paganelli, F; Rossi, P; Ruf, J | 1 |
| Joob, B; Wiwanitkit, V | 1 |
| Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF | 1 |
| Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A | 1 |
| Becher, A; Jennings, E; Johansson, S; Westergaard, M; Zeymer, U | 1 |
| Bhatt, DL; Cannon, CP; Cohen, M; Cryer, BL; Doros, G; Goldsmith, MA; Hsieh, WH; Laine, L; Lanas, A; Lapuerta, P; Liu, Y; Schnitzer, TJ; Shook, TL; Vaduganathan, M | 1 |
| Aquino, M; Baber, U; Baker, B; Chandrasekhar, J; DeFranco, A; Effron, M; Faggioni, M; Henry, T; Kapadia, S; Keller, S; Kini, A; Mehran, R; Muhlestein, B; Pocock, S; Rao, S; Sartori, S; Strauss, C; Toma, C; Weintraub, W; Weiss, S | 1 |
| Borna, C; Brown, P; Erlinge, D; Gidlöf, O; Jakubowski, JA; Lood, C; Truedsson, L; Wagner, H; Winters, K; Zhou, C | 1 |
| Armstrong, PW; Boden, WE; Fox, KA; Hafley, G; Hagström, E; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Sidhu, MS; White, HD; Winters, KJ | 1 |
| Berbis, J; Bonello, L; Dignat-George, F; Frere, C; Kerbaul, F; Laine, M; Lemesle, G; Paganelli, F; Roch, A; Thuny, F | 1 |
| Bal Dit Sollier, C; Deye, N; Dillinger, JG; Drouet, L; Henry, P; Llitjos, JF; Megarbane, B; Sideris, G; Voicu, S | 1 |
| Fukuda, K; Ishikawa, S; Kodaira, M; Kohsaka, S; Maekawa, Y; Miyata, H; Negishi, K; Numasawa, Y; Ohki, T; Sueyoshi, K; Ueda, I | 1 |
| Kulmurzaeva, N; Kurmanalina, G; Seytmaganbetova, N; Smagulova, G; Talipova, I | 1 |
| Dadjou, Y; Kojuri, J; Safavi, S | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D | 1 |
| Borzi, M; Caporale, R; Casolo, G; Colivicchi, F; Di Bartolomeo, R; Formigli, D; Geraci, G; Gerometta, P; Gulizia, MM; Ledda, A; Menozzi, A; Musumeci, G; Romeo, F; Scherillo, M; Tarantini, G | 1 |
| Angiolillo, DJ; Barozzi, C; Bartorelli, A; Calabrò, P; Capodanno, D; Cattaneo, M; Crimi, G; De Carlo, M; De Servi, S; Della Riva, D; Maffeo, D; Palmerini, T; Palmieri, C; Piscione, F; Tomasi, L; Toso, A | 1 |
| Guo, YM; Li, HZ; Li, Z; Sun, HL; Zhang, L; Zhao, ZC | 1 |
| Aksakal, E | 1 |
| Abaci, A | 1 |
| Tokgözoğlu, L | 1 |
| French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
| Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W | 1 |
| Goudevenos, JA; Ntalas, IV; Tatsidou, PT; Tselepis, AD; Tsoumani, ME | 1 |
| Chao, TH; Chen, IC; Chen, Y; Cheng, CL; Fang, CC; Lee, CH; Li, YH; Lin, CC; Lin, CY; Yu, CL | 1 |
| Lai, Y; Li, J; Liu, X; Luo, Y; Wang, Y; Xu, J; Yao, Y; Zheng, SL | 1 |
| Caiazzo, G; Carino, A; De Rosa, S; Filippis, C; Indolfi, C; Mongiardo, A; Polimeni, A; Sabatino, J; Sorrentino, S; Spaccarotella, C; Strangio, A; Torella, D | 1 |
| Chang, K; Choi, IJ; Choi, YS; Chung, WS; Her, SH; Kim, HS; Kim, PJ; Koh, YS; Park, CS; Park, HJ; Park, MW; Seung, KB; Shin, JG | 1 |
| Batrićević, G; Bošković, A; Bulatović, N; Kalezić, M; Knežević, B; Musić, L; Nenezić, A; Vujović, J | 1 |
| Abu-Assi, E; Alexopoulos, D; Alfonso, E; Ariza-Sole, A; Chen, Y; Correia, L; D'Ascenzo, F; Fan, JY; Filipiak, K; Fujii, T; Gaita, F; Garay, A; García-Acuña, JM; Giordana, F; González-Juanatey, JR; Henriques, JP; Huczek, Z; Ikari, Y; Kalpak, O; Kawaji, T; Kawashiri, MA; Kedev, S; Kikkert, WJ; Kowara, M; Liebetrau, C; Möllmann, H; Montefusco, A; Moretti, C; Nakahayshi, T; Nie, SP; Nuñez-Gil, I; Osman, N; Raposeiras-Roubín, S; Sakata, K; Saucedo, J; Scarano, S; Shiomi, H; Song, X; Southern, D; Terol, B; Wang, X; Wilton, SB; Xanthopoulou, I; Yamagishi, M; Yan, Y; Zhang, D | 1 |
| Chen, C; Chen, EZ; Cui, M; Tan, SC; Tu, CC; Wang, XL | 1 |
| Khan, N | 1 |
| Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L | 1 |
| Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X | 1 |
| Guzauskas, GF; Serbin, MA; Veenstra, DL | 1 |
| Armstrong, PW; Bhatt, DL; Corbalán, R; Cyr, DD; Fox, KA; Jackson, LR; Lopes, RD; Lüscher, TF; Magnus Ohman, E; Martinez, F; Neely, ML; Piccini, JP; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ | 1 |
| Fukumoto, Y; Katsuda, Y; Katsuki, Y; Kawasaki, T; Koiwaya, H; Murasato, Y; Otsuka, Y; Sasaki, KI; Shibata, Y; Shimamatsu, J; Ueno, T; Umeji, K | 1 |
| Chang, CY; Chen, YC; Lin, SY; Tsai, CH; Tsai, JR | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Anstrom, KJ; Armstrong, PW; Boden, WE; Clapp-Channing, N; Cowper, P; Davidson-Ray, L; Fakhouri, W; Fox, KA; Gašparović, V; Hochman, JS; Kaul, P; Knight, JD; Mark, DB; McCollam, P; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD | 1 |
| Ariotti, S; Baldo, A; Esposito, G; Franzone, A; Gargiulo, G; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Valgimigli, M; Windecker, S | 1 |
| Ahn, JH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, K; Koh, JS; Kwak, CH; Park, HW; Park, JR; Park, Y; Tantry, US | 1 |
| De Servi, S; Ferlini, M; Goedicke, J; Montalescot, G; Palmerini, T; Syvänne, M | 1 |
| Althouse, AD; Conrad Smith, AJ; Khandhar, SJ; Kudaravalli, M; Lee, JS; Marroquin, OC; Mulukutla, SR; Schindler, JT; Sharbaugh, MS; Toma, C | 1 |
| Bhat, A; Pang, M; Wu, Y; Zhang, H; Zhang, Y; Zhao, Y; Zhuang, K | 1 |
| Adriaenssens, T; Bernlochner, I; Byrne, RA; Fischer, M; Han, Y; Ibrahim, T; Jacobshagen, C; Kastrati, A; Kufner, S; Lahmann, AL; Laugwitz, KL; Lohaus, R; Maeng, M; Mayer, K; Mehilli, J; Michel, J; Morath, T; Neumann, FJ; Schulz-Schüpke, S; Schunkert, H; Seyfarth, M; Ten Berg, JM; Tölg, R; Wöhrle, J; Wolk, A; Zrenner, B | 1 |
| Choi, JL; Han, JY; Kim, BR; Kim, JM; Kim, KH; Kim, MH; Woo, KS | 1 |
| Aradi, D; Baylacher, M; Dézsi, CA; Felix, SB; Geisler, T; Gori, T; Gross, L; Hadamitzky, M; Hausleiter, J; Holdt, L; Horstkotte, J; Huber, K; Huczek, Z; Ince, H; Jacobshagen, C; Kiss, RG; Koltowski, L; Komócsi, A; Löw, A; Malek, L; Massberg, S; Mehilli, J; Merkely, B; Mudra, H; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, R; Sibbing, D; Teupser, D; Thalmeier, A; Trenk, D | 1 |
| Agueznai, M; Ardouin, P; Beygui, F; Blanchart, K; Collet, JP; Lemaître, A; Milliez, P; Montalescot, G; Roule, V; Sabatier, R | 1 |
| Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Lev, EI | 1 |
| Gershlick, AH; Gunarathne, A; Hussain, S | 1 |
| Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A | 1 |
| Gurbel, PA; Kubica, J; Myat, A; Tantry, US | 1 |
| Kinsara, AJ | 1 |
| Bernick, J; Chong, AY; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Lugomirski, P; Marquis, JF; Maze, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY; Wells, G | 1 |
| Anstrom, KJ; Baker, BA; Cohen, DJ; Effron, MB; Fosbøl, EL; Ju, C; Messenger, JC; Peterson, ED; Waksman, R; Wang, TY; Zettler, ME | 1 |
| Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M | 1 |
| Ardissino, D; Armstrong, PW; Bhatt, DL; Cornel, JH; Erlinge, D; Fox, KA; Gurbel, PA; Jakubowski, JA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD | 1 |
| Choi, HK; Choi, YK; Ghim, JL; Jung, JA; Shon, J | 1 |
| Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A | 1 |
| Bensenor, IM; Bittencourt, MS; Brandão, RM; Goulart, AC; Kisukuri, AL; Lotufo, PA; Santos, IS; Santos, RC; Sitnik, D; Staniak, HL | 1 |
| Cho, K; Do, JM; Dufour, AB; Faxon, DP; Gagnon, DR; Kinlay, S; Ly, S; Michael Gaziano, J; Ostrowski, S; Quach, L; Wimmer, NJ | 1 |
| Bortolin, RH; Bravo, M; Brion, M; Carracedo, A; Concheiro, M; Cruz, A; Germano, JF; Hirata, MH; Hirata, RD; Iñiguez, A; López-Rivadulla, M; Luchessi, AD; Quintela, O; Silbiger, VN; Sousa, AG | 1 |
| Gao, Y; Guan, QG; Guo, L; Jia, DL; Li, YZ; Qi, GX; Sun, YX; Tian, W; Xin, YG; Xu, F; Yu, HJ; Zhang, HS; Zhang, XG; Zhang, YL | 1 |
| Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C | 1 |
| Cavallari, LH; Obeng, AO | 1 |
| Mukherjee, D; Naidu, SS; Nairooz, R; Pothineni, NV; Raina, S; Rochlani, Y; Sardar, P; Shavelle, DM; Valgimigli, M | 1 |
| Cho, DK; Choi, JH; Choi, SH; Doh, JH; Gwon, HC; Hahn, JY; Kim, SH; Lee, JB; Lee, JM; Lee, SH; Oh, JH; Park, TK; Song, YB; Yang, JH | 1 |
| Dong, W; Dong, Y; Feng, W; He, H; Lu, J; Ma, J; Tian, H; You, H; Zhang, L | 1 |
| Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A | 1 |
| Berringer, R; Wonnacott, D | 1 |
| Bian, S; Dong, P; Yang, X | 1 |
| Bustos, L; De la Puente, C; Lanas, F; Vallejos, C; Velasquez, M; Zaror, C | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Q; Xue, Y | 1 |
| Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J | 1 |
| Hsiao, FY; Huang, TY; Lee, CM; Lin, ZF; Shen, LJ; Tsai, YW; Wang, CY | 1 |
| Farkouh, ME; Fuster, V; Goodman, SG; Hamza, TH; Siami, FS; van Diepen, S; Verma, S | 1 |
| Abizaid, A; Angelini, GD; Bacchi Reggiani, L; Benedetto, U; Bhatt, DL; Biondi-Zoccai, G; Chieffo, A; Colombo, A; Della Riva, D; Feres, F; Généreux, P; Gilard, M; Hong, MK; Jang, Y; Kim, BK; Kim, HS; Morice, MC; Palmerini, T; Park, KW; Pufulete, M; Sangiorgi, D; Stone, GW; Valgimigli, M; White, J | 1 |
| Chen, N; Ding, P; Liu, H; Wei, Y | 1 |
| Lee, VWY; Liew, D; Wang, Y; Yan, BP | 1 |
| Beauloye, C; Claeys, MJ; Pourbaix, S; Sinnaeve, PR | 1 |
| Barbour, C; Gesheff, T | 1 |
| Cui, C; Qiao, R; Yang, S; Zhang, J | 1 |
| Liu, N; Zhang, H; Zhang, J; Zhang, L | 1 |
| Castillo-Moreno, JA; Conesa-Zamora, P; Consuegra-Sánchez, L; García de Guadiana, L; García-Lagunar, MH; Melgarejo-Moreno, A; Ruiz-Cosano, J; Soria-Arcos, F; Vivar, PC | 1 |
| Angiolillo, DJ; Gaglia, MA; Kiramijyan, S; Lhermusier, T; Lipinski, MJ; Pokharel, S; Steinvil, A; Storey, RF; Torguson, R; Waksman, R; Wallentin, L | 1 |
| Hu, D; Li, C; Shen, X; Sun, Y; Tao, M; Wang, DW; Yu, T; Zhang, L; Zhang, X | 1 |
| Kang, PF; Li, H; Li, MN; Li, Y; Lu, DY; Shi, XJ; Tang, Y; Wang, HJ | 1 |
| Chan, R; Kong, SL; Kwok, J; Lee, S; Shea, C; Siu, D; Tam, CC; Tang, WH; Wong, A; Yung, A | 1 |
| Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW | 1 |
| Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M | 1 |
| Bae, JW; Hur, SH; Jeon, DW; Kim, BS; Kim, HS; Koo, BK; Lee, H; Lee, JH; Lee, NH; Lim, SW; Oh, SK; Park, KW; Park, TH; Rha, SW; Shin, ES | 1 |
| Jennings, LK; Saucedo, JF | 1 |
| Alberts, MJ; Hanley, DF; Serebruany, VL | 1 |
| Dixon, SR; Grines, CL; O'Neill, WW | 1 |
| Becker, RC; Cannon, CP; Goodman, SG; Gutterman, D; Guyatt, GH; Harrington, RA; Lincoff, AM; Popma, JJ; Steg, G | 1 |
| Filipiak, KJ; Grabowski, M; Huczek, Z; Kisiel, B; Kostrzewa, G; Malek, LA; Opolski, G; Ploski, R; Spiewak, M | 1 |
| Cundiff, DK | 1 |
| Kasyanova, O; Shpektor, A; Vasilieva, E | 1 |
| Barker, CM; Price, MJ | 1 |
| Antonino, MJ; Gurbel, PA; Tantry, US | 1 |
| Sosnowski, C | 1 |
| Cambronero, F; Caro, C; Garrido, IP; Lip, GYH; Manzano-Fernández, S; Marín, F; Pascual-Figal, DA; Pastor, FJ; Pinar, E; Valdés, M | 1 |
| Angiolillo, DJ; Bass, TA; Guzman, LA | 1 |
| Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD | 1 |
| Chen, L; Gai, LY; Jin, J; Li, HY; Li, RB; Lin, L; Liu, CX; Liu, HB; Ren, YH; Wang, CY; Wang, HY; Wang, Y; Xin, YH; Xu, XL; Yang, TS | 1 |
| Alessi, MC; Bonnet, JL; Cuisset, T; Frere, C; Quilici, J; Uhry, S | 1 |
| Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF | 1 |
| Preobrazhenskiĭ, DV | 2 |
| D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Nusca, A; Patti, G | 1 |
| Asghar, O; McKay, E; Ramsdale, DR; Ramsdale, KA; Rao, A | 1 |
| Cayla, G; Leclercq, F; Macia, JC; Piot, C; Rabesendratana, H; Roubille, F; Schved, JF | 1 |
| Ajani, AE; Al-Fiadh, A; Andrianopoulos, N; Black, A; Brennan, AL; Clark, DJ; Duffy, SJ; Gurvitch, R; Lefkovits, J; Lew, R; New, G; Reid, CM; Shaw, JA; Yan, BP | 1 |
| Wiviott, SD | 1 |
| Banerjee, S; Brilakis, ES; Kelly, KC; Little, BB; Rao, SV; Reilly, RF; Samuel, J; Varghese, C; Weideman, RA | 1 |
| Halperin, JL; Rubboli, A | 1 |
| Marín, F; Roldán, V | 1 |
| Becker, RC; Berger, JS; Edwards, FH; Frye, CB; Harshaw, Q; Steinhubl, SR | 1 |
| Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S | 1 |
| Dachs, R; Darby-Stewart, A; Graber, MA | 1 |
| Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G | 1 |
| Amoroso, G; Kiemeneij, F; Laarman, GJ; Patterson, MS; Riezebos, RK; Ronner, E; Slagboom, T; Smits, PC; Suttorp, MJ; ten Berg, JM; Ter Bals, E; Tijssen, JG | 1 |
| Bauer, T; Gitt, AK; Heer, T; Juenger, C; Senges, J; Towae, F; Zahn, R; Zeymer, U | 1 |
| Shen, J; Zhang, Q; Zhang, RY | 1 |
| De Servi, S; Mariani, G; Mariani, M | 1 |
| Antman, EM; Brandt, JT; Braunwald, E; Close, SL; Hockett, RD; Macias, W; Mega, JL; Sabatine, MS; Shen, L; Walker, JR; Wiviott, SD | 1 |
| Storey, RF | 1 |
| Di Sciascio, G; Patti, G | 1 |
| Bajorek, BV; Vermeer, NS | 1 |
| Freedman, JE; Hylek, EM | 1 |
| Bhatt, DL | 3 |
| Price, MJ | 4 |
| Collet, JP; Montalescot, G | 2 |
| Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R | 1 |
| Alonso Orcajo, N; Alonso Rodríguez, D; Carbonell de Blas, R; Cuellas Ramón, C; de Miguel Castro, A; Diego Nieto, A; Fernández Vázquez, F; Pascual Vicente, C; Pérez de Prado, A; Samaniego Lampón, B | 1 |
| Faxon, DP; Freedman, JE | 1 |
| Fihn, SD; Ho, PM; Jesse, RL; Maddox, TM; Peterson, ED; Rumsfeld, JS; Wang, L | 1 |
| Giugliano, RP; Thomas, D | 2 |
| Husted, S | 2 |
| Kala, P; Motovska, Z | 1 |
| Pollack, CV; Slattery, D | 1 |
| Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| DeYoung, JP; Fox, KA; Gallo, R; Goodman, SG; Gore, JM; Grondin, FR; Rao, RV; Rose, B; Spencer, FA; Yan, AT; Yan, RT | 1 |
| Han, Y; Jing, Q; Li, Y; Shu, Q; Tang, X; Wang, D; Wang, S; Wang, Z | 1 |
| Sabatine, MS | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Mitchell, P; Storey, RF | 1 |
| Abdoo, AD; Brackbill, ML; Harralson, AF; Kidd, RS; Warner, JG | 1 |
| Caraccciolo, EA; Chrissoheris, M; Ionescu, CN | 1 |
| Spinler, SA | 1 |
| Bonvini, RF; Fontana, P; Mach, F; Reny, JL; Zeller, T | 1 |
| Ebina, T; Hashiba, K; Hibi, K; Kimura, K; Kiyokuni, M; Komura, N; Kosuge, M; Morita, S; Nakayama, N; Umemura, S | 1 |
| Marian, AJ | 1 |
| Chua, D; Ignaszewski, A | 1 |
| Ahn, CM; Hong, SJ; Kim, KA; Kim, YH; Lim, DS; Park, JS; Park, JY; Park, SM; Shim, WJ | 1 |
| Angiolillo, DJ; Capranzano, P; Ferreiro, JL | 1 |
| Gibler, WB; Harrington, RA; Ohman, EM; Ou, FS; Peterson, ED; Roe, MT; Wang, TY | 1 |
| Alonso-Orcajo, N; Calabozo, RG; Carbonell, R; Cuellas, C; de Miguel, A; Diego, A; Fernandez-Vazquez, F; Pascual, C; Perez de Prado, A; Samaniego, B | 1 |
| Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP | 1 |
| Marzot, F; Pengo, V | 1 |
| Budziaszek, Ł; Czaniecka, M; Gajos, G; Kleczkoska, A; Podolec, J; Zmudka', K | 1 |
| Bilińska, ZT; Kłopotowski, M; Małek, LA; Ruzyłło, W; Sitkiewicz, D; Witkowski, A | 1 |
| Das, K; Das, P; Koshy, SK; Robinson, A | 1 |
| Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD | 1 |
| Bass, TA | 1 |
| Ball, J | 1 |
| Burrill, PD | 1 |
| Anderson, HV; Barker, CM | 1 |
| Cox, DA; Dyke, C; Ebrahimi, R; Feit, F; Gersh, BJ; Lincoff, AM; Manoukian, SV; Mehran, R; Moses, JW; Ohman, EM; Stone, GW; Ware, JH; White, HD | 1 |
| Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH | 1 |
| Kapoor, JR | 2 |
| Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L | 1 |
| Angiolillo, DJ; Ferreiro, JL | 1 |
| Bjessmo, S; Lindvall, B; Lindvall, G; Sartipy, U; Svenarud, P; van der Linden, J | 1 |
| Amsterdam, EA | 1 |
| Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, B; Wang, DM; Wang, G; Wang, SL; Wang, ZL; Xu, K | 1 |
| Rees, C; Spinler, SA | 1 |
| Alessi, MC; Cuisset, T; Frére, C; Gaborit, B; Hulot, JS | 1 |
| Gibson, CM; Hollander, JE; Pollack, CV | 1 |
| Harrington, RA; Sellers, MB; Tricoci, P | 1 |
| Eberli, FR; Roffi, M | 1 |
| Mascarenhas, D; Patel, SS | 1 |
| Brophy, JM; Filion, KB; Schneider-Lindner, V | 1 |
| Chae, YK; Kim, J | 1 |
| Hayes, S | 1 |
| Barada, K; Dakik, HA | 1 |
| Burch, J; Craigs, C; Golder, S; Palmer, S; Rogowski, W; Woolacott, N | 1 |
| Husted, S; van Giezen, JJ | 1 |
| Wallentin, L | 1 |
| Kittisupamongkol, W | 1 |
| Cheng, WJ; Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ | 1 |
| Duggan, ST; Keating, GM | 1 |
| Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD | 1 |
| Carrel, T; Englberger, L | 1 |
| Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C | 1 |
| Armero, S; Bonello, L; Camoin-Jau, L; Paganelli, F; Palot-Bonello, N | 1 |
| Schömig, A | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L | 1 |
| Antman, EM; Bates, ER; Braunwald, E; Close, SL; Hautvast, RW; Mega, JL; Michelson, AD; Murphy, SA; O'Donoghue, ML; Rozenman, Y; Sabatine, MS; Shen, L; Ver Lee, PN; Wiviott, SD | 1 |
| Abbate, R; Bandinelli, B; Cecchi, E; Gensini, GF; Giglioli, C; Lazzeri, C; Mannini, L; Marcucci, R; Paniccia, R; Valente, S | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Cayla, G; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J | 1 |
| Bett, N; Juneja, M; Ray, MJ; Walters, DL | 1 |
| Diercks, DB; Fermann, GJ; Gibler, WB; Hoekstra, JW; Milford-Beland, S; Ohman, EM; Peacock, WF; Peterson, ED; Pollack, CV; Raja, AS; Roe, MT; Summers, R | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Brissy, O; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J | 1 |
| Aranki, SF; Body, SC | 1 |
| Bertrand, ME; Cox, DA; Dangas, GD; Fahy, M; Feit, F; Kirtane, AJ; Lansky, AJ; Lincoff, AM; Manoukian, SV; McLaurin, B; Mehran, R; Moses, JW; Nikolsky, E; Ohman, EM; Stone, GW; White, HD | 1 |
| Filipiak, KJ; Kisiel, B; Kostrzewa, G; Małek, ŁA; Opolski, G; Płoski, R; Serafin, A; Spiewak, M | 1 |
| Aoki, J; Brodie, BR; Caixeta, A; Dangas, G; Dudek, D; Guagliumi, G; Kornowski, R; Mehran, R; Parise, H; Peruga, JZ; Rabbani, LE; Stone, GW; Witzenbichler, B | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J | 1 |
| Bae, JP; Dobesh, PP; Khoynezhad, A; McCollam, PL | 1 |
| Chastek, B; Hauch, O; Riedel, AA; Wygant, G | 1 |
| Bhatt, DL; Cannon, CP; Depta, JP; Fonarow, GC; Peacock, WF; Zhao, X | 1 |
| Bagur, R; Bertrand, OF; Costerousse, O; De Larochellière, R; Gleeton, O; Larose, E; Proulx, G; Rinfret, S; Rodés-Cabau, J; Roy, L | 1 |
| Bigalke, B; Gawaz, M; Henkelmann, N; Stakos, D; Stellos, K | 1 |
| Furuta, T | 1 |
| Zahn, R; Zeymer, U | 1 |
| Menon, V; Raymond, C | 1 |
| Abu-Fadel, M; Norgard, NB | 1 |
| Eshaghian, S; Kaul, S; Shah, PK | 1 |
| Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD | 1 |
| Howard, PA; Vacek, JL | 1 |
| Cowen, M; Goraya, TY; Poppe, T; Singal, B; Srikanth, A | 1 |
| Avorn, J; Choudhry, NK; Rassen, JA; Schneeweiss, S | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| Kremneva, LV; Shalaev, SV | 1 |
| Dobesh, PP | 1 |
| Baker, WL; Reinhart, KM; White, CM | 1 |
| Farid, NA; Kurihara, A; Wrighton, SA | 1 |
| Bielis, L; Boinska, J; Budzyński, J; Kasprzak, M; Koziński, M; Kubica, J; Marciniak, A; Plazuk, W; Rość, D; Siller-Matula, J | 1 |
| Lazar, LD; Lincoff, AM | 1 |
| Banihashemi, B; Goodman, SG; Gyenes, G; Kornder, JM; Mehta, SR; Montalescot, G; Steg, PG; Welsh, RC; Wong, GC; Yan, AT; Yan, RT | 1 |
| Bittira, B; Brister, S; Eikelboom, J; Fitchett, D; Fremes, S; Graham, J; Gupta, M; Karkouti, K; Lee, A; Love, M; Mazer, D; McArthur, R; Peterson, M; Singh, S; Verma, S; Yau, T | 1 |
| del Río, A; Heras, M | 1 |
| Grove, EL; Storey, RF | 1 |
| Tomoda, H | 1 |
| Atar, D; Serebruany, VL | 1 |
| Guerra, DR; Tcheng, JE | 1 |
| Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S | 1 |
| Herszényi, L; Juhász, M; Tulassay, Z | 1 |
| Bhatt, DL; Chhatriwalla, AK | 1 |
| Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A | 1 |
| Hussain, J; Robinson, D | 1 |
| Damman, P; de Winter, RJ; Hirsch, A; Tijssen, JG; Windhausen, F | 1 |
| Alagona, P | 1 |
| Parra, D; Rosenstein, RS | 1 |
| Lotfi, A; Rothberg, M; Wartak, SA | 1 |
| Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G | 1 |
| Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Keltai, M; Khurmi, NS; Kontny, F; Lewis, BS; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Stone, GW | 2 |
| Bergman, G; Fakorede, F; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC | 1 |
| Resnic, FS; Sparling, JM | 1 |
| Solomon, S; Vacek, JL | 1 |
| Anderson, SD; Epstein, BJ; Shah, NK; Yim, J | 1 |
| Goto, S; Ikeda, Y; Jensen, P; Kato, K; Yamaguchi, H; Yamaguchi, T | 1 |
| Serebruany, V | 2 |
| Alessi, MC; Barbato, E; Bartunek, J; Bonnet, JL; Cuisset, T; Delrue, M; Eijgelsheim, M; Frère, C; Hamilos, M; Saut, N; Verhamme, K; Wijns, W | 1 |
| Ahluwalia, J; Bhalla, A; Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Brissy, O; Cuisset, T; Frere, C; Gaborit, B; Lambert, M; Morange, PE; Poyet, R; Quilici, J | 1 |
| Bal-Dit-Sollier, C; Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Collet, JP; Drouet, L; Ducrocq, G; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Silvain, J; Slama, M | 1 |
| Faxon, DP | 1 |
| Han, CL; Lin, GM | 1 |
| Islam, AM; Patel, PM | 1 |
| Dorsch, MP; Momary, KM | 1 |
| Fareed, J; Jeske, WP; Mousa, SA | 1 |
| Gebel, JM | 1 |
| Cimino, E; Conca, P; Coppola, A; De Simone, C; Di Capua, M; Di Minno, G; Guida, A; Morisco, C; Tufano, A | 1 |
| Clarke, CL; Go, AS; Ho, PM; Magid, DJ; Peterson, ED; Rumsfeld, JS; Sedrakyan, A; Shetterly, SM; Tsai, TT; Wang, TY | 1 |
| Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Storey, RF | 1 |
| Maclean, JR; Mozaffari, E; Philipson, TJ | 1 |
| Bareiss, P; Kessler, L; Morel, O; Ohlmann, P | 1 |
| Amoah, V; Cotton, JM; Curzen, N; Dunmore, S; Hobson, AR; Nevill, AM; Raghuraman, RP; Rajendra, R; Smallwood, A; Vickers, J; Worrall, AM | 1 |
| Abbate, R; Crea, F; De Servi, S; Filippi, E; Gensini, GF; Golinos, P; Savonitto, S | 1 |
| Janion, M; Piatek, K; Piatek, L; Polewczyk, A; Sielski, J | 1 |
| Billinger, M; Cook, S; Eshtehardi, P; Garachemani, A; Hess, OM; Meier, B; Togni, M; Wenaweser, P; Windecker, S | 1 |
| Neumann, FJ | 1 |
| Amin, AP; Marso, SP | 1 |
| Kartasheva, ED; Linchak, RM | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
| Bagust, A; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Fleeman, N; Greenhalgh, J; Kolamunnage-Dona, R; McLeod, C; Proudlove, C; Saborido, CM | 1 |
| Cannon, CP | 1 |
| Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C | 1 |
| Anderson, FA; Avezum, A; Brieger, D; Chew, DP; Dedrick, R; Eagle, KA; FitzGerald, G; Gore, JM | 1 |
| Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW | 1 |
| Berger, PB; Kalyanasundaram, A | 1 |
| Chen, CP; Cheng, CI; Kuan, PL; Lai, WT; Lei, MH; Liau, CS; Ueng, KC; Wu, CJ | 1 |
| Zeymer, U | 1 |
| Chan, FK; Kuo, KN; Lin, JT; Tsao, CR; Wang, CB; Wu, CY; Wu, MS | 1 |
| Bonassin, F; Schneemann, M; Wyss, C | 1 |
| Alexopoulos, D; Davlouros, P | 1 |
| Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J | 1 |
| Cavallari, LH; Momary, K | 1 |
| Cui, W; Li, Z; Liu, F; Liu, J; Lu, JC; Ren, XJ; Xie, RQ; Yang, XC; Zheng, HM | 1 |
| Gratsianskiĭ, NA | 1 |
| Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II | 1 |
| Pakhomov, IaM | 1 |
| Antman, EM; Braunwald, E; Wiviott, SD | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM | 1 |
| Tebaldi, M; Valgimigli, M | 1 |
| Le Lorier, J; Potter, BJ | 1 |
| Marín, F; Merino, A; Roldán, I; Worner, F | 1 |
| Ait Mokhtar, O; Aldebert, P; Armero, S; Arques, S; Barragan, P; Bartholomei, MN; Bonello, L; Bonello, N; Bonello-Burignat, C; Camoin-Jau, L; Dignat-George, F; Giacomoni, MP; Mancini, J; Paganelli, F; Saut, N | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Bae, JP; Dean, BB; Emons, MF; Fiske, S; Meadows, E; Xiong, Y; Yu, HT | 1 |
| Hwang, JY; Hwang, SJ; Jeong, YH; Kang, MK; Kim, IS; Koh, JS; Kwak, CH; Park, Y; Yoon, SE | 1 |
| Bjelland, TW; Dale, O; Haugen, BO; Hjertner, Ø; Kaisen, K; Klepstad, P | 1 |
| Aichele, S; Bigalke, B; Fateh-Moghadam, S; Flather, M; Gawaz, M; Geisler, T; Herkommer, M; Htun, P; May, AE; Müller, K; Stellos, K | 1 |
| Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN | 1 |
| Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Brieger, D; Cayla, G; Collet, JP; Montalescot, G; Pena, A; Silvain, J | 1 |
| Antman, EM; Braunwald, E; Close, SL; Mega, JL; Sabatine, MS; Shen, L; Simon, T; Walker, JR; Wiviott, SD | 1 |
| Abbate, R; Giusti, B | 1 |
| Armstrong, M; Barratt, BJ; Becker, RC; Horrow, J; Husted, S; James, S; Katus, H; Shah, SH; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L | 1 |
| Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D | 1 |
| Chen, PF; Hsiao, FY; Huang, WF; Kuo, KN; Tsai, YW; Wen, YW | 1 |
| Di Sciascio, G; Melfi, R; Nusca, A; Patti, G | 1 |
| Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S | 1 |
| Fuster, V | 1 |
| Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Moro, PJ; Poyet, R; Quilici, J | 1 |
| Di Girolamo, G; Giorgi, MA; González, CD | 1 |
| Bode, C; Duerschmied, D; Moser, M | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Moro, PJ; Pons, C; Quilici, J | 1 |
| Batyraliev, TA; Besnili, F; Fettser, DV; Niiazova-Karben, ZA; Preobrazhenskiĭ, DV; Sidorenko, BA | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Desai, B; Ecob, R; Emanuelsson, H; Husted, S; Patil, SB; Storey, RF; Wallentin, L | 1 |
| Laizure, SC; Parker, RB | 1 |
| Angiolillo, DJ; Costigan, TM; Deraad, R; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF | 1 |
| Miller, JM; Pham, PA; Pham, PC; Pham, PM; Pham, PT; Pham, SV | 1 |
| Ardissino, D; Caracciolo, M; D'Urbano, M; De Servi, S | 1 |
| Morais, J | 2 |
| Dobrovol'skiĭ, AB; Frolova, NS; Ruda, MIa; Shakhnovich, RM; Sirotkina, OV | 1 |
| Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC | 1 |
| Gilchrist, IC | 1 |
| Fletcher, B; Thalinger, KK | 1 |
| Marcucci, R | 1 |
| Brozovic, I; Farhan, S; Geppert, A; Huber, K; Jarai, R; Siller-Matula, J; Smetana, P; Tentzeris, I; Wojta, J | 1 |
| Radke, PW; Schunkert, H | 1 |
| Chen, SL; Hu, ZY; Xie, HG; Ye, F; Zhang, JJ; Zou, JJ | 1 |
| Anderson, JL; Antman, EM; Bliden, K; Cannon, CP; Collet, JP; Danchin, N; Giusti, B; Gurbel, P; Horne, BD; Hulot, JS; Kastrati, A; Mega, JL; Montalescot, G; Neumann, FJ; Sabatine, MS; Shen, L; Sibbing, D; Simon, T; Steg, PG; Trenk, D; Wiviott, SD | 1 |
| Fuster, V; Sweeny, JM | 1 |
| Anand, SS; Bhatt, DL; Connolly, SJ; Eikelboom, JW; Fox, KA; Hirsh, J; Mehta, SR; Paré, G; Simonsen, K; Yusuf, S | 1 |
| Abergel, E; Nikolsky, E | 1 |
| Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD | 1 |
| Pollack, CV | 1 |
| Páramo, JA | 1 |
| Kleiman, NS; Mangalpally, KK | 1 |
| Tan, HJ | 1 |
| Antman, EM; Baracioli, L; Braunwald, E; Giugliano, RP; Heuer, H; Lotan, C; Merkely, B; Murphy, SA; Ruff, CT; Schersten, F; Seabro-Gomes, R; Wiviott, SD | 1 |
| Brieger, D; Eagle, KA; Fox, KA; Goodman, SG; Gore, JM; Huang, W; Montalescot, G; Sibbald, M; Steg, PG; Yan, AT | 1 |
| Curzen, N; Sambu, N; Warner, T | 1 |
| Lettino, M | 1 |
| Armani, AM | 1 |
| Menown, IB | 1 |
| Jilma, B; Siller-Matula, JM | 1 |
| Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A | 1 |
| Frey, N; Ivandic, B | 1 |
| Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH | 1 |
| Casu, G; Meloni, I; Merella, P | 1 |
| Vassiliou, VS | 1 |
| Padrini, R; Pengo, V | 1 |
| Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Montalescot, G; Rangé, G; Vicaut, E | 1 |
| Chen, F; Wang, L; Wang, X | 1 |
| Ebina, T; Endo, M; Hibi, K; Ishikawa, T; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Okada, K; Umemura, S | 1 |
| Akazawa, Y; Hirata, A; Kashiwase, K; Kashiyama, T; Kodama, K; Masumura, Y; Matsuo, K; Muller, JE; Nemoto, T; Nishio, M; Ueda, Y; Wada, M | 1 |
| Asenblad, N; Bassand, JP; Becker, RC; Cannon, CP; Claeys, MJ; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Nicolau, JC; Scirica, BM; Storey, RF; Vintila, M; Wallentin, L; Ycas, J | 1 |
| Schneider, DJ | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Buffet, P; Cottin, Y; Gudjoncik, A; L'Huillier, I; Lorgis, L; Richard, C; Zeller, M | 1 |
| Táborský, M; Václavík, J | 1 |
| Anderson, J; Bae, JP; Fu, H; Lenarz, L; McCollam, P; Zettler, M; Zhao, Z; Zhu, B | 1 |
| Gaglia, MA; Waksman, R | 2 |
| Caillard, S; Campia, U; El Ghannudi, S; Gachet, C; Jesel, L; Meyer, N; Morel, O; Moulin, B; Ohlmann, P; Radulescu, B; Wiesel, ML | 1 |
| Branzi, A; De Palma, R; Marino, M; Marzocchi, A; Ortolani, P | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Dimitriou, AA; Goudevenos, IA; Kalantzi, KI; Milionis, HJ; Tselepis, AD | 1 |
| Schiele, F | 1 |
| Vassiliou, V | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G; Ricottini, E; Vizzi, V | 1 |
| Azevedo, P; Brandāo, A; Correia, A; Gaspar, A; Nabais, S; Pereira, MA; Ribeiro, S; Rocha, S; Salgado, A | 1 |
| Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N | 1 |
| Siasos, G; Stefanadis, C; Tousoulis, D | 1 |
| Bigalke, B; Geisler, T; Schwab, M | 1 |
| Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W | 1 |
| Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U | 1 |
| Anderson, MR; Blann, AD; Disney, BR; Lip, GY; Watson, RD | 1 |
| Desilets, AR; Goodwin, MM; Willett, KC | 1 |
| Arsava, EM; Ay, H; Topçuoglu, MA | 1 |
| Chauret, D; Deyoung, JP; Eagle, KA; Edwards, J; Goodman, SG; Kornder, JM; Picard, JP; Welsh, RC; Yan, AT; Yan, RT | 1 |
| Bakhai, A; Belger, M; Ferrieres, J; Iñiguez, A; Sartral, M; Schmitt, C; Zeymer, U | 1 |
| de Boer, A; Deneer, VH; Harmsze, AM; Maitland-van der Zee, AH; Peters, BJ; ten Berg, JM; Tjoeng, MM | 1 |
| Collet, JP; Hulot, JS; Montalescot, G | 1 |
| Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M | 1 |
| Capodanno, D; Cicorella, N; Gavazzi, A; Guagliumi, G; Lettieri, C; Lortkipanidze, N; Musumeci, G; Nijaradze, T; Romano, M; Rosiello, R; Rossini, R; Sirbu, V; Tarantini, G; Valsecchi, O | 1 |
| Ebina, T; Endo, M; Hibi, K; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Sugano, T; Tsukahara, K; Umemura, S | 1 |
| Smetana, GW; Srour, JF | 1 |
| Birkmeier, KA; Byrne, RA; Dommasch, M; Dotzer, F; Kastrati, A; Kufner, S; Mehilli, J; Ndrepepa, G; Schömig, A; Schulz, S; Tiroch, K | 1 |
| White, HD | 1 |
| Ohman, EM; Roe, MT | 1 |
| Becker, RC; Harrington, RA; James, SK; Wallentin, L | 1 |
| Aout, M; Barthelemy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Connor, S'; Montalescot, G; Payot, L; Silvain, J; Vicaut, E | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C | 1 |
| Chang, CL; Cziraky, MJ; Devecchis Wygant, G; Hauch, O; Stephenson, JJ | 1 |
| Freynhofer, M; Geppert, A; Hahne, S; Huber, K; Jarai, R; Kalla, K; Kozanli, I; Nürnberg, M; Smetana, P; Unger, G; Vogel, B | 1 |
| Jørgensen, NR; Schwarz, P; Steinberg, TH; Vestergaard, P | 1 |
| Baty, SR; Griffith, CB; Phillippe, HM | 1 |
| Chung, HS; Han, JY; Kim, HJ; Kim, SR; Lee, SY; Park, KJ | 1 |
| Bainey, KR; Lai, TF; Mehta, SR | 1 |
| Calabrese, D; Casella, G; Di Pasquale, G; Pallotti, MG; Riva, L; Zagnoni, S | 1 |
| Bernlochner, I; Byrne, RA; Kastrati, A; Sibbing, D | 2 |
| Darius, H; Glunz, HG; Hauptmann, KE; Hochadel, M; Kerber, S; Mudra, H; Schwarz, AK; Zahn, R; Zeymer, U | 1 |
| Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M | 1 |
| Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U | 1 |
| Dart, AM; Fernando, H; Peter, K; Shaw, JA | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Michelson, EL; Pais, P; Raev, D; Scirica, BM; Spinar, J; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L | 1 |
| Ardissino, D; Demola, MA; Magnani, G; Mantovani, F; Patti, G | 1 |
| Burke, MA; Fintel, DJ; Lee, R | 1 |
| Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M | 1 |
| Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
| Curkendall, S; Ernst, FR; Johnston, S; Mozaffari, E; Stemkowski, S | 1 |
| Chen, W; Ge, H; Guo, Y; Liu, X; Nie, X; Wang, Z; Yang, Q; Zhou, Y | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G | 1 |
| Brozovic, I; Bruno, V; Farhan, S; Freynhofer, MK; Huber, K; Hübl, W; Jakl, G; Vogel, B; Willheim, M; Wojta, J | 1 |
| Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC | 1 |
| Martin, MT; Nutescu, EA; Spinler, SA | 1 |
| Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN | 1 |
| Ben-Dor, I; Gaglia, MA; Gonzalez, M; Mahmoudi, M; Maluenda, G; Pichard, AD; Sardi, G; Satler, LF; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z | 1 |
| Timmis, A | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; Husted, S; James, SK; Katus, H; Morais, J; Roe, MT; Steg, PG; Stevens, S; Storey, RF; Wallentin, L | 1 |
| Bassler, N; Dart, AM; Fernando, H; Habersberger, J; Peter, KH; Sharma, R; Shaw, JA; Sheffield, LJ | 1 |
| Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N | 1 |
| Gardner, EE; Hulot, JS; Johnson, JA; Klein, TE; Roden, DM; Sangkuhl, K; Scott, SA; Shuldiner, AR; Stein, CM | 1 |
| Carballo, D; Carballo, S; Keller, PF; Roffi, M | 1 |
| Byrne, RA; Kastrati, A; Sibbing, D | 1 |
| Chen, YG; Gao, F; Hao, PP; Liu, YP; Zhang, C; Zhang, MX; Zhang, Y | 1 |
| Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
| Alessi, MC; Bonnet, JL; Carrieri, P; Cohen, W; Cuisset, T; Fourcade, L; Gaborit, B; Morange, PE; Pankert, M; Quilici, J; Saut, N | 1 |
| Becker, RC; Cairns, R; Cannon, CP; Cools, F; Cooper, A; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Khurmi, NS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Dimitriou, AA; Goudevenos, JA; Kalantzi, KI; Tselepis, AD | 1 |
| Ahmad, WA; Ramesh, SV; Zambahari, R | 1 |
| Hinneburg, I | 1 |
| Akbulut, M; Bilen, MN; Bulut, M; Cekici, Y; Celik, A; Korkmaz, H | 1 |
| Clough, JD; Cope, MW; Martin, SS | 1 |
| Bauer, T; Bouman, HJ; Ford, NF; Taubert, D; ten Berg, JM; van Werkum, JW | 1 |
| Abdelrahman, NM; Alcalai, R; Briskin, E; Bulut, A; Loncar, S; Mosseri, M; Spectre, G; Varon, D | 1 |
| Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW | 1 |
| Höchtl, T; Huber, K; Schrör, K; Tentzeris, I | 1 |
| Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L | 1 |
| Alessi, MC; Bonnet, JL; Cuisset, T; Fourcade, L; Gaborit, B; Grosdidier, C; Molines, L; Morange, PE; Pankert, M; Quilici, J | 1 |
| Begg, A; Boggon, R; Emmas, C; Fox, KA; Hemingway, H; Ray, KK; Timmis, A; van Staa, TP | 1 |
| Angiolillo, DJ; Berger, PB; Cannon, CP; Lillie, E; Manoukian, SV; Price, MJ; Tanguay, JF; Teirstein, PS; Topol, EJ | 1 |
| Golubeva, NV; Iakushkin, VV; Khaspekova, SG; Mazurov, AV; Ruda, MIa; Ziuriaev, IT | 1 |
| Al Suwaidi, J; Alsheikh-Ali, AA; Anderson, FA; Awad, HH; Goldberg, RJ; Gore, JM; Zubaid, M | 1 |
| Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D | 1 |
| Chen, M; Huang, DJ; Liu, XJ; Wei, JF; Xu, YN | 1 |
| Becker, RC; Cannon, CP; Cools, F; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Katus, HA; Khurmi, NS; Lim, ST; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Collet, JP; O'Connor, S | 1 |
| D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Hajjar, R; Hulot, JS; Montalescot, G | 1 |
| Ardissino, D; Conte, G; Demola, MA; Giacalone, R; Mantovani, F; Marziliano, N; Notarangelo, MF | 1 |
| Collyer, TC; Corcoran, T; Kilshaw, L; Reynolds, HC; Truyens, E | 1 |
| Aradi, D; Komócsi, A | 1 |
| Dimitriou, AA; Goudevenos, IA; Kalantzi, KI; Tellis, CC; Tselepis, AD; Tsoumani, ME | 1 |
| Bett, JH; Syed, FA; Walters, DL | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
| Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Harrison, RW; Mahaffey, KW | 1 |
| Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Chan, FK; Lam, KF; Lau, YK; Ng, FH; Tunggal, P | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Brilakis, ES; de Lemos, JA | 1 |
| Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC | 1 |
| Bernal, A; Hurtado, JA; Jover, E; Lozano, ML; Marín, F; Pastor, FJ; Rivera, J; Sánchez-Vega, B; Tello-Montoliu, A; Valdés, M; Vicente, V | 1 |
| Érlikh, AD; Gratsianskiĭ, NA | 2 |
| Akerblom, Å; Åsenblad, N; Becker, RC; Buck, K; Budaj, A; Giannitsis, E; Horrow, J; Husted, S; James, SK; Katus, HA; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Thompson, CA | 1 |
| Dimitriou, AA; Goudevenos, IA; Kalantzi, KI; Ntalas, IV; Tselepis, AD; Tsoumani, ME | 2 |
| Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH | 1 |
| Cantor, WJ | 1 |
| Asher, E; Beigel, R; Buber, J; Hod, H; Matetzky, S; Vatury, O | 1 |
| Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Jeger, R; Kaiser, C; Pfisterer, M | 1 |
| Iino, K; Ishida, M; Ito, H; Kosaka, T; Okawa, M; Watanabe, H | 1 |
| Braunwald, E | 1 |
| Li, J; Luo, M; Sheng, W; Sun, X; Xu, X | 1 |
| Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL | 1 |
| Janknegt, R; Ruiters, L; Ten Cate, H | 1 |
| Calvi, V; Capodanno, D; Tamburino, C | 1 |
| Abbate, R; Armillis, A; Galora, S; Giusti, B; Saracini, C; Vestrini, A | 1 |
| Kim, HS; Park, KW | 1 |
| Aradi, D; Finkov, B; Hazarbasanov, D; Kostov, E; Postadjian, A; Rifai, N; Velchev, V | 1 |
| Al Faleh, H; Al Saif, S; Al Suwaidi, J; Al-Lawati, J; Al-Motarreb, A; Al-Sagheer, NQ; AlHabib, KF; Almahmeed, W; AlQahtani, A; Alsheikh-Ali, AA; Amin, H; Asaad, N; El-Menyar, A; Hersi, A; Singh, R; Sulaiman, K | 1 |
| Gurbel, PA; Jeong, YH; Ohman, EM; Tantry, US | 1 |
| Amri, A; Farhati, A; Larbi, N; Mechmèche, R; Mourali, MS; Zghal, FM | 1 |
| Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ | 1 |
| Bergmeijer, TO; ten Berg, JM | 1 |
| Alessi, MC; Bessereau, J; Bonello, L; Camoin-Jau, L; Dignat-George, F; Grosdidier, C; Mancini, J; Ostorero, M; Paganelli, F | 1 |
| Angiolillo, DJ; Cequier, AR; Ferreiro, JL | 1 |
| Mackay, SM; Tcheng, JE | 1 |
| Crea, F; D'Amario, D; Porto, I | 1 |
| Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Bai, CH; Gau, CS; Lin, CF; Shen, LJ; Wu, FL | 1 |
| Abbate, R; Antoniucci, D; Gensini, GF; Giglioli, C; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Parodi, G; Saracini, C; Valente, S | 1 |
| Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS | 1 |
| Askari, AT; Stephens, JC | 1 |
| Kavvoura, F; Rowlands, DB; Schofield, R; Silva, A; Vassiliou, V | 1 |
| Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES | 1 |
| Dick, A; Druce, I; Froeschl, M; Glover, C; Gollob, MH; Goncalves, S; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, E; Roberts, JD; So, DY; Stewart, A; Wells, GA | 1 |
| Harding, SA; Johnston, LR; La Flamme, AC; Larsen, PD; Michel, JM; Simmonds, MB | 1 |
| Ammann, P; Borovicka, J; Haile, SR; Häuptle, R; Knellwolf, C; Schneider, T; Weilenmann, D | 1 |
| Guan, SY; Guo, L; Han, YL; Jing, QM; Li, Y; Liu, XD; Ma, YY; Wang, SL; Wang, XZ; Yang, BS | 1 |
| Armero, S; Barragan, P; Berbis, J; Bessereau, J; Bonello, C; Bonello, L; Camillieri, E; Camoin-Jau, L; Dignat-George, F; Jacquin, L; Laine, M; Paganelli, F | 1 |
| Armstrong, PW; Das, D; Fu, Y; James, S; Siha, H; Storey, RF; Wallentin, L; Westerhout, CM; Zheng, Y | 1 |
| Held, C | 1 |
| Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF | 1 |
| Duvoisin, N; Erne, P; Goy, JJ; Radovanovic, D; Rickli, H; Stauffer, JC | 1 |
| Angiolillo, DJ; Azmoon, S | 1 |
| Lyseng-Williamson, KA | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S | 1 |
| Angiolillo, DJ; Lillie, E; Murray, SS; Price, MJ; Schork, NJ; Smith, EN; Teirstein, PS; Tisch, RL; Topol, EJ | 1 |
| Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA | 1 |
| Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ | 2 |
| Acconcia, MC; Barillà, F; Dominici, T; Gaudio, C; Mangieri, E; Paravati, V; Pellicano, M; Pulcinelli, FM; Tanzilli, G; Torromeo, C | 1 |
| Ikonomidis, I; Kalamara, E; Kapsimali, V; Karakitsos, P; Kardoulaki, A; Kopterides, P; Kottaridi, C; Lekakis, J; Papadakis, I; Travlou, A; Tsante, A; Tsantes, A | 1 |
| Berwanger, O; Carvalho, V; Cavalcanti, AB; Guimarães, HP; Kodama, AA; Laranjeira, LN; Lopes, RD; Mira, VL; Mota, LH; Peterson, ED; Pieper, KS; Santucci, EV; Tenuta, M; Victor, E; Weber, B; Zazula, AD | 1 |
| Fragoulakis, V; Kourlaba, G; Maniadakis, N | 1 |
| Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
| Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Bhatt, DL; Kar, S | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Crimizade, U; El Ghannudi, S; Gachet, C; Hess, S; Jesel, L; Morel, O; Ohlmann, P; Radulescu, B; Reydel, A; Wiesel, ML | 1 |
| Bhurke, SM; Bursac, Z; Franks, AM; Li, C; Martin, BC; Said, Q | 1 |
| Bae, JP; Heiselman, D; McCracken, R; Meadows, ES; Ramaswamy, K; Sugihara, T; Zagar, A | 1 |
| Carrié, D; Garcia, C; Lhermusier, T; Mejean, S; Sié, P; Voisin, S | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Curzen, N | 1 |
| Controtto, F; Cristofori, R; D'Amico, M; Grasso, C; Marra, S; Pennone, M; Scacciatella, P | 1 |
| Angiolillo, DJ; Rollini, F; Tello-Montoliu, A | 2 |
| de la Peña, NC; Isordia-Salas, I; Olalde-Román, MJ; Santiago-Germán, D; Valencia-Sánchez, JS | 1 |
| Deng, J; Geng, DF; Jin, DM; Liu, M; Wang, JF; Wu, W | 1 |
| Limper, U; Lynch, J | 1 |
| Ferreira, MJ; Freitas, M; Gonçalves, F; Lourenço, M; Marques, G; Monteiro, P; Monteiro, S; Pego, JM; Providência, LA; Reboredo, A; Ribeiro, G; Tavares, C; Teixeira, R | 1 |
| Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Erdoğan, E; Göktekin, Ö; Tasal, A; Vatankulu, MA | 1 |
| Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C | 1 |
| de Caterina, R; Renda, G | 1 |
| Fassa, AA; Urban, P | 1 |
| Rao, SV; Vavalle, JP | 1 |
| Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ | 1 |
| Burgess, S; Juergens, CP; Mallard, TA | 1 |
| Antignan, A; De Amicis, V; Di Tommaso, L; Mannacio, VA; Vosa, C | 1 |
| Can, MM; DiNicolantonio, JJ; Serebruany, VL | 1 |
| Lincoff, AM; May, CH | 1 |
| Kenyeres, P; Papp, J; Toth, K | 1 |
| Ge, J; Qian, J; Sun, A; Wang, Q; Wu, H | 1 |
| Brown, PM; Gladding, P; Panattoni, L; Te Ao, B; Webster, M | 1 |
| Ge, J; Qian, J; Sun, A; Sun, W; Wang, Q; Wu, H; Xu, J | 1 |
| Alessi, MC; Bonnet, JL; Cuisset, T; Fourcade, L; Gaborit, B; Gil, JM; Grosdidier, C; Loosveld, M; Morange, PE; Moro, PJ; Quilici, J | 1 |
| Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L | 1 |
| Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Er, F | 1 |
| Horiuchi, H | 1 |
| Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG | 1 |
| Alström, U; Åsenblad, N; Becker, RC; Brandrup-Wognsen, G; Cannon, CP; Held, C; Hogue, CW; Horrow, J; James, S; Mahaffey, KW; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Elefteriades, JA; Meier, P | 1 |
| Sadanandan, S; Singh, IM | 1 |
| Alessi, MC; Beguin, S; Bonnet, JL; Cuisset, T; Dubois, N; Dutour, A; Gaborit, B; Loosveld, M; Loundou, AD; Morange, PE; Moro, PJ; Quilici, J | 1 |
| Braun, OÖ; Koul, S; Lumsden, J; Ohman, J; Rydell, E; Scherstén, F; Smith, JG; Svensson, PJ; van der Pals, J; Wieloch, M | 1 |
| Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A | 1 |
| Komarov, AL; Panchenko, EP | 1 |
| Li, L; Qiao, R; Zhang, J | 1 |
| Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C | 1 |
| Bellomo, G; De Luca, G; Iorio, S; Marino, P; Secco, GG; Verdoia, M | 1 |
| Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G | 1 |
| Akerblom, A; Asenblad, N; Becker, RC; Budaj, A; Claeys, MJ; Horrow, J; Husted, S; James, SK; Katus, H; Siegbahn, A; Storey, RF; Wallentin, L | 1 |
| Dhruvakumar, S; Gerula, C; Kaluski, E; Klapholz, M; Maher, J; Mathur, AP; Mazza, V; Waller, AH | 1 |
| Amoah, V; Armesilla, AL; Cotton, JM; Goodridge, K; Lovatt, T; Nevill, AM; Smallwood, A; Storey, RF; Worrall, AP | 1 |
| Abbate, R; Giusti, B; Gori, AM; Marcucci, R | 1 |
| Abrams, J; Berra, K; Blankenship, JC; Dallas, AP; Douglas, PS; Fihn, SD; Foody, JM; Gardin, JM; Gerber, TC; Hinderliter, AL; King, SB; Kligfield, PD; Krumholz, HM; Kwong, RY; Lim, MJ; Linderbaum, JA; Mack, MJ; Munger, MA; Prager, RL; Sabik, JF; Shaw, LJ; Sikkema, JD; Smith, CR; Smith, SC; Spertus, JA; Williams, SV | 1 |
| Bolognese, L; De Servi, S | 1 |
| Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
| Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K | 1 |
| Angiolillo, DJ; Costigan, TM; DeRaad, R; Duvvuru, S; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG; Yun, SC | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Hahalis, G; Mavronasiou, E; Plakomyti, TE; Theodoropoulos, KC; Xanthopoulou, I | 1 |
| Amarasuriya, M; Constantine, GR; Rodrigo, C; Wickramasinghe, S | 1 |
| Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R | 1 |
| Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L | 1 |
| Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Fareed, J; Jeske, W; Thethi, I | 1 |
| Griffiths, R; Halsey, T; Parker, MJ; Wordsworth, DR | 1 |
| Daly, RL; Dhutia, AJ; Ecob, R; Howgego, KE; Judge, HM; Mehra, S; Morton, AC; Storey, RF; Sumaya, W | 1 |
| Goto, S; Tomiya, A | 1 |
| Maddox, TM | 1 |
| Alessi, MC; Bonnet, JL; Cuisset, T; Morange, PE; Quilici, J | 1 |
| Bakhai, A; Barrett, A; Davies, A; Graham-Clarke, P; Schmitt, C; Sculpher, M | 1 |
| Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N | 1 |
| Cervinski, MA; Lebel, KA; Lefferts, JA; Lewis, LD; Pflueger, SM; Schwab, MC; Tsongalis, GJ; Tyropolis, AM | 1 |
| Chen, YD; Jin, ZN; Liu, H; Liu, X; Lü, SZ; Song, XT | 1 |
| Bai, Y; Chen, T; Feng, GX; Liang, Y; Liu, X; Wang, XY; Yang, YJ; Yang, YM; Zhu, J | 1 |
| Armstrong, PW; Westerhout, CM | 1 |
| Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN | 1 |
| Chow, WH; Hwang, JJ; Javier, S; Kwok, OH; Mak, KH; Piyamitr, S; Suryawan, R; Tri Ho, HQ; Zambahari, R | 1 |
| Chaiyakunapruk, N; Nathisuwan, S; Niruntraporn, S; Thamlikitkul, V | 1 |
| Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giglioli, C; Gori, AM; Marcucci, R; Paniccia, R | 1 |
| Bigalke, B; Daub, K; Dösch, C; Gawaz, M; Geisler, T; Göhring-Frischholz, K; Herdeg, C; Kapp, M; Langer, H | 1 |
| Dick, R; Hiscock, M; Oqueli, E | 1 |
| Beer, JC; Buffet, P; Cottin, Y; L'Huillier, I; Lagrost, AC; Lorgis, L; Nguyen, C; Obbee, P; Schaad, F; Zeller, M | 1 |
| Bae, JP; Griffin, B; He, J; Kereiakes, DJ; McCollam, P; Wang, C | 1 |
| Ferguson, JJ; Tom, CW | 1 |
| Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M | 1 |
| Chiche, L; Hamon, M; Plaud, B; Riddell, JW | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Carvajal, J; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J | 1 |
| Bruskina, O; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Schömig, A; Schulz, S | 1 |
| Bigalke, B; Dietz, K; Drosch, T; Gawaz, M; Geisler, T; Grass, D; Herdeg, C; Stellos, K | 1 |
| Eagle, KA; Froehlich, J; Gurm, HS; Li, J; Moscucci, M; Motivala, AA; Rogers, EK; Saab, F; Tamhane, U | 1 |
| Davis, KE; Denardo, SJ; Tcheng, JE | 1 |
| Berg, JM; Hackeng, CM; Seesing, TH; van der Stelt, CA; van Werkum, JW | 1 |
| Angelillo-Scherrer, A; Cairoli, A; Ferrario, C; Renders, F; Spertini, O; Vuffray, A | 1 |
| Becker, RC; Gurbel, PA; Mann, KG; Michelson, AD; Steinhubl, SR | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF | 1 |
| Cannon, CP; Emanuelsson, H; Grande, P; Gurbel, P; Harrington, RA; Heptinstall, S; Husted, S; Peters, G; Storey, RF; Wickens, M; Wilcox, RG | 1 |
| Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD | 1 |
| Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y | 1 |
| Horowitz, J; Kaski, JC; McMurray, JJ; Recio-Mayoral, A; Remme, WJ; van Veldhuisen, DJ | 1 |
| Abbate, R; Antoniucci, D; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Saracini, C; Sestini, I; Valente, S | 1 |
| Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J | 1 |
| Ardissino, D; Bolognesi, MG; Dangas, G; Fahy, M; Gobbi, G; Ippolito, L; Mehran, R; Merlini, PA; Ruenes, R; Solinas, E; Vitale, M | 1 |
| Han, YL; Kang, J; Li, CY; Li, Y; Yan, CH | 1 |
| Cannon, CP; Laine, L; Murphy, SA; Schreiner, GC | 1 |
| Dawley, CA; Fletcher, SF; Walker, CW | 1 |
| Ortigosa, J | 1 |
| Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D | 1 |
| Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M; ten Berg, J | 1 |
| Salzman, BE; Simmons, BB | 1 |
| Michelson, AD | 1 |
| Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY | 1 |
| Aylward, PG; Califf, RM; Chew, DP; Ferguson, JJ; Huang, Z; Mahaffey, KW; Pieper, KS; White, H | 1 |
| Danchin, N; Decalf, V; Durand, E; Lafont, A; Sabbah, L | 1 |
| Kwa, AT; Rogers, JH | 1 |
| Fihn, SD; Ho, PM; Jesse, RA; Larsen, GC; Magid, DJ; Peterson, ED; Rumsfeld, JS; Wang, L | 1 |
| Bramkamp, M; Szucs, TD | 1 |
| Mukherjee, D; Roffi, M | 1 |
| Bareiss, P; Bernhard, N; Desprez, D; Freyssinet, JM; Grunebaum, L; Morel, O; Toti, F | 1 |
| Dorsch, MP; Reaume, KT; Regal, RE | 1 |
| Brady, WJ; Thomas, J | 1 |
| Keltai, M | 1 |
| Bonaca, M; Giugliano, R; Hoekstra, JW; Lefebvre, CW | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G | 1 |
| Paulus, W; Riggert, J; von Lewinski, F | 1 |
| Hollander, JE; Pollack, CV | 1 |
| Lee, S; Song, SW; Yi, G; Yoo, KJ; Youn, YN | 1 |
| Gladding, P; Olsen, S; Ormiston, J; Webster, M; White, H | 1 |
| Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD | 1 |
| Eikelboom, JW; Hankey, GJ; Langton, PE | 1 |
| Alessi, MC; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Faille, D; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Saut, N | 1 |
| Brandslund, I; Buck, TC; Christensen, C; Jørgensen, LG; Nielsen, AA; Veien, KT | 1 |
| De Servi, S; Lettino, M | 1 |
| Bhatt, DL; Depta, JP | 1 |
| Dirschinger, J; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Pache, J; Schömig, A; Seyfarth, M | 1 |
| Hoekstra, JW | 1 |
| Cannon, CP; Giugliano, GR; Lotfi, A; Murphy, SA; Schweiger, MJ | 1 |
| Angiolillo, D; Bates, E; Berger, PB; Bhatt, D; Braunwald, E; Cannon, CP; Furman, MI; Gurbel, P; Michelson, AD; Peterson, E; Wiviott, S | 1 |
| Cairns, JA; Eikelboom, J | 1 |
| Weintraub, WS | 1 |
| Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD | 1 |
| Alessi, MC; Bali, L; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J | 1 |
| Alvarez, W | 1 |
| Haber, SL; Riley, AB; Tafreshi, MJ | 1 |
| Kim, DH | 1 |
| Goyal, SK; Punnam, SR | 1 |
369 review(s) available for clopidogrel and Acute Coronary Syndrome
| Article | Year |
|---|---|
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Oral P2Y12 Inhibitors in Older Patients with Acute Coronary Syndrome: A Frequentist Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Receptors, Proteinase-Activated; Stroke; Treatment Outcome | 2023 |
Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Dabigatran; Drug Therapy, Combination; Hemorrhage; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Ticagrelor; Warfarin | 2022 |
Risk of bleeding with ticagrelor in elderly patients over 75 years old: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Saudi Arabia; Ticagrelor; Treatment Outcome | 2021 |
Antiplatelet therapy in cardiovascular disease: Current status and future directions.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Effects of the
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Loss of Function Mutation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome-A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Treatment Outcome | 2022 |
The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Canada; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Ticagrelor | 2023 |
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dyspnea; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2022 |
Comparative efficacy and safety of oral P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2022 |
Safety and Efficacy of Selective, Clopidogrel-Based Strategies in Acute Coronary Syndrome: A Study-Level Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2022 |
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2022 |
Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Efficacy of ticagrelor compared to clopidogrel in improving endothelial function in patients with coronary artery disease: a systematic review.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Dual Antiplatelet Therapy in Patients Aged 75 Years and Older with Coronary Artery Disease: A Meta-Analysis and Systematic Review.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Ticagrelor; Treatment Outcome | 2022 |
De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Pharmacogenetics of P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Utilization Trends In Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor and Cost Among Medicare Beneficiaries.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Humans; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; United States | 2023 |
Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Immature platelet fraction in cardiovascular diagnostics and antiplatelet therapy monitoring.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab.
Topics: Acute Coronary Syndrome; Antibodies, Monoclonal; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2023 |
P2Y12 Inhibitors for Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Strategy of dual antiplatelet therapy for patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndromes: A systematic review and network meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Treatment Outcome | 2023 |
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticagrelor; Treatment Outcome | 2023 |
Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Network Meta-Analysis; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Lower Plasma miR-223 Level Is Associated with Clopidogrel Resistance in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Topics: Acute Coronary Syndrome; Asian People; Biomarkers; Clopidogrel; Databases, Factual; Drug Resistance; Humans; MicroRNAs | 2023 |
The effect of ticagrelor on coronary microvascular function after PCI in patients with ACS compared to clopidogrel: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Microcirculation; Percutaneous Coronary Intervention; Ticagrelor | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Treatment Outcome | 2023 |
Smoking and cardiovascular diseases: paradox greater than expected?
Topics: Acute Coronary Syndrome; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Tobacco Smoking; Treatment Outcome | 2019 |
Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor | 2020 |
Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During Gastrointestinal Bleeding.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Societies, Medical; Stroke | 2019 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Heart Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticagrelor | 2020 |
Assessing platelet reactivity after drug eluting stent implantation: state of the art.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists | 2020 |
Efficacy and Safety of Potent Oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
Topics: Acute Coronary Syndrome; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Costs; Humans; Patient Selection; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Ticagrelor; Treatment Outcome | 2020 |
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor | 2020 |
Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis.
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Withholding Treatment | 2020 |
Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Off-Label Use; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Risk of infections in patients treated with ticagrelor vs. clopidogrel: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2021 |
Effects of the
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide | 2020 |
Challenges of Combining Opioids and P2Y
Topics: Acute Coronary Syndrome; Analgesics, Opioid; Clopidogrel; Humans; Non-ST Elevated Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Treatment Outcome | 2021 |
Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticagrelor | 2020 |
Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Administration, Oral; Age Factors; Aged; Clopidogrel; Dose-Response Relationship, Drug; Humans; Purinergic P2Y Receptor Antagonists; Risk Assessment; Treatment Outcome | 2021 |
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Pyrazoles; Pyridones; Risk Factors | 2021 |
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Ischemic Stroke; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide | 2021 |
New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Exome Sequencing; Female; Humans; Machine Learning; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Predictive Value of Tests; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2021 |
Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists | 2021 |
Increased risk of adverse events in patients with low-on clopidogrel platelet reactivity after percutaneous coronary intervention: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.
Topics: Acute Coronary Syndrome; Clopidogrel; Comorbidity; Drug Interactions; Humans; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2Y12; Severity of Illness Index; Socioeconomic Factors; Ticlopidine; Treatment Outcome | 2017 |
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Treatment Outcome | 2017 |
Duration of dual antiplatelet therapy after coronary stent insertion: Does the benefit of extended therapy outweigh the risk?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Meta-Analysis as Topic; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Time Factors | 2016 |
Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Discovery; Drug Resistance; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Thiophenes; Ticlopidine | 2017 |
Differences in relative and absolute effectiveness of oral P2Y
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Sex Characteristics; Ticagrelor; Treatment Outcome; Young Adult | 2018 |
Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Asia; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2018 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticlopidine | 2017 |
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stents; Ticagrelor | 2018 |
Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Registries; Ticagrelor | 2018 |
Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Asian People; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Stents; Ticlopidine | 2018 |
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Genetic Association Studies; Genome-Wide Association Study; Humans; Internationality; Male; Middle Aged; Molecular Targeted Therapy; Pharmacogenetics; Prognosis; Receptors, Purinergic P2Y12; Risk Assessment; Survival Rate; Treatment Outcome | 2018 |
Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Precision Medicine | 2018 |
Acetylsalicylic acid and clopidogrel hyporesponsiveness following acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period | 2018 |
Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; France; Hemorrhage; Humans; Odds Ratio; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Survival Analysis; Ticagrelor; Treatment Outcome | 2018 |
[Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Thrombosis | 2018 |
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Ticagrelor; Treatment Outcome | 2018 |
Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Humans; London; Monte Carlo Method; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Time Factors | 2019 |
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Alleles; Biotransformation; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Loss of Function Mutation; Meta-Analysis as Topic; Patient Selection; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Precision Medicine; Purinergic P2Y Receptor Antagonists; Risk | 2019 |
Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Ticagrelor | 2019 |
Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Safety; Ticagrelor; Treatment Outcome | 2019 |
Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cigarette Smoking; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.
Topics: Acute Coronary Syndrome; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Humans; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Survival Analysis; Ticagrelor; Time Factors | 2019 |
De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Hospitalization; Humans; Patient Discharge; Prevalence; Ticagrelor | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochrome P-450 CYP2C19; Gene Expression; Genotype; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Survival Analysis; Thrombosis | 2019 |
Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis | 2019 |
Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; PubMed; Risk Assessment; Stents; Surgical Procedures, Operative; Thrombosis; Ticlopidine | 2013 |
The role of clopidogrel in the management of ischemic heart disease.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic; Preoperative Care; Randomized Controlled Trials as Topic; Ticlopidine | 2013 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Cigarette smoking and clopidogrel interaction.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Smoking; Smoking Cessation; Ticlopidine | 2013 |
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2013 |
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Proton pump inhibitors and clopidogrel: an association to avoid?
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Lansoprazole; Monitoring, Physiologic; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2014 |
Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine | 2013 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2013 |
What's new about clopidogrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stents; Thrombosis; Ticlopidine; Treatment Failure | 2013 |
Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angina, Stable; Case Management; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2014 |
[Antiplatelet therapy: resistance to traditional antiaggregation drugs and role of new antiplatelet agents].
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2014 |
Genetic and nongenetic factors influencing the response to clopidogrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Genotype; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Risk Assessment; Ticlopidine; Treatment Outcome | 2013 |
Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Genetic Testing; Genotype; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2013 |
Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2013 |
Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Drug Monitoring; Genetic Predisposition to Disease; Genetic Testing; Humans; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Ticlopidine; Treatment Outcome | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Efficacy and safety of prasugrel in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2014 |
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Ticlopidine; Time Factors | 2014 |
Update: Acute coronary syndromes (V). Personalized antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Precision Medicine; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Failure | 2014 |
Role of phenotypic and genetic testing in managing clopidogrel therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Humans; Odds Ratio; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Humans; Hypothermia, Induced; Intensive Care Units; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Risk Assessment; Shock, Cardiogenic; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
[Antiplatelet drugs].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2014 |
Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2014 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2014 |
Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Hematoma, Subdural; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke, Lacunar; Ticlopidine | 2015 |
Clinical pharmacokinetics and pharmacodynamics of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Humans; Polymorphism, Genetic; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2015 |
Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2015 |
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Stroke; Thrombosis; Ticlopidine | 2015 |
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Enzyme-Linked Immunosorbent Assay; Eptifibatide; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Risk Assessment; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2015 |
Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Drug Therapy, Combination; Female; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Male; Odds Ratio; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Survival Analysis; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
Practical experience with ticagrelor: an Australian and New Zealand perspective.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Clopidogrel and Genotyping.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Genotype; Humans; Omeprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine | 2015 |
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Trends in pharmacological therapy following an acute coronary syndrome in Portugal: a systematic review.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clopidogrel; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Secondary Prevention; Ticlopidine | 2016 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Stents; Ticagrelor; Ticlopidine | 2016 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Heparin; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Ticlopidine | 2015 |
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents; Tetrazoles; Thrombosis; Ticlopidine | 2015 |
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Glomerular Filtration Rate; Hemorrhage; Humans; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Renal Insufficiency; Ticagrelor; Ticlopidine | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Sex Factors; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
Topics: Acute Coronary Syndrome; Aged; Amino Acid Substitution; Aryldialkylphosphatase; Clopidogrel; Female; Humans; Male; Middle Aged; Mutation, Missense; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticlopidine | 2016 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Premedication; Ticlopidine; Time Factors | 2016 |
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Thrombosis; Ticlopidine | 2016 |
Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine | 2016 |
Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Gene Frequency; Humans; Inactivation, Metabolic; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2016 |
Systematic review of the clinical impact of dual antiplatelet therapy discontinuation after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Time Factors; Withholding Treatment | 2017 |
[Subgroup analysis results of platelet inhibition trial in acute coronary syndrome patients (PLATO) who underwent intervention or medical treatment].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2013 |
Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Combined Modality Therapy; Drug Interactions; Humans; Percutaneous Coronary Intervention; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine; Treatment Outcome | 2016 |
Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Immature Platelets: Clinical Relevance and Research Perspectives.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Humans; Megakaryocytes; RNA, Messenger; Ticlopidine | 2016 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticlopidine | 2016 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Genetic Determinants of P2Y
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticlopidine | 2017 |
Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Ticlopidine | 2017 |
Meta-analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticlopidine | 2017 |
Spontaneous coronary artery dissection: Case report and review of the literature.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Echocardiography; Electrocardiography; Female; Humans; Metoprolol; Platelet Aggregation Inhibitors; Ticlopidine; Vascular Diseases | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2017 |
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Disease Management; Humans; Nurse Practitioners; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Ticlopidine | 2008 |
The year in interventional cardiology.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; United States | 2008 |
Antiplatelet treatment of cardiovascular disease: a translational research perspective.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2008 |
Current antiplatelet therapies: benefits and limitations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Humans; Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Ticlopidine; Treatment Outcome | 2008 |
Contemporary issues on clopidogrel therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Humans; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Variability in responsiveness to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Signal Transduction; Ticlopidine; Treatment Outcome | 2009 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk Factors; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2009 |
Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2009 |
Clopidogrel resistance: pharmacokinetic or pharmacogenetic?
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Humans; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2009 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Ticlopidine | 2008 |
Does timing matter? Upstream or downstream administration of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Algorithms; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Ticlopidine | 2009 |
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine | 2009 |
Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Resistance; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2009 |
Clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2009 |
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2009 |
Prasugrel for the treatment of patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
[New approach to interventional cardiology treatment with personalized medicine].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Drug Resistance; Hematologic Diseases; Humans; Myocardial Infarction; Personal Health Services; Ticlopidine; Treatment Failure | 2008 |
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2009 |
Clopidogrel in the management of acute coronary syndromes: indications, results, obstacles.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2009 |
Review of prasugrel for the secondary prevention of atherothrombosis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Emergency Service, Hospital; Enoxaparin; Fondaparinux; Health Services Accessibility; Hirudins; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Polysaccharides; Recombinant Proteins; Ticlopidine; Triage; United States | 2009 |
A new generation of antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Receptors, Thrombin; Ticlopidine; von Willebrand Factor | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine | 2009 |
The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom; Withholding Treatment; Young Adult | 2009 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Vasoconstriction | 2009 |
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine | 2009 |
Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Tissue Distribution; Young Adult | 2009 |
Coronary bypass surgery in patients treated with clopidogrel. Is it safe?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome | 2009 |
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Antiplatelet resistance--fact or myth?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Factors; Stents; Thrombosis; Ticlopidine | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2009 |
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Advances in antiplatelet treatment for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
[Acute coronary syndrome in patients with carbohydrate metabolic disturbances (a review)].
Topics: Acute Coronary Syndrome; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2009 |
Prasugrel: a critical comparison with clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Drug Inverse Agonism; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States | 2009 |
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2010 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Prasugrel: Clinical development and therapeutic application.
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastroenterology; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Ticlopidine | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Thrombosis; Ticlopidine; United States | 2009 |
Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Time Factors | 2010 |
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine | 2010 |
Factors associated with clopidogrel nonresponsiveness.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Smoking; Ticlopidine; Treatment Failure | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2010 |
Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine | 2010 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine | 2010 |
[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
Acute coronary syndrome in the patient with diabetes: is the management different?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2010 |
[The role of clopidogrel in the treatment and prevention of acute coronary syndrome and repetitive atherothrombotic events].
Topics: Acute Coronary Syndrome; Clopidogrel; Embolism, Cholesterol; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine; Treatment Outcome | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Economic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality of Life; Quality-Adjusted Life Years; Risk Assessment; Thiophenes; Ticlopidine; United Kingdom | 2010 |
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Contraindications; Critical Pathways; Heparin; Humans; Myocardial Infarction; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Thrombolytic Therapy; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Prasugrel.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
[Platelet inhibition with prasugrel].
Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogrel; Coronary Artery Disease; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Double-Blind Method; Drug Resistance; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Multicenter Studies as Topic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2010 |
[Reduction of haemorrhagic risk in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2011 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2011 |
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Postoperative Complications; Purinergic P2 Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Ticlopidine | 2010 |
Nonresponders to clopidogrel: pharmacokinetics and interactions involved.
Topics: Acute Coronary Syndrome; Biotransformation; Clopidogrel; Drug Interactions; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Ticlopidine | 2010 |
Clopidogrel in acute coronary syndrome: implications of recent study findings.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Circulation; Death, Sudden, Cardiac; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Streptokinase; Stroke; Thrombosis; Ticlopidine; Time Factors | 2010 |
A comparison of the metabolism of clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine | 2010 |
Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2010 |
Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2010 |
Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Evaluation; Humans; Individuality; Pharmacogenetics; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Treatment Outcome | 2011 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Risk; Stents; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
[New era in antiplatelet therapy based on results from recent clinical trials].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine | 2011 |
The safety of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; Ticlopidine | 2011 |
Controversy of proton pump inhibitor and clopidogrel interaction: a review.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Stomach Ulcer; Ticlopidine | 2010 |
Clopidogrel withdrawal: is there a "rebound" phenomenon?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Factors; Thrombosis; Ticlopidine | 2010 |
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2010 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Agonists; Randomized Controlled Trials as Topic; Registries; Secondary Prevention; Ticlopidine; Time Factors; United Kingdom | 2010 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Perioperative Period; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Ticlopidine | 2011 |
Thienopyridines in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thienopyridines; Ticlopidine | 2011 |
Antiplatelet resistance in stroke.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk; Secondary Prevention; Stroke; Ticlopidine | 2011 |
[Current options to manage clopidogrel poor responsiveness].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Triple therapy in hospitalized patients: facts and controversies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin | 2011 |
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2011 |
Triple therapy: boon or bane for high-risk CV patients?
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin | 2011 |
Clopidogrel in acute coronary syndromes: where are we now?
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Platelet Activation; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Survival Analysis; Ticlopidine; Treatment Outcome | 2011 |
High platelet reactivity and clinical outcome - fact and fiction.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Variation; Humans; Phenotype; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Interactions; Enzyme Activation; Genetic Testing; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Postoperative Complications; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Female; Hemorrhage; Humans; Length of Stay; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Preoperative Care; Reoperation; Research Design; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Treatment Outcome | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor for acute coronary syndrome?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; In Vitro Techniques; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Precision Medicine; Prospective Studies; Receptors, Purinergic P2Y12; Risk Factors; Signal Transduction; Stents; Thrombosis; Ticlopidine; Translational Research, Biomedical | 2011 |
[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2; Stents; Ticlopidine | 2011 |
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Role of platelet function testing in clinical practice: current concepts and future perspectives.
Topics: Acute Coronary Syndrome; Biotransformation; Brain Ischemia; Clopidogrel; Drug Monitoring; Drug Resistance; Humans; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk; Ticlopidine | 2011 |
Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Humans; Male; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Assessment; Selection Bias; Thromboembolism; Ticlopidine; Treatment Outcome | 2011 |
Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Design; Drug Interactions; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Ticlopidine | 2012 |
The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2011 |
A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Data Interpretation, Statistical; Drug Interactions; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticlopidine | 2012 |
Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Drug Design; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticlopidine | 2012 |
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Humans; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2012 |
Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Clopidogrel and PPI interaction: clinically relevant or not?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Thienopyridines; Ticlopidine | 2012 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Drug Interactions; Genotype; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine | 2011 |
Medical groups, researchers fine-tune clopidogrel therapy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Randomized Controlled Trials as Topic; Ticlopidine | 2011 |
[Clopidogrel resistance--clinical significance, pathogenesis and potential solutions].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Prevalence; Thrombosis; Ticlopidine | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis.
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Female; Humans; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Risk Factors; Ticlopidine | 2012 |
A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
InforMatrix: ADP antagonists in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Options to overcome clopidogrel response variability.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Genotype; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Dipyridamole; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Stroke; Survival Rate; Ticlopidine | 2012 |
Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cilostazol; Clopidogrel; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine; Treatment Outcome | 2010 |
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticlopidine | 2012 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Therapy, Combination; Heart Failure; Humans; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Prodrugs; Risk; Stents; Tetrazoles; Thrombosis; Ticlopidine | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Acute coronary syndromes: identifying the appropriate patient for prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Secondary Prevention; Thiophenes; Ticlopidine | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2012 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Precision Medicine; Risk; Thrombosis; Ticlopidine | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome | 2012 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Heart Diseases; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Thromboembolism; Ticlopidine; Treatment Outcome | 2012 |
Genetic considerations.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Genome-Wide Association Study; Genotype; Humans; Liver; Pharmacogenetics; Phenotype; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2012 |
Stents and antiplatelet therapy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Prosthesis Design; Risk Factors; Stents; Thienopyridines; Thrombosis; Ticlopidine | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Risk Assessment; Ticlopidine | 2012 |
Review of ticagrelor in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2012 |
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
Clinical importance of antiplatelet drugs in cardiovascular diseases.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cyclooxygenase Inhibitors; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2013 |
Clopidogrel: the data, the experience, and the controversies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2012 |
A critical overview on ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Pharmacogenetics of clopidogrel and its clinical significance].
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Humans; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2012 |
Dual antiplatelet therapy for primary and secondary prevention.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Primary Prevention; Secondary Prevention; Ticlopidine | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Randomized Controlled Trials as Topic; Registries; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Metabolic differences of current thienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Clinical use of clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Ticlopidine; Treatment Outcome | 2007 |
Clopidogrel resistance.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2; Ticlopidine; Treatment Failure | 2007 |
[Management coronary syndrome in the acute phase].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2007 |
[Long-term management of post acute coronary syndrome with oral antiplatelet therapy].
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Registries; Ticlopidine | 2007 |
Coronary stents and noncardiac surgery.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Surgical Procedures, Operative; Thrombosis; Ticlopidine | 2007 |
Management of an acute coronary syndrome in a patient with severe haemophilia A.
Topics: Acute Coronary Syndrome; Antifibrinolytic Agents; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemophilia A; Hemostatics; Heparin; Humans; Life Expectancy; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resistance; Humans; Monitoring, Physiologic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Treatment Outcome | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-Based Medicine; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Thrombosis; Ticlopidine | 2007 |
[Optimizing antithrombotic therapy in non-ST-elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Fibrinolytic Agents; Fondaparinux; Hirudins; Humans; Peptide Fragments; Polysaccharides; Recombinant Proteins; Ticlopidine | 2007 |
P2Y12 antagonism: promises and challenges.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Education, Medical, Continuing; Female; Humans; Male; Maximum Tolerated Dose; Membrane Proteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Risk Assessment; Survival Analysis; Ticlopidine; Treatment Outcome | 2008 |
[Gp IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Hirudins; Humans; Myocardial Infarction; Myocardial Revascularization; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Recombinant Proteins; Ticlopidine; Troponin T | 2007 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Enoxaparin; Eptifibatide; Fibrinolytic Agents; Heart Conduction System; Hemorrhage; Heparin; Hirudins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Peptide Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Ticlopidine | 2008 |
[Pharmacoeconomic evaluation of clopidogrel in acute coronary syndromes. Long-term treatment, secondary prophylaxis, and percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Economics, Pharmaceutical; Health Care Costs; Humans; Internationality; Longitudinal Studies; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Evidence-Based Medicine; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2008 |
[Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Resistance; Drugs, Investigational; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Emergency Medicine; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2008 |
Antiplatelet drug nonresponsiveness.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2008 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2008 |
Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Contraindications; Europe; Humans; North America; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Ticlopidine | 2008 |
Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticlopidine; Treatment Outcome | 2008 |
Managing antiplatelet therapy in the ACS patient: straight from the emergency department to you.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Emergency Treatment; Hospitalists; Humans; Myocardial Revascularization; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Prasugrel: a novel antiplatelet agent.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2008 |
347 trial(s) available for clopidogrel and Acute Coronary Syndrome
| Article | Year |
|---|---|
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes.
Topics: Acute Coronary Syndrome; Clopidogrel; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2021 |
ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Treatment Outcome | 2022 |
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Medication Adherence; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2022 |
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2022 |
Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III).
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thrombotic Stroke; Treatment Outcome | 2023 |
Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sex Factors; Treatment Outcome | 2022 |
In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: Findings from the CCC-ACS project.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Hospitals; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Impact of hemoglobin levels at admission on outcomes among elderly patients with acute coronary syndrome treated with low-dose Prasugrel or clopidogrel: A sub-study of the ELDERLY ACS 2 trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Hospitalization; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2022 |
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Biomarkers; Clopidogrel; Growth Differentiation Factor 15; Humans; Myocardial Infarction; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombosis; Treatment Outcome | 2023 |
Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Ticagrelor; Treatment Outcome | 2022 |
In-hospital outcomes of ticagrelor versus clopidogrel in patients 75 years or older with acute coronary syndrome: findings from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome Project.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; China; Clopidogrel; Hemorrhage; Hospitals; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality Improvement; Ticagrelor | 2022 |
Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
Topics: Acute Coronary Syndrome; Brain Ischemia; Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke | 2023 |
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes-a substudy of the TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemia; Overweight; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2023 |
Genetic-Guided Oral P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2023 |
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Drug-Eluting Stents; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Early Effects of Ticagrelor Versus Clopidogrel on Peripheral Endothelial Function After Non-ST-Elevation Acute Coronary Syndrome and Assessment of Its Relationship With Coronary Microvascular Function.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Infarction; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticlopidine | 2023 |
Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.
Topics: Acute Coronary Syndrome; Alleles; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; China; Clopidogrel; Cytochrome P-450 CYP2C19; Gene Frequency; Genetic Association Studies; Humans; Logistic Models; Middle Aged; Polymorphism, Single Nucleotide; Risk Factors | 2019 |
Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Circulation; Female; Hemodynamics; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2019 |
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Female; Fibrinolysis; Humans; Male; Platelet Aggregation Inhibitors; Rivaroxaban; Thrombelastography; Thrombosis; Ticagrelor | 2020 |
Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Vessels; Endothelium; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography.
Topics: Acute Coronary Syndrome; Aged; Analgesics, Opioid; Clopidogrel; Coronary Angiography; Female; Humans; Male; Middle Aged; Morphine; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Treatment Outcome | 2020 |
Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
Topics: Acute Coronary Syndrome; Ammonia; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Positron-Emission Tomography; Prospective Studies; Ticagrelor; Time Factors | 2020 |
Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Cause of Death; Clopidogrel; Comorbidity; Female; Frail Elderly; Geriatric Assessment; Hemorrhage; Humans; Italy; Male; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2020 |
Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Death; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies | 2020 |
60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Cross-Over Studies; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Single-Blind Method; Ticagrelor; Treatment Outcome | 2020 |
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Ticagrelor | 2020 |
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized
Topics: Acute Coronary Syndrome; Adult; Area Under Curve; Asian People; Aspirin; Clopidogrel; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Therapeutic Equivalency; Thrombosis; Ticlopidine | 2020 |
Pharmacokinetics and Bioequivalence of Clopidogrel Hydrogen Sulfate Tablets in Fed and Fasted Conditions: An Open-Label, Randomized, Semireplicated Crossover Study in Healthy Chinese Volunteers.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Area Under Curve; Asian People; Atherosclerosis; Chromatography, Liquid; Clopidogrel; Coronary Restenosis; Cross-Over Studies; Drug Compounding; Fasting; Female; Healthy Volunteers; Humans; Male; Platelet Aggregation Inhibitors; Stents; Tandem Mass Spectrometry; Therapeutic Equivalency; Thrombosis | 2020 |
TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Secondary Prevention; Thrombosis; Ticagrelor; Young Adult | 2020 |
Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Egypt; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Young Adult | 2020 |
A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALO
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Double-Blind Method; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Outcome and Process Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Adjustment; Stroke | 2020 |
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Atherosclerosis; Case-Control Studies; Clopidogrel; Cysteine Endopeptidases; Cysteine Proteases; Death; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Female; Genotype; Genotyping Techniques; Hemorrhage; Heterozygote; Humans; Loss of Function Mutation; Male; Middle Aged; Percutaneous Coronary Intervention; Point-of-Care Testing; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2021 |
Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Fatty Acids, Unsaturated; Female; Humans; Lipid Metabolism; Male; Metabolomics; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Long-Term Vascular Function in CTO Recanalization: A Randomized Clinical Trial of Ticagrelor vs. Clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Global Health; Hemorrhage; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Ticlopidine; Time Factors | 2017 |
Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ranitidine; Republic of Korea; Single-Blind Method; Ticlopidine | 2017 |
Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Troponin; Up-Regulation | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Growth Differentiation Factor 15; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
[IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
Topics: Acute Coronary Syndrome; Aspirin; Atorvastatin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Drug Interactions; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Rosuvastatin Calcium; Ticlopidine | 2017 |
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopidogrel; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymers; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Drug-Eluting Stents; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Ticlopidine | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Ticlopidine | 2017 |
Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Elimination; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Recurrence; Risk Factors; Smoking; ST Elevation Myocardial Infarction; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Osteoprotegerin; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Up-Regulation | 2018 |
Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Ticlopidine | 2018 |
Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Circulation; Female; Humans; Male; Microcirculation; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Randomized Controlled Trials as Topic; Republic of Korea; Ticagrelor; Time Factors; Treatment Outcome; Vascular Resistance; Young Adult | 2018 |
Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.
Topics: Acute Coronary Syndrome; Aged; Blood Coagulation; Clopidogrel; Double-Blind Method; Female; Fibrin; Fibrin Clot Lysis Time; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2018 |
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Capsules; Clopidogrel; Double-Blind Method; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Endothelium, Vascular; Female; Humans; Male; Outcome Assessment, Health Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2018 |
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Ticlopidine; Treatment Outcome | 2018 |
Study of the Association of PEAR1, P2Y12, and UGT2A1 Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Asian People; Aspirin; Blood Platelets; China; Clopidogrel; Female; Glucuronosyltransferase; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Receptors, Purinergic P2Y12; Thrombelastography | 2018 |
CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors | 2018 |
Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Incidence; Male; Myocardial Infarction; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Survival Rate; Time Factors; Treatment Outcome; United States | 2018 |
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2018 |
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Clopidogrel; Coronary Vessels; Cross-Over Studies; Endothelium, Vascular; Europe; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation | 2018 |
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis.
Topics: Acute Coronary Syndrome; Aged; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Clopidogrel; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticagrelor | 2018 |
Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Blood Platelets; Clopidogrel; Europe; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Single-Blind Method; Stroke | 2018 |
Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
Topics: Acute Coronary Syndrome; Aged; Alleles; Blood Platelets; Cells, Cultured; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Patient Selection; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2018 |
Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Treatment Outcome | 2018 |
Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Revascularization; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Treatment Outcome | 2018 |
Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Creatine Kinase, MB Form; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardium; Necrosis; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Seoul; Time Factors; Tirofiban; Treatment Outcome; Troponin I | 2018 |
Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Double-Blind Method; Feasibility Studies; Female; Health Status; Hospitalization; Humans; Length of Stay; Male; Non-ST Elevated Myocardial Infarction; Patient-Centered Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Ticagrelor | 2019 |
Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Single-Blind Method; Survival Rate; Time Factors | 2019 |
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Circadian Rhythm; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Time Factors | 2019 |
Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thrombosis; Tissue Scaffolds; Young Adult | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Comorbidity; Diabetes Mellitus; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Survival Rate; Ticagrelor; United States | 2019 |
Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aging; Clopidogrel; Comorbidity; Exercise; Female; Frailty; Hand Strength; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Prognosis; Self Report; Sex Factors; Walking Speed | 2019 |
Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Time Factors; Tokyo; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Blood Platelets; Brachial Artery; Clopidogrel; Endothelium, Vascular; Humans; Non-ST Elevated Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Republic of Korea; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation | 2019 |
Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
Topics: Acute Coronary Syndrome; Aged; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Treatment Outcome | 2019 |
Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor | 2019 |
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor | 2019 |
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Stu
Topics: Acute Coronary Syndrome; Adult; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; United Kingdom | 2019 |
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk Assessment; Stroke; Treatment Outcome | 2019 |
Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Dual Anti-Platelet Therapy; Europe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Prasugrel Hydrochloride; Sex Factors; Treatment Outcome | 2019 |
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Severity of Illness Index; Ticlopidine | 2013 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELO
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2013 |
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Myocardial Infarction; Platelet Activation; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Ticlopidine | 2013 |
Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Topics: Abciximab; Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Administration Routes; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Quality of Life; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Follow-Up Studies; Heart Diseases; Humans; Internationality; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET):
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Practice Guidelines as Topic; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2013 |
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Diagnostic Imaging; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Health Care Costs; Hospitalization; Humans; Markov Chains; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Switzerland; Ticagrelor; Ticlopidine | 2013 |
Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; United Kingdom | 2014 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Sweden; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentiation Factor 15; Hospital Mortality; Humans; Kaplan-Meier Estimate; Myocardial Revascularization; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Troponin T | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Sirolimus; Stroke; Thrombosis; Ticlopidine | 2013 |
Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; MicroRNAs; Middle Aged; Platelet Aggregation Inhibitors; Real-Time Polymerase Chain Reaction; Retrospective Studies; Ticlopidine; Troponin | 2014 |
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, Liquid; Clopidogrel; Cyclic AMP; Erythrocytes; Female; Humans; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; Drug Synergism; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor; Ticlopidine | 2014 |
Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Double-Blind Method; Drug-Eluting Stents; Female; Fibrinolytic Agents; Humans; Maintenance Chemotherapy; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Denmark; Humans; Purinergic P2Y Receptor Antagonists; Sweden; Ticagrelor; Ticlopidine | 2014 |
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2014 |
Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, control
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxidative Stress; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2014 |
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary Vessels; Humans; Microcirculation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Research Design; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography | 2014 |
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom; United States | 2014 |
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cause of Death; Clopidogrel; Confidence Intervals; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2015 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine | 2014 |
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2014 |
Platelet function in Takotsubo cardiomyopathy.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Epinephrine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Registries; Takotsubo Cardiomyopathy; Ticlopidine | 2015 |
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Topics: Acute Coronary Syndrome; Aged; Antithrombins; Clopidogrel; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hirudins; Humans; Internationality; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Recombinant Proteins; Ticlopidine; Treatment Outcome | 2015 |
Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Testing; Prospective Studies; Therapeutic Equivalency; Ticlopidine | 2014 |
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Topics: Acute Coronary Syndrome; Adenosine; Brazil; Clopidogrel; Cost-Benefit Analysis; Disease Management; Electrocardiography; Female; Germany; Health Care Costs; Humans; Male; Markov Chains; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Quality of Life; Quality-Adjusted Life Years; Secondary Prevention; Sweden; Ticagrelor; Ticlopidine; United Kingdom | 2015 |
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Cardiotonic Agents; Clopidogrel; Contrast Media; Coronary Angiography; Creatine Kinase, MB Form; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardium; Necrosis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ticlopidine; Treatment Outcome; Troponin I | 2014 |
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Secondary Prevention; Stroke; Survival Analysis; Ticlopidine; Treatment Outcome | 2014 |
Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and st
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Humans; Inactivation, Metabolic; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ticlopidine | 2015 |
Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2015 |
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
Topics: Acute Coronary Syndrome; Acute Disease; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Switzerland; Ticlopidine; Treatment Outcome | 2016 |
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Hemorrhage; Humans; Hyperplasia; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Stents; Stroke; Ticlopidine; Tunica Intima | 2015 |
Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Antigens, CD34; Body Mass Index; Clopidogrel; Endothelial Progenitor Cells; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Double-Blind Method; Female; Frail Elderly; Health Surveys; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Platelet Aggregation; Platelet Count; Reproducibility of Results; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2015 |
Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Stroke; Ticlopidine; Treatment Outcome | 2016 |
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.
Topics: Acute Coronary Syndrome; Adult; Aftercare; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Cl
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acu
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Analysis; Thrombosis; Ticlopidine; Ultrasonography, Interventional | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2016 |
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Transplantation, Homologous; Treatment Outcome | 2015 |
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Long-Term Care; Male; Neoplasms; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2016 |
Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2016 |
Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; Clopidogrel; Drug Interactions; Drug-Eluting Stents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Polypharmacy; Prospective Studies; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2015 |
VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Single-Blind Method; Ticlopidine; Treatment Outcome | 2015 |
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Cause of Death; Clopidogrel; Death, Sudden, Cardiac; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Preoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Troponin | 2016 |
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticlopidine; Treatment Outcome | 2016 |
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Extremities; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Severity of Illness Index; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Humans; Japan; Ticagrelor; Ticlopidine; Treatment Outcome; United States; White People | 2016 |
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Omeprazole; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2016 |
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Humans; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Ticlopidine | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Adult; Aged; Aspirin; Cardiopulmonary Resuscitation; Clopidogrel; Coma; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticlopidine | 2016 |
Effect of Smoking Status on Clinical Outcome and Efficacy of Clopidogrel in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Disease-Free Survival; Female; Hospital Mortality; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Smoking; Survival Rate; Ticlopidine | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
[The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2015 |
[TRILOGY-ACS and ACCOAST trial from an expert's perspective].
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Ticlopidine | 2015 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Fatty Alcohols; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Substitution; Female; Gene Expression Regulation; Humans; Male; MicroRNAs; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Humans; Male; Markov Chains; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticlopidine | 2016 |
The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Prognosis; Risk Factors; Ticlopidine | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prosthesis Implantation; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic; Stents; Ticlopidine | 2017 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syn
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality of Life; Ticlopidine | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Myocardial Infarction; Neointima; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Assessment; Risk Factors; Sex Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Thrombelastography; Ticlopidine; Treatment Outcome | 2017 |
Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Vessels; Double-Blind Method; Female; Humans; Male; Middle Aged; Mortality; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2016 |
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Long Term Adverse Effects; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Ticlopidine; Time Factors | 2016 |
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes
Topics: Acute Coronary Syndrome; Adult; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Research Design; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2017 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Administration Schedule; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Ontario; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Area Under Curve; Aspirin; Biological Availability; Clopidogrel; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Healthy Volunteers; Humans; Male; Middle Aged; Therapeutic Equivalency; Ticlopidine; Young Adult | 2016 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolimus; Female; Hemorrhage; Humans; Immunosuppressive Agents; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; China; Clopidogrel; Drug Resistance; Drugs, Chinese Herbal; Female; Heart Rate; Humans; Male; Matrix Metalloproteinase 2; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Tablets; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Expression; Gene Frequency; Genotype; Genotyping Techniques; Humans; Male; Middle Aged; Mutation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Incidence; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atorvastatin; C-Reactive Protein; Clopidogrel; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2008 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reac
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prognosis; Prospective Studies; ROC Curve; Ticlopidine; Treatment Outcome | 2008 |
Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2008 |
Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardium; Necrosis; Platelet Aggregation Inhibitors; Ticlopidine; Troponin | 2009 |
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2008 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Retrospective Studies; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Radiography; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2009 |
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Resistance; Female; Gene Frequency; Genetic Variation; Genotype; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Ticlopidine; Treatment Failure | 2009 |
Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Heptanoic Acids; Humans; Korea; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Single-Blind Method; Sirolimus; Ticlopidine; Time Factors | 2009 |
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatine Kinase, MB Form; Death, Sudden, Cardiac; Double-Blind Method; Humans; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Thiophenes; Ticlopidine; Time Factors; Troponin T | 2009 |
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Care Units; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome; Triage | 2009 |
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; Troponin; Young Adult | 2008 |
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Ticlopidine; Young Adult | 2009 |
A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2009 |
The FDA prasugrel review: adjudication of myocardial infarction controversy.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
[Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine | 2009 |
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; Blood Coagulation; CD40 Ligand; Clopidogrel; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Hirudins; Humans; Lipoproteins; Male; Membrane Glycoproteins; Middle Aged; Monocytes; Peptide Fragments; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Recombinant Proteins; Thromboplastin; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Stents; Ticlopidine | 2009 |
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Artery Bypass; Female; Gastrointestinal Hemorrhage; Heparin; Hirudins; Humans; Incidence; Ischemia; Length of Stay; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Sex Factors; Stents; Thrombosis; Ticlopidine | 2009 |
Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Clopidogrel; Confidence Intervals; Female; Hirudins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recombinant Proteins; Ticlopidine; Treatment Outcome | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Female; Follow-Up Studies; Hematoma; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Count; Premedication; Retreatment; Sex Factors; Stents; Ticlopidine; Troponin T; Whole Blood Coagulation Time | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Treatment Failure | 2009 |
Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Angiography; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Stents; Tablets, Enteric-Coated; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary
Topics: Abciximab; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Revascularization; Netherlands; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2010 |
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2010 |
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Double-Blind Method; Female; Heparin; Humans; Japan; Lactones; Male; Middle Aged; Placebos; Pyridines; Receptor, PAR-1; Ticlopidine | 2010 |
Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine | 2010 |
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Double-Blind Method; Female; Humans; Interleukin-6; Male; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hospitalization; Humans; Incidence; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New Zealand; Odds Ratio; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; United States | 2011 |
Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Algorithms; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine; Young Adult | 2010 |
[Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Circadian Rhythm; Clopidogrel; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Time Factors | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Secondary Prevention; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Service, Hospital; Enoxaparin; Female; Follow-Up Studies; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Reference Values; Severity of Illness Index; Survival Rate; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2010 |
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Research Design; Stroke; Ticlopidine | 2010 |
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronar
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stents; Sulfonamides; Ticlopidine | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world.
Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Aspirin; Carotid Arteries; Carotid Stenosis; Chi-Square Distribution; Cilostazol; Clopidogrel; Coronary Angiography; Disease Progression; Drug Therapy, Combination; Hemorrhage; Humans; Inflammation Mediators; Middle Aged; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Risk Assessment; Risk Factors; Single-Blind Method; Stents; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Factors; Thrombosis; Ticlopidine | 2010 |
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Stents; Stroke; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2011 |
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Hemorrhage; Humans; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Ticlopidine; Treatment Outcome | 2011 |
Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke Volume; Ticlopidine; Treatment Outcome; Troponin; Ventricular Function, Left | 2011 |
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2011 |
Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Ticlopidine; Treatment Outcome | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Phenotype; Phosphoproteins; Placebo Effect; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Proton Pump Inhibitors; Risk Assessment; Ticlopidine; Time Factors; Victoria | 2011 |
Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2011 |
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Clopidogrel; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prosthesis Failure; Receptors, Purinergic P2Y12; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Oxygen Consumption; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Respiratory Function Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Blood Platelets; Clopidogrel; Double-Blind Method; Esomeprazole; Famotidine; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2011 |
Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Esomeprazole; Famotidine; Female; Fibrinolytic Agents; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intestinal Perforation; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Ticlopidine; Treatment Outcome | 2012 |
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; Cystatin C; Double-Blind Method; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Precursors; Ticagrelor; Ticlopidine; Troponin I | 2012 |
Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Clopidogrel; Drugs, Generic; Humans; Long-Term Care; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2012 |
[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Tirofiban; Tyrosine | 2011 |
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2012 |
Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Disease-Free Survival; Female; Humans; Male; Middle Aged; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine; Time Factors | 2012 |
Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Dosage Calculations; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2012 |
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Length of Stay; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Risk Factors; Ticlopidine | 2012 |
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Carrier Screening; Genetic Testing; Genotype; Humans; Loss of Heterozygosity; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
[Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation].
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Ticlopidine | 2012 |
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Troponin T | 2012 |
Lessons from platelet inhibition and patient outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Statistics as Topic; Ticagrelor; Ticlopidine; United States | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine | 2012 |
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Genotype; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Ticlopidine; Treatment Outcome | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine | 2012 |
Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Isoindoles; Male; Middle Aged; Percutaneous Coronary Intervention; Phenylbutyrates; Platelet Aggregation Inhibitors; Risk Factors; Thromboxane B2; Ticlopidine; Treatment Outcome | 2013 |
Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Brazil; Case Management; Checklist; Clopidogrel; Developing Countries; Education, Medical, Continuing; Evidence-Based Practice; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality Improvement; Reminder Systems; Single-Blind Method; Ticlopidine; Urban Population | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP3A; Drug Resistance; Female; Genetic Predisposition to Disease; Genetic Variation; Humans; Male; Mexico; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Single Nucleotide; Prevalence; Receptors, Purinergic P2Y12; Risk Factors; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antagonism; Famotidine; Female; Humans; Male; Middle Aged; Myocardial Infarction; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine | 2012 |
Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass, Off-Pump; Coronary Occlusion; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2012 |
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Stents; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Thrombosis; Ticlopidine | 2012 |
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
[Acute non ST-elevation coronary syndrome in real practice of hospitals in Russia. Comparative data from RECORD 2 and RECORD registries].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Hospital Mortality; Hospitals; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Russia; Survival Rate; Ticlopidine; Treatment Outcome; Young Adult | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Analysis of Variance; Biomarkers; Clopidogrel; Cystatin C; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Substitution; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Pharmacogenetics; Phenotype; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angiography; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Diabetes Complications; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Count; Ticlopidine; Time Factors; Treatment Outcome | 2007 |
To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet-Rich Plasma; Prospective Studies; Reproducibility of Results; Ticlopidine | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2007 |
Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Canada; Clopidogrel; Cost of Illness; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hospitalization; Humans; Length of Stay; Life Expectancy; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticlopidine; Time Factors | 2007 |
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Biomarkers; Cardiovascular Surgical Procedures; Clopidogrel; Electrocardiography; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Platelet Aggregation Inhibitors; Preoperative Care; Survival Analysis; Ticlopidine; Time Factors; Treatment Outcome; Troponin T | 2008 |
Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Animals; Clopidogrel; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Tirofiban; Tyrosine | 2009 |
[The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Proton Pump Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome; Warfarin | 2007 |
Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet-Rich Plasma; ROC Curve; Sensitivity and Specificity; Ticlopidine | 2008 |
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Double-Blind Method; Epidemiologic Methods; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Infarction; Perioperative Care; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2008 |
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Survival Analysis; Ticlopidine; Treatment Outcome | 2008 |
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Ischemia; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Recurrence; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
[The TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Humans; Immunoglobulin Fab Fragments; Male; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Treatment Outcome | 2008 |
High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) a
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2008 |
911 other study(ies) available for clopidogrel and Acute Coronary Syndrome
| Article | Year |
|---|---|
N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Humans; Indoles; Injections, Intravenous; Male; Models, Chemical; Molecular Structure; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridazines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2Y12; Thrombosis | 2014 |
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2022 |
Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Inflammation; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and Simulation.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Comparative Effectiveness Research; Computer Simulation; Female; Hospitalization; Humans; Intention to Treat Analysis; Latent Class Analysis; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Selection Bias; Stroke; Ticagrelor; Treatment Outcome; Treatment Switching | 2022 |
Safety and efficacy of clopidogrel versus ticagrelor in acute coronary syndrome in the prehospital setting.
Topics: Acute Coronary Syndrome; Clopidogrel; Emergency Medical Services; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality of Life; Ticagrelor; Treatment Outcome | 2021 |
Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2021 |
Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Treatment Outcome | 2022 |
Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel-An observational cohort study in Sweden.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sweden; Ticagrelor; Treatment Outcome | 2022 |
Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Bilateral multifocal muscular hemorrhage in the triceps surae during antiplatelet therapy: a case report.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Leg; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Ticlopidine; Treatment Outcome | 2022 |
Prolonged dual antiplatelet therapy in selected patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Identifying Racial, Ethnic, and Socioeconomic Inequities in the Use of Novel P2Y12 Inhibitors After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Clopidogrel; Drug-Eluting Stents; Ethnicity; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Socioeconomic Factors; Treatment Outcome | 2022 |
Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation.
Topics: Acute Coronary Syndrome; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Cell Surface; Ticlopidine; Treatment Outcome | 2022 |
Predictors and long-term outcomes of in-hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Diabetes Mellitus, Type 2; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel or ticagrelor in elderly patients with acute coronary syndromes - Nihil nocere!
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2022 |
Predictors of In-Hospital De-Escalation of P2Y12 Inhibitors to Clopidogrel in Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hospitals; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors | 2022 |
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel.
Topics: Acute Coronary Syndrome; Brain Ischemia; China; Clopidogrel; Hemorrhage; Hemorrhagic Stroke; Humans; Intracranial Hemorrhages; Ischemic Stroke; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stroke; Ticagrelor | 2022 |
P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
How do type of preoperative P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Systematic Reviews as Topic; Ticagrelor | 2022 |
Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Atrial Fibrillation; Clopidogrel; Cost-Benefit Analysis; Decision Support Systems, Clinical; Humans; Markov Chains; Middle Aged; Pharmacogenetics; Quality-Adjusted Life Years; Vitamin K Epoxide Reductases; Warfarin | 2022 |
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Performance of the ABCD-GENE Score for Predicting Clinical Outcomes in Clopidogrel-Treated Patients with ACS.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2022 |
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Topics: Acute Coronary Syndrome; Aspirin; Australia; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
[Multimorbidity in elderly patients with acute coronary syndrome: insights from BleeMACS registry].
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Multimorbidity; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Treatment Outcome | 2022 |
The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2023 |
Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Veterans | 2023 |
Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride | 2022 |
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cost-Benefit Analysis; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2022 |
[Dual antiplatelet therapy (DAPT) after acute coronary syndrome: short DAPT versus de-escalation].
Topics: Acute Coronary Syndrome; Clopidogrel; Dinucleoside Phosphates; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2022 |
In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Hospitals; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Prasugrel for Secondary Prevention of Thrombotic Stroke.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thrombotic Stroke; Treatment Outcome | 2023 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2022 |
Prescribing Trends and Health Care Expenditure of P2Y
Topics: Acute Coronary Syndrome; Australia; Clopidogrel; Health Expenditures; Humans; Percutaneous Coronary Intervention; Pharmaceutical Preparations; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescriptions; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Impact of Ticagrelor Versus Clopidogrel on Bleeding Outcomes of Isolated Coronary Artery Bypass Grafting.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Renal Insufficiency; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dimaprit; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Ticagrelor; Treatment Outcome | 2022 |
The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.
Topics: Acute Coronary Syndrome; Albumins; Blood Platelets; Clopidogrel; Cyclic AMP Response Element-Binding Protein A; Glycated Hemoglobin; Humans; Platelet Aggregation Inhibitors; RNA, Messenger; Ticlopidine; Uric Acid | 2022 |
Preoperative treatment with clopidogrel and ticagrelor on bleeding complications in off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Answer Regarding: Potent P2Y12 Inhibitors and Bleeding Complications.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Potent P2Y12 Inhibitors and Bleeding Complications.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2022 |
Real-World Data on Potent P2Y12 Inhibition in Patients with Suspected Chronic Coronary Syndrome, Referred for Coronary Angiography.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2023 |
Eptifibatide-induced acute profound thrombocytopenia: A case report.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Eptifibatide; Glycoproteins; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombocytopenia | 2022 |
Are there other factors that influence the assessment of bleeding risk comparing potent P2Y12 inhibitors with clopidogrel?
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Oral P2Y12 inhibiting therapy in patients with acute coronary syndrome: finding the sweet spot.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2023 |
Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Ventricular Function, Left | 2022 |
Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Female; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome; United States | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Ticagrelor; Treatment Outcome | 2023 |
Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adolescent; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Estimation of adverse events associated with P2Y12 receptor inhibitors stratified by academic research consortium for high bleeding risk criteria in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Treatment Outcome | 2023 |
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Humans; Male; Pandemics; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Propensity-matched analysis of the protective effect of ticagrelor versus clopidogrel on the risk of developing Staphylococcus aureus bacteremia.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Ticagrelor; Treatment Outcome | 2023 |
Duration more than type of dual antiplatelet therapy matters in ACS patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2023 |
P2Y12 inhibitor intensity de-escalation in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors | 2023 |
Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Genotype-Guided Selection of Antiplatelet Therapy: The Evidence Moves East.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Replay to "duration more than type of dual antiplatelet therapy matters in ACS patients with high bleeding risk".
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Prasugrel-related hepatotoxicity.
Topics: Acute Coronary Syndrome; Chemical and Drug Induced Liver Injury; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2022 |
A Comparative Study on Ticagrelor and Clopidogrel in Patients With Acute Coronary Syndrome Treated With Primary Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Genotype-Guided Antiplatelet Therapy After Coronary Intervention in Patients With High Bleeding Risk - Never Judge a Book by Its Cover.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Heart; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Medicaid; Medicare; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome; United States | 2023 |
Another Step Toward CYP2C19 Genotype-Guided Therapy in Treatment With Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2023 |
How is pharmacogenetics changing clinical trial design for percutaneous coronary intervention?
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2023 |
Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2023 |
[Debate on antiplatelet monotherapy: Why not leaving out good old aspirin for clopidogrel or ticagrelor in monotherapy in chronic coronary syndromes after a percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Canada; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors | 2023 |
Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor and primidone interaction masquerading as dual antiplatelet therapy noncompliance.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Primidone; Ticagrelor; Treatment Outcome | 2023 |
Differential Impact of Clinical Factors for Predicting High Platelet Reactivity on Clinical Outcomes in Acute Myocardial Infarction Patients Treated With Clopidogrel and Prasugrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Humans; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2023 |
Clopidogrel vs Aspirin in the Chronic Maintenance Period for Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Treatment Outcome | 2023 |
A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A GRACE Risk Score Stratification-Based Analysis in a Large-Scale, Real-World Study From China.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Risk Assessment; Risk Factors; Ticagrelor; Treatment Outcome | 2023 |
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2023 |
Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thrombosis; Treatment Outcome | 2023 |
Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013-2018.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prescriptions; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome; United States | 2023 |
Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: Exploring the Role of Genotype-Guided Therapy in Reducing Readmission Rates.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2023 |
Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Streptokinase; Ticagrelor; Treatment Outcome | 2023 |
Comparison of clopidogrel vs. ticagrelor medication adherence in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Medication Adherence; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Arachidonic Acid; Aspirin; Clopidogrel; Gelsolin; Humans; Mean Platelet Volume; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Ventricular Function, Left | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Age- and Sex-Specific Disparities in Outcomes After Ticagrelor Versus Clopidogrel in East Asian Patients.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; East Asian People; Female; Hemorrhage; Humans; Ischemia; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2023 |
Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pupil; Treatment Outcome | 2023 |
Clopidogrel-induced non-diabetic hypoglycemia reported from Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a case report.
Topics: Acute Coronary Syndrome; Adult; Blood Glucose; Clopidogrel; Ethiopia; Hospitals; Humans; Hypoglycemia; Male | 2023 |
De-escalation from potent P2Y12 inhibitors to clopidogrel: an alternative to short DAPT duration in HBR patients?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2023 |
Refining percutaneous coronary intervention: intracoronary imaging, haemodynamics, P2Y12 antagonists, and public outcomes reporting.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Restenosis; Coronary Vessels; Hemodynamics; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Spectroscopy, Near-Infrared; Switzerland; Ticagrelor; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional | 2019 |
Efficacy and Safety of Different Antiplatelet Strategies in Survivors of Myocardial Infarction With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Survivors; Ticagrelor; Treatment Outcome | 2019 |
Microvesicles from patients with acute coronary syndrome enhance platelet aggregation.
Topics: Acute Coronary Syndrome; Aged; Cell-Derived Microparticles; Clopidogrel; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors | 2019 |
Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Making; Drug Interactions; Humans; Models, Economic; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Quality-Adjusted Life Years; Risk Assessment; Technology Assessment, Biomedical; Ticagrelor; Uncertainty | 2019 |
Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Thrombelastography | 2020 |
Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cardiovascular System; Clopidogrel; Female; Humans; Longitudinal Studies; Male; Middle Aged; Middle East; Myocardial Infarction; Patient Readmission; Platelet Aggregation Inhibitors; Treatment Outcome | 2020 |
Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel
Topics: Acute Coronary Syndrome; Atrial Fibrillation; Clopidogrel; Cross-Sectional Studies; Echocardiography, Doppler; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
Global Trial or Local One?
Topics: Acute Coronary Syndrome; Clopidogrel; Fibrinolytic Agents; Humans; Republic of Korea; Thrombolytic Therapy; Ticagrelor | 2019 |
Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Carboxylic Ester Hydrolases; Clopidogrel; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12 | 2019 |
Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients.
Topics: Acute Coronary Syndrome; Aged; Asian People; China; Clopidogrel; Coronary Thrombosis; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
Topics: Acute Coronary Syndrome; Clopidogrel; Europe; Female; Hemorrhage; Humans; Male; Medication Therapy Management; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Risk Adjustment; Therapeutic Equivalency; Ticagrelor | 2020 |
Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Thrombosis; Databases, Factual; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Incidence; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Prospective Studies; Registries; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2020 |
Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; CpG Islands; DNA Methylation; Drug Resistance; Female; Gene Expression; Germinal Center Kinases; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors | 2020 |
Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; Deprescriptions; Drug Substitution; Dual Anti-Platelet Therapy; Dyspnea; Factor Xa Inhibitors; Female; Humans; Male; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
[Relation of Functional Activity of Platelets to Prognosis of Unfavorable Cardiovascular Events in Patients with Acute Coronary Syndrome. Results of a Registry Study].
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prognosis; Registries; Russia; Ticlopidine | 2019 |
Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cross-Sectional Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; ROC Curve; Thailand; Treatment Outcome | 2020 |
Logistical Challenges Associated With Implementing Precision Medicine-Reply.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Precision Medicine | 2019 |
Logistical Challenges Associated With Implementing Precision Medicine.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Neoplasms; Precision Medicine | 2019 |
CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
Topics: Acute Coronary Syndrome; Aged; Asian People; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies | 2020 |
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndrome and Stable Coronary Artery Disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine | 2019 |
microRNA-605 rs2043556 polymorphisms affect clopidogrel therapy through modulation of CYP2B6 and P2RY12 in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2B6; Female; Genotype; Humans; Male; MicroRNAs; Middle Aged; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12 | 2020 |
Mind the Gap: Platelet Inhibition in Low-Risk Acute Coronary Syndrome Undergoing Percutaneous Revascularization.
Topics: Acute Coronary Syndrome; Clopidogrel; Eptifibatide; Humans; Percutaneous Coronary Intervention; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Troponin | 2019 |
Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Aspirin; Case-Control Studies; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Risk Factors; Thrombelastography; Treatment Outcome | 2019 |
Concomitant use of drugs known to cause interactions with oral antiplatelets-polypharmacy in acute coronary syndrome outpatients in Finland.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Finland; Hemorrhage; Humans; Male; Middle Aged; Outpatients; Platelet Aggregation Inhibitors; Polypharmacy; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2020 |
Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Transfusion; Preoperative Care; Retrospective Studies | 2019 |
Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population.
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Platelet Aggregation Inhibitors; Poland; Polymorphism, Single Nucleotide; Ticlopidine | 2019 |
Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Recurrence; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors | 2020 |
Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Sex Factors; Stents; Ticagrelor; Ticlopidine | 2019 |
Low-dose prasugrel versus clopidogrel in elderly patients with high clinical and PCI complexity.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2020 |
Concealed Wolff-Parkinson-White Syndrome revealed by acute coronary syndrome.
Topics: Acute Coronary Syndrome; Analgesics, Opioid; Aspirin; Clopidogrel; Drug-Eluting Stents; Electrocardiography; Fibrinolytic Agents; Humans; Male; Middle Aged; Morphine; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Wolff-Parkinson-White Syndrome | 2020 |
Platelet-derived miRNAs as determinants of the antiplatelet response in clopidogrel-treated patients with ACS.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Recurrence; Thrombosis; Young Adult | 2020 |
Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Vessels; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Treatment Outcome | 2020 |
Opiates and Clopidogrel Efficacy: Lost in Transit?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Humans; Morphine; Opiate Alkaloids; Prasugrel Hydrochloride | 2020 |
Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption.
Topics: Acute Coronary Syndrome; Aged; ATP Binding Cassette Transporter, Subfamily B; Blood Platelets; Clopidogrel; Drug Monitoring; Female; Gastrointestinal Absorption; Humans; Male; Middle Aged; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Treatment Outcome | 2020 |
Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial).
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2020 |
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Dual Anti-Platelet Therapy; Humans; Molecular Diagnostic Techniques; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Predictive Value of Tests; Quality-Adjusted Life Years; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
Smoking and antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Smoking; Ticlopidine | 2020 |
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?]
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clinical Trials, Phase IV as Topic; Clopidogrel; Hemorrhage; Humans; Multicenter Studies as Topic; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2020 |
A Reconciliation Attempt of the Acute Coronary Syndrome Clinical Trials on Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Stroke | 2020 |
Letter by Kim et al Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine | 2020 |
Letter by Chen et al Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine | 2020 |
Response by Park and Park to Letter Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Ticlopidine | 2020 |
Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome; Ventricular Function, Left | 2020 |
Antiplatelet strategies in ageing patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aging; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2020 |
Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Intensive Care Units; Male; Middle Aged; Patient Discharge; Propensity Score; Risk Factors; Ticagrelor; Treatment Outcome | 2020 |
Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization: From TSOC ACS-DM registry.
Topics: Acute Coronary Syndrome; Clopidogrel; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Mortality; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Secondary Prevention; Taiwan; Ticagrelor; Treatment Outcome | 2020 |
Prasugrel in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
The Frequency of the Minor Polymorphisms in the
Topics: Acute Coronary Syndrome; Aged; Alleles; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Ethnicity; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Russia; Siberia; Ticlopidine; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Clopidogrel is a favourable alternative to ticagrelor in older patients with NSTE-ACS.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2020 |
Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2022 |
Double Trouble: Reducing Gastrointestinal Bleeding due to DAPT Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2021 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor | 2020 |
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Treatment Outcome | 2020 |
Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Measuring preferences for
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Italy; Male; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk; Ticagrelor | 2021 |
Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Databases, Factual; Dual Anti-Platelet Therapy; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Evaluation of a Novel Antiplatelet Therapy Strategy in Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
Topics: Acute Coronary Syndrome; Aged; Algorithms; Asian People; Clopidogrel; Data Mining; Decision Trees; Female; Hemorrhage; Hospitalization; Humans; Machine Learning; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2020 |
Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Retrospective Studies; Thromboembolism; Ticagrelor; Treatment Outcome; United States | 2020 |
Real-World Comparison of Ticagrelor and Clopidogrel: Rosetta Stone or Lost in Translation?
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Coronary Angiography; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Sweden; Ticagrelor | 2020 |
Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Registries; Sweden; Ticagrelor | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality Therapy; Cyclophosphamide; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stents; Stroke; Vitamin K | 2020 |
Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Ticagrelor | 2020 |
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational cohort study (STROBE compliant).
Topics: Acute Coronary Syndrome; Aged; Clinical Decision Rules; Clopidogrel; Cohort Studies; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Male; Middle Aged; Partial Thromboplastin Time; Peptic Ulcer; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Renal Insufficiency; Research Design; Risk Assessment | 2020 |
Risk of Pneumonia with Ticagrelor Versus Clopidogrel: a Population-Based Cohort Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Pneumonia; Ticagrelor; Treatment Outcome | 2021 |
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Hyperuricemia; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thienopyridines; Ticagrelor; Ticlopidine; Uric Acid | 2021 |
Editorial - out with the old and in with the new? Gastrointestinal bleeding risk of P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Ticagrelor | 2020 |
Comparison of Oral P2Y12 Inhibitors in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists | 2020 |
Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insights From the SWEDEHEART Registry.
Topics: Acute Coronary Syndrome; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clopidogrel; Female; Humans; Male; Prognosis; Registries; Ticagrelor; Treatment Outcome | 2020 |
Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors | 2020 |
Clopidogrel-induced sweet syndrome: severe dermatological complication after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Sweet Syndrome; Ticlopidine; Treatment Outcome | 2021 |
Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Deaminase; Aftercare; Clopidogrel; Drug Therapy, Combination; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2020 |
In ACS, prasugrel reduces 30-day MACE and mortality vs. ticagrelor or clopidogrel; no differences for major bleeding.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Hemorrhage; Humans; Patients; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2020 |
Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Ticagrelor in the management of coronary artery disease.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Letter: the risk of gastrointestinal bleeding in patients taking third-generation P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2020 |
High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Beijing; Biomarkers; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Resistance; Dual Anti-Platelet Therapy; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Serum Albumin; Thrombelastography; Treatment Outcome; Up-Regulation | 2020 |
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopidogrel; Cyclic AMP; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Function Tests | 2021 |
In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Network Meta-Analysis; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2020 |
Factors Influencing Provider and Patient Choice of P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Preference; Patient Selection; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; Cause of Death; Clopidogrel; Databases, Factual; Dyspnea; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Propensity Score; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Retrospective Studies; Stroke; Ticagrelor; United States | 2020 |
Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor | 2020 |
Risk of infectious events in acute myocardial infarction patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Frequency and Reasons for Non-Administration and Suspension of Drugs During an Acute Coronary Syndrome Event. The ERICO Study.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Pharmaceutical Preparations; Platelet Aggregation Inhibitors | 2020 |
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Topics: Acute Coronary Syndrome; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Ticlopidine | 2021 |
Acute coronary syndromes: summary of updated NICE guidance.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Modality Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Secondary Prevention; ST Elevation Myocardial Infarction; Ticagrelor; United Kingdom | 2021 |
Adherence and persistence analysis in patients treated with double antiplatelet therapy (DAPT) at two years in real life.
Topics: Acute Coronary Syndrome; Clopidogrel; Dinucleoside Phosphates; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Treatment Outcome | 2021 |
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; Genotype; Humans; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Singapore; Ticagrelor; Ticlopidine | 2021 |
Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Qatar; Ticagrelor | 2021 |
Response by Navarese et al to Letters Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic | 2021 |
Comparison of the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome after risk stratification.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention-Reply.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome | 2021 |
The use of clinical biomarkers in acute coronary syndrome to predict responsiveness to dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Biomarkers; Clopidogrel; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors | 2021 |
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2021 |
Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Hospitals; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2022 |
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2021 |
Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cause of Death; Clopidogrel; England; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor | 2021 |
Hide and seek. Ticagrelor and central apneas after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Sleep Apnea, Central; Ticagrelor | 2021 |
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Antiplatelet therapy in ACS elderly patients: Another piece of this intriguing puzzle.
Topics: Acute Coronary Syndrome; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Efficacy and safety of prasugrel and clopidogrel in st-segment elevation myocardial infarction in prehospital setting.
Topics: Acute Coronary Syndrome; Clopidogrel; Emergency Medical Services; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Treatment Outcome | 2022 |
Ticagrelor use and practice patterns among Canadian cardiac surgeons.
Topics: Acute Coronary Syndrome; Canada; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Surgeons; Ticagrelor | 2021 |
Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Hong Kong; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor and CABG for acute coronary syndrome?-It is complicated.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
A comparison of the safety and effectiveness of prasugrel and clopidogrel in younger population undergoing percutaneous coronary intervention: A retrospective study using a Japanese claims database.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Japan; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Treatment Outcome | 2021 |
Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Retrospective Studies; Taiwan; Ticagrelor; Treatment Outcome | 2022 |
Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective.
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2021 |
Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2021 |
Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Registries; Retrospective Studies; Ticagrelor | 2021 |
Is there a benefit for
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2021 |
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Body Mass Index; Case-Control Studies; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prodrugs; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Beijing; Clopidogrel; Databases, Factual; Diabetes Mellitus; Hospitalization; Humans; Insurance, Health; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2021 |
Clopidogrel versus Ticagrelor in CYP2C19 Loss-of-Function Allele Noncarriers: A Real-World Study in China.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Clopidogrel; Cytochrome P-450 CYP2C19; Hemorrhage; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Clinical events beyond one year after an acute coronary syndrome: insights from the RECLOSE 2-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Gene Regulatory Networks; Humans; Machine Learning; Male; Middle Aged; Neural Networks, Computer; Platelet Activation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Ticlopidine; Treatment Outcome | 2017 |
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Troponin | 2017 |
Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Incidence; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2017 |
Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Blood Urea Nitrogen; Clopidogrel; Creatinine; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine; Time Factors; Treatment Outcome; Uric Acid | 2016 |
Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention - A multicenter study.
Topics: Acute Coronary Syndrome; Aged; Asian People; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2017 |
GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiopulmonary Resuscitation; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Shock, Cardiogenic; Slovenia; Survival Rate; Ticagrelor; Ticlopidine; Time Factors | 2018 |
Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Ticlopidine | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Heterozygote; Homozygote; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome; Vitamin D Deficiency; Vitamin D-Binding Protein | 2017 |
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Retrospective Studies; Safety; Ticagrelor; Ticlopidine | 2017 |
Effects of four novel genetic polymorphisms on clopidogrel efficacy in Chinese acute coronary syndromes patients.
Topics: Acute Coronary Syndrome; Aged; Case-Control Studies; Clopidogrel; Female; Genetic Loci; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine; Treatment Outcome | 2017 |
[A Case of Intramural Hematoma of the Esophagus Mimicking Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Diagnosis, Differential; Endoscopy, Gastrointestinal; Esophageal Diseases; Esophagus; Hematoma; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Tomography, X-Ray Computed | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator | 2017 |
Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Greece; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Registries; Risk Factors; Sex Characteristics; Stents; Ticlopidine; Treatment Outcome | 2017 |
Clopidogrel instead of prasugrel or ticagrelor after 1 month in stabilized ACS patients: back to square one for DAPT?
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2017 |
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction | 2018 |
Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; Databases, Factual; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2017 |
Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Preoperative Period; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Survival Rate; Ticlopidine; Treatment Outcome | 2017 |
Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Disease Management; Female; Hospitalization; Humans; Hyperglycemia; Italy; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies | 2018 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Reversal of the platelet inhibitory effect of the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Comparison of platelet aggregation response in switching regimen from prasugrel to clopidogrel between CYP2C19 extensive versus non-extensive metabolizers.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies | 2018 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Middle Aged; Models, Economic; Monte Carlo Method; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; MicroRNAs; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Ticlopidine | 2017 |
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2017 |
Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Amino Acid Substitution; Carboxylic Ester Hydrolases; Clopidogrel; Comorbidity; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Treatment Outcome | 2017 |
P2Y
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Databases, Factual; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States | 2017 |
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
[Dual Antiplatelet Therapy in the Perioperative Period - To Continue or Discontinue Treatment?]
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Perioperative Period; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticlopidine | 2017 |
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization Review; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine | 2018 |
High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Female; Graft Occlusion, Vascular; Humans; Incidence; Male; Middle Aged; Netherlands; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Risk Factors; Stents; Ticlopidine | 2017 |
Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Ticlopidine | 2017 |
Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Retrospective Studies; Secondary Prevention; Ticagrelor; Ticlopidine | 2017 |
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Withholding Treatment | 2017 |
Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Implantation; Stents; Time Factors | 2018 |
Safety and efficacy of prasugrel in East Asian patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2018 |
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Registries; Retrospective Studies; Ticagrelor; Ticlopidine | 2017 |
[Focused update on dual antiplatelet treatment : ESC guidelines 2017].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Humans; Long-Term Care; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors | 2017 |
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Ticagrelor | 2018 |
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Hemorrhage; Hospital Mortality; Humans; Italy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-ST Elevated Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Research and Therapeutic Nihilisms in Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Kidney Failure, Chronic; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Renal Insufficiency, Chronic | 2017 |
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Guideline Adherence; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Risk Factors; Stents; Stroke; Thrombosis; Vitamin K | 2018 |
Cost-effectiveness of prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2018 |
Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts - Response to the letter to the Editor.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2018 |
Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Cigarette Smoking; Clopidogrel; Comorbidity; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2018 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Comparison of Single Nucleotide Polymorphism genotyping of CYP2C19 by Loop-mediated isothermal amplification and real-time PCR melting curve analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Genotyping Techniques; Humans; Nucleic Acid Amplification Techniques; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ticlopidine; Transition Temperature | 2018 |
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Angiography; Dabigatran; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Incidence; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Patient Safety; Phenindione; Propensity Score; Proportional Hazards Models; Risk; Treatment Outcome; Vitamin K | 2018 |
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Postoperative Complications; Prasugrel Hydrochloride; Retrospective Studies; Stroke; Ticlopidine | 2018 |
The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insight from the Diabetes and Acute Coronary Syndrome Registry.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Humans; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Registries; Ticagrelor | 2018 |
Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Female; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Postoperative Hemorrhage; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Time Factors; Treatment Outcome; Withholding Treatment | 2019 |
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Gene Frequency; Genetic Variation; Genotype; Humans; Male; Middle Aged; Morocco; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Databases, Factual; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Factors; Saphenous Vein; Ticagrelor; Time Factors; Treatment Outcome; United Kingdom | 2018 |
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Community Pharmacy Services; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Delivery of Health Care, Integrated; Drug Costs; Female; Genetic Testing; Humans; Male; Markov Chains; Medication Therapy Management; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Point-of-Care Testing; Precision Medicine; Predictive Value of Tests; Program Evaluation; Quality of Life; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; United States | 2018 |
Effect of Antiplatelet Therapy on Cardiac Outcomes in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Out-of-Hospital Cardiac Arrest; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
Chronic Kidney Disease and Antiplatelet Therapy: A Worrying Gap Between Evidence Based Medicine and Clinical Practice.
Topics: Acute Coronary Syndrome; Clopidogrel; Evidence-Based Medicine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic | 2018 |
Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2018 |
Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Thrombosis; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Ticlopidine; Treatment Outcome; United States | 2018 |
Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Function Tests; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2019 |
[Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Fibrinolytic Agents; Humans; Italy; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Drug Substitution; Drugs, Generic; Female; Hemorrhage; Humans; Male; Ontario; Patient Admission; Patient Readmission; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Dual antiplatelet therapy in the 'real world'.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2018 |
In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Corona
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality Improvement; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Asia; Brazil; Canada; Clopidogrel; Decision Support Techniques; Erythrocyte Transfusion; Europe; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Middle Aged; Patient Discharge; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Effect of Low-Dose Versus Standard-Dose Ticagrelor and Clopidogrel on Platelet Inhibition in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Thrombosis; Ticlopidine; Treatment Failure | 2018 |
Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Area Under Curve; Case-Control Studies; Clopidogrel; Drug Monitoring; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; ROC Curve; Thrombelastography; Ticlopidine; Time Factors; Whole Blood Coagulation Time; Young Adult | 2018 |
Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asia; China; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Female; Health Care Costs; Hong Kong; Humans; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Republic of Korea; Taiwan; Ticagrelor; Ticlopidine | 2018 |
Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Registries; Stents; Thrombosis; Tomography, Optical Coherence; Treatment Outcome | 2018 |
Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Topics: Acute Coronary Syndrome; Aged; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proton Pump Inhibitors; Siberia; Stomach Ulcer | 2018 |
Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Drug Administration Schedule; Drug Substitution; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Switzerland; Tertiary Care Centers; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; ATP Binding Cassette Transporter, Subfamily B; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Female; Gene Frequency; Genotype; Humans; Iran; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Precision Medicine; Risk Assessment; Stents; Treatment Outcome | 2018 |
Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Risk; Stroke; Ticlopidine | 2018 |
Prasugrel or Ticagrelor for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Does it Matter?
Topics: Acute Coronary Syndrome; Biomarkers; Clopidogrel; Cross-Over Studies; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2018 |
Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study.
Topics: Acute Coronary Syndrome; Biomarkers; Blood Platelets; Cause of Death; Clopidogrel; Equilibrative Nucleoside Transporter 1; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2019 |
Prasugrel in the Elderly.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2018 |
Twenty-four-hour time dependency of clopidogrel effects in patients with acute coronary syndromes: The CiCAD-Study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Time Factors | 2019 |
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Hemorrhage; Humans; Male; Phenotype; Pilot Projects; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Risk; Thrombosis | 2018 |
Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Costs and Cost Analysis; Female; Health Care Costs; Humans; Length of Stay; Male; Middle Aged; Patient Acceptance of Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine | 2018 |
Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Aspirin; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Activation; Postoperative Complications; Recurrence; Treatment Outcome | 2019 |
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic | 2018 |
Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Chronic Disease; Clopidogrel; Coloring Agents; Coronary Angiography; Drug Therapy, Combination; Female; Heart Failure; Hematoma; Humans; Male; Middle Aged; Neoplasms; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; Texas; Thrombocytopenia | 2018 |
Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenetics; Platelet Aggregation Inhibitors; Risk Factors; Stroke | 2018 |
Chronic Kidney Disease and Third-Generation P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prognosis; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic | 2019 |
The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects.
Topics: Acute Coronary Syndrome; Aftercare; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hospitalization; Humans; Italy; Male; Medication Adherence; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor | 2019 |
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Drug Prescriptions; Follow-Up Studies; Hemorrhage; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Survival Rate; Ticagrelor | 2019 |
Laboratory monitoring of P2Y
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Coagulation; Cardiology; Clopidogrel; Genetic Variation; Humans; International Cooperation; Monitoring, Physiologic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Societies, Medical; Ticlopidine | 2018 |
Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Female; Humans; Inpatients; Male; Middle Aged; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; United States; United States Food and Drug Administration; Young Adult | 2019 |
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Chest Pain; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; ST Elevation Myocardial Infarction; Ticlopidine; Treatment Outcome | 2018 |
Impact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Mean Platelet Volume; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Sleep Apnea, Obstructive; Thrombelastography | 2018 |
Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Comorbidity; Comparative Effectiveness Research; Diabetes Mellitus; Female; Hemorrhage; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Ticagrelor; Treatment Outcome; United States | 2018 |
Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Comorbidity; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; United States | 2019 |
Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Female; Humans; Insurance, Health, Reimbursement; Male; Markov Chains; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years | 2018 |
Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Galactosyltransferases; Gene Frequency; Genotype; Hispanic or Latino; Humans; Male; Middle Aged; Myocardial Infarction; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Stents; Thrombosis | 2019 |
Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Testing; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12 | 2019 |
Discontinuation of dual antiplatelet therapy and bleeding in intensive care in patients undergoing urgent coronary artery bypass grafting: a retrospective analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Female; Humans; Inpatients; Intensive Care Units; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Ticagrelor | 2019 |
Switching antiplatelet therapy in real-world clinical practice.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2018 |
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug-Eluting Stents; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; United States | 2019 |
Switching of Oral P2Y
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor | 2019 |
"No Such Thing as a Free Lunch": Personalized P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine | 2019 |
[Correlation between CYP2C19 Gene Polymorphism with Clopidogrel Resistance and Distribution of Chinese Medicine Syndrome in 229 Acute Coronary Syndrome Patients].
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Humans; Medicine, Chinese Traditional; Platelet Aggregation Inhibitors; Syndrome; Yin Deficiency | 2017 |
Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Black or African American; Cause of Death; Clopidogrel; Comorbidity; Female; Health Status Disparities; Healthcare Disparities; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Race Factors; Registries; Risk Assessment; Risk Factors; Sex Factors; Stroke; Time Factors; Treatment Outcome; United States | 2019 |
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Topics: Acute Coronary Syndrome; Administrative Claims, Healthcare; Aged; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; France; Hemorrhage; Humans; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Factors; Secondary Prevention; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Ticagrelor versus clopidogrel in high bleeding risk patients with acute coronary syndromes treated with drug-eluting stents.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Alleles; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2019 |
Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Treatment Outcome | 2019 |
Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Cardiovascular Diseases; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Prasugrel Hydrochloride; Registries; Retrospective Studies; ST Elevation Myocardial Infarction; Treatment Outcome; United States | 2019 |
Ticagrelor induced neutrophilic eccrine hidradenitis: a unique adverse effect of a new antiplatelet drug.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Eruptions; Hand; Hidradenitis; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2019 |
Derivation and Evaluation of the Ischemic Risk Model in High-Risk Chinese Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; China; Clopidogrel; Female; Humans; Ischemia; Male; Middle Aged; Models, Biological; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Risk; Ticagrelor | 2019 |
Atrial fibrillation, with ACS and PCI: walking a tightrope.
Topics: Acute Coronary Syndrome; Atrial Fibrillation; Clopidogrel; Dabigatran; Humans; Percutaneous Coronary Intervention; Ticagrelor | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Retrospective Studies; Stroke; Ticagrelor | 2019 |
Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Homozygote; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Cell Surface; Risk Assessment; Risk Factors; Stents; Time Factors; Treatment Outcome | 2019 |
Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Substitution; Electrocardiography; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Magnetic Resonance Angiography; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Duration of Clopidogrel-Based Dual Antiplatelet Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention - A Real-World Observation in Taiwan From 2012 to 2015.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk; Taiwan; Time Factors; Treatment Outcome | 2019 |
Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor | 2019 |
Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease.
Topics: Acute Coronary Syndrome; Aftercare; Clopidogrel; Comorbidity; Coronary Disease; Drug Utilization; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Smoking; Spain; Stroke; Tertiary Care Centers; Ticagrelor | 2019 |
Genotyping and phenotyping CYP3A4\\CYP3A5: no association with antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Alleles; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic | 2019 |
Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Ticlopidine | 2019 |
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2019 |
Secondary prophylaxis of an acute coronary syndrome during rituximab infusion.
Topics: Acute Coronary Syndrome; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Clopidogrel; Cyclophosphamide; Diltiazem; Doxorubicin; Female; Humans; Lymphoma, Follicular; Platelet Aggregation Inhibitors; Prednisone; Rituximab; Secondary Prevention; Vincristine | 2020 |
[Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2019 |
Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel.
Topics: Acute Coronary Syndrome; Animals; Aryldialkylphosphatase; Atherosclerosis; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, LDL; Ticagrelor | 2019 |
Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Insights From a Single Institution Registry.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Ticagrelor; Treatment Outcome; United States | 2019 |
Safety and Effectiveness of Contemporary P2Y
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Asian People; Cardiovascular Diseases; Cause of Death; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Minnesota; Patient Outcome Assessment; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Ticlopidine | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prognosis; Proportional Hazards Models; ST Elevation Myocardial Infarction; Stroke | 2019 |
A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Labeling; Drug Monitoring; Dual Anti-Platelet Therapy; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Platelet Function Tests; Practice Guidelines as Topic; Prasugrel Hydrochloride; Ticagrelor | 2019 |
Therapy with ticagrelor for ST-elevated acute coronary syndrome accompanied by diabetes mellitus.
Topics: Acute Coronary Syndrome; Aged; Atrial Function, Left; Clopidogrel; Diabetes Mellitus; Electrocardiography; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Random Allocation; Ticagrelor; Treatment Outcome | 2019 |
Exploring the ticagrelor-statin interplay in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Simvastatin; Ticagrelor; Ticlopidine | 2013 |
Switching from prasugrel to clopidogrel: navigating in unknown waters.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Substitution; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
[Gastrointestinal bleeding after treatment with ticagrelor].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Female; Gastrointestinal Hemorrhage; Humans; Pulmonary Disease, Chronic Obstructive; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Middle Aged; Mutation; Polymorphism, Genetic; Receptors, Purinergic P2Y12; Ticlopidine | 2013 |
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus.
Topics: Acute Coronary Syndrome; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Thrombosis; Enoxaparin; Humans; Inpatients; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Thrombectomy; Thrombolytic Therapy; Ticlopidine | 2013 |
Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Clopidogrel; Female; Humans; Incidence; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2013 |
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Drug Costs; Humans; Markov Chains; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Republic of Korea; Singapore; Ticagrelor; Ticlopidine | 2013 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Analysis; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Left | 2014 |
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Spontaneous platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Alprostadil; Antibodies; Aspirin; Blood Platelets; Clopidogrel; Humans; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Ticlopidine; von Willebrand Factor | 2013 |
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Alcohol Drinking; Angina, Stable; Aspirin; Case-Control Studies; Clopidogrel; Female; Gastrointestinal Hemorrhage; Humans; Male; Peptic Ulcer; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Ticlopidine | 2013 |
Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Hospitalization; Hospitals, Veterans; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Ticlopidine; Treatment Outcome | 2013 |
Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ticlopidine | 2013 |
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Is clopidogrel adequate in 2013?
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Blood Platelets; Clopidogrel; Female; Genotype; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2013 |
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2013 |
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2013 |
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation; Cardiac Catheterization; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Stroke; Survival Analysis; Ticlopidine | 2014 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
P2Y12 Receptor Blockade and Myocardial Perfusion.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2013 |
Personalised antiplatelet therapy: are we ready for prime time? Data from China.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine | 2013 |
Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Ticlopidine | 2013 |
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ischemia; China; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Resistance; Drug-Eluting Stents; Female; Genotype; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Receptors, Purinergic P2Y12; Risk Factors; ROC Curve; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Drug Therapy, Combination; Endpoint Determination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Patient Readmission; Platelet Aggregation Inhibitors; Postoperative Complications; Prognosis; Retrospective Studies; Ticlopidine; Time Factors | 2013 |
Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Phenotype; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2013 |
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benefit Analysis; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[The ARCTIC study].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Heart Diseases; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2013 |
Provision of gastroprotective medication and bleeding risk following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Treatment Outcome | 2013 |
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Clopidogrel; Female; Fibrinogen; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombelastography; Ticlopidine | 2013 |
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cell Adhesion Molecules; Cell Separation; Clopidogrel; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Ticlopidine | 2013 |
Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve; Blood Platelets; Blood Vessel Prosthesis; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Activation; Ticlopidine | 2013 |
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Registries; Renal Insufficiency, Chronic; Taiwan; Ticlopidine; Treatment Outcome | 2013 |
Stratified reporting of high sensitivity troponin I assay is associated with suboptimal management of patients with acute coronary syndrome and intermediate troponin elevation.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Clopidogrel; Cohort Studies; Coronary Angiography; Female; Humans; Male; Myocardial Infarction; Retrospective Studies; Risk; Ticlopidine; Troponin I; Withholding Treatment | 2013 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Function Tests; Practice Guidelines as Topic; Prognosis; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticlopidine | 2014 |
Impact of initial clinical presentation on clopidogrel low response.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Female; Humans; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Prognosis; Registries; Stroke; Taiwan; Ticlopidine; Treatment Outcome | 2014 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Hospitalization; Humans; Male; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Factors; Stents; Stroke; Ticlopidine; Treatment Outcome | 2014 |
Value of high-sensitivity troponin in assessing the extent of benefit provided by ticagrelor versus clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Revascularization; Ticagrelor; Ticlopidine | 2014 |
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genetic Testing; Genotype; Health Personnel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Sequence Deletion; Thiophenes; Ticlopidine | 2013 |
Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Fibrinogen; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Assessment; Ticlopidine | 2014 |
Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Europe; Female; Health Care Costs; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Quality of Life; Registries; Secondary Prevention; Stents; Ticlopidine; Treatment Outcome | 2013 |
Drug interactions with good old clopidogrel: case closed.
Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Clopidogrel; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
The enigmatic search for optimal DAPT duration.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Australia; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Markov Chains; Ticagrelor; Ticlopidine | 2013 |
Sex differences in the treatment and outcome of patients with acute coronary syndrome after percutaneous coronary intervention: a population-based study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Insurance, Health; Male; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Population Surveillance; Propensity Score; Regression Analysis; Retrospective Studies; Sex Factors; Taiwan; Ticlopidine; Treatment Outcome | 2014 |
Japanese postmarketing surveillance of clopidogrel for patients with non-ST-segment-elevation acute coronary syndrome indicated for percutaneous coronary intervention (J-PLACE NSTE-ACS).
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Risk Factors; Ticlopidine | 2014 |
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor as an alternative in clopidogrel-associated neutropenia.
Topics: Acute Coronary Syndrome; Adenosine; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Humans; Male; Neutropenia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Male; P-Selectin; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2014 |
Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thromboxane B2; Ticlopidine; Treatment Outcome | 2015 |
Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
[The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prognosis; Ticlopidine | 2013 |
Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Anesthesia; Aspirin; Blood Transfusion; Chest Tubes; Clopidogrel; Confidence Intervals; Coronary Artery Bypass; Critical Care; Erythrocyte Count; Female; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Postoperative Hemorrhage; Prospective Studies; Risk Factors; Ticlopidine | 2014 |
Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Area Under Curve; Blood Platelets; Clopidogrel; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Predictive Value of Tests; Prospective Studies; Ticlopidine | 2014 |
Discrepancies in the primary PLATO trial publication and the FDA reviews.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Congresses as Topic; Humans; Information Dissemination; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2014 |
Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Reproducibility of Results; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2014 |
Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study.
Topics: Acute Coronary Syndrome; Case-Control Studies; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Propensity Score; Prospective Studies; Risk Factors; Suspensions; Ticlopidine | 2014 |
Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Multivariate Analysis; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taiwan; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Combinations; Drug Interactions; Humans; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2014 |
[Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Omeprazole; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Ticlopidine | 2014 |
Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2014 |
Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Alleles; Asian People; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Gene Expression; Genotype; Humans; Isoenzymes; Microarray Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2Y12; Ticlopidine | 2014 |
Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine; Treatment Outcome | 2015 |
"East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Asia, Eastern; Asian People; Blood Platelets; Clopidogrel; Drug Administration Schedule; Evidence-Based Medicine; Female; Guideline Adherence; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Ticlopidine; Treatment Outcome; Young Adult | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; Stroke Volume; Ticlopidine; Ventricular Dysfunction, Left | 2014 |
Is it appropriate to compare the results from two clinical trials with one drug in common?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Cardiopulmonary Resuscitation; Case-Control Studies; Clopidogrel; Cohort Studies; Coma; Coronary Angiography; Eptifibatide; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Peptides; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Thrombin; Ticlopidine | 2015 |
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Models, Economic; Poland; Secondary Prevention; State Medicine; Ticagrelor; Ticlopidine | 2014 |
Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Administration Schedule; Humans; Medication Adherence; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan | 2014 |
Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Clopidogrel; Drug Hypersensitivity; Female; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine | 2014 |
Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2014 |
Ticagrelor and the prevention of cardiovascular mortality: more than just platelet inhibition?
Topics: Acute Coronary Syndrome; Adenosine; Cause of Death; Clopidogrel; Female; Humans; Male; Ticagrelor; Ticlopidine | 2014 |
Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzofurans; Blood Platelets; Clopidogrel; Drugs, Chinese Herbal; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Salvia miltiorrhiza; Ticlopidine | 2014 |
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality of Life; Spain; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Treatment Outcome | 2015 |
Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Stable; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
Topics: Acute Coronary Syndrome; Aged; Biotransformation; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.
Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Cohort Studies; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
How to optimize an individualized strategy for antiplatelet drug administration and discontinuation management using platelet function testing?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticlopidine | 2014 |
Reply to the editor.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticlopidine | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sex Factors; Thrombosis; Ticlopidine | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Kounis syndrome secondary to food allergy.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Anti-Allergic Agents; Aspirin; Clopidogrel; Electrocardiography; Female; Fibrinolytic Agents; Food Hypersensitivity; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome; Urticaria | 2014 |
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticlopidine | 2014 |
A new mechanism of action of thienopyridine antiplatelet drugs - a role for gastric nitrosthiol metabolism?
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Models, Biological; Nitrates; Nitric Oxide; Nitrogen; Oxygen; Platelet Aggregation Inhibitors; Pyridines; Receptors, Purinergic P2Y12; S-Nitrosothiols; Sulfhydryl Compounds; Ticlopidine | 2014 |
Right here waiting...?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticlopidine | 2014 |
Joint effects of CYP2C19*2 and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Smoking; Ticlopidine | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Primary Health Care; Proton Pump Inhibitors; Retrospective Studies; Secondary Prevention; Stroke; Ticlopidine; United Kingdom | 2015 |
[Factors influencing platelet aggregation in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation Tests; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Mean Platelet Volume; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Statistics as Topic; Ticlopidine; Time Factors | 2014 |
[Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Polymorphism, Genetic; Ticlopidine | 2014 |
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization | 2014 |
The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; China; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2015 |
[Changes in the diagnosis and treatment of hospitalized patients with acute coronary syndrome from 2006 to 2012 in China].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Female; Hospitalization; Hospitals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Ticlopidine | 2014 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Markov Chains; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Adjustment; Risk Assessment; Thrombosis; Ticlopidine; Time; Treatment Outcome | 2015 |
A delicate balance: the cost effectiveness of new antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Preoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ROC Curve; Ticlopidine | 2015 |
Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Preoperative Care; Prognosis; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Spain; Thrombosis; Ticlopidine; Treatment Outcome | 2015 |
CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2015 |
Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Antioxidants; Chemokine CCL4; Clopidogrel; Female; Humans; Interleukin-6; Male; Middle Aged; Oxidation-Reduction; Platelet Aggregation Inhibitors; Proteomics; Reactive Oxygen Species; Ticlopidine | 2015 |
CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Alleles; Blood Platelets; Clopidogrel; Cohort Studies; Confidence Intervals; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Geriatric Assessment; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Risk Assessment; Sex Factors; Ticlopidine; Treatment Outcome | 2015 |
Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Drug Design; Female; Humans; Male; Middle Aged; Patient Admission; Percutaneous Coronary Intervention; Platelet Count; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Ticagrelor; Ticlopidine | 2015 |
Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Stents; Ticlopidine | 2015 |
Ticagrelor-induced acute generalized exanthematous pustulosis.
Topics: Acute Coronary Syndrome; Acute Generalized Exanthematous Pustulosis; Adenosine; Aged; Biopsy; Clopidogrel; Drug Eruptions; Female; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Monitoring Residual Platelet Activity Among Patients With Acute Coronary Syndrome Post-PCI by Modified Impedance Whole Blood Platelet Aggregation and Release Method.
Topics: Acute Coronary Syndrome; Adult; Blood Platelets; Clopidogrel; Drug Monitoring; Electric Impedance; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Function Tests; Postoperative Period; Ticlopidine | 2016 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Registries; Ticlopidine; Treatment Outcome | 2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genetic Testing; Genotype; Humans; Managed Care Programs; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic?
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Conflict of Interest; Humans; Peer Review; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Selection Bias; Ticagrelor; Ticlopidine | 2015 |
Redesigning TRACER trial after TRITON.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Hemorrhage; Humans; Lactones; Neoplasms; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Ticlopidine | 2015 |
An Extraordinary Case Associated with an Allergic Reaction to Clopidogrel: Coronary Artery Spasm or Kounis Syndrome?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Vasospasm; Drug Hypersensitivity; Humans; Male; Middle Aged; Syndrome; Ticlopidine | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Genetic Predisposition to Disease; Genotype; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prodrugs; Prognosis; Prospective Studies; Recurrence; Stents; Ticlopidine; Treatment Outcome | 2015 |
Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Republic of Korea; Sirolimus; Ticlopidine; Treatment Outcome | 2015 |
The change in platelet count in patients with acute coronary syndrome 6 months after coronary stent implantation.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Stents; Ticlopidine; Time Factors | 2015 |
[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Fibrillation; Cardiology Service, Hospital; Clopidogrel; Female; Hospital Departments; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Israel; Male; Medication Therapy Management; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Retrospective Studies; Secondary Prevention; Ticlopidine | 2015 |
Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
Topics: Acute Coronary Syndrome; Alleles; Cells, Cultured; China; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Testing; Genotype; Health Plan Implementation; Humans; Laboratory Proficiency Testing; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Polymorphism, Genetic; Ticlopidine | 2015 |
Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Area Under Curve; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronary Angiography; Logistic Models; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Risk Factors; Smoking; Thrombosis; Ticlopidine; Treatment Outcome | 2016 |
CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Thrombelastography; Ticlopidine | 2015 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Echocardiography; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Plasminogen Activator Inhibitor 1; Postoperative Complications; Prospective Studies; Risk Factors; Thrombosis; Ticlopidine; Treatment Outcome; von Willebrand Factor | 2015 |
Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Male; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Ticlopidine | 2015 |
Anti-platelet pre-treatment for atrial fibrillation patients on warfarin referred for coronary angiography/stenting because of non-ST-elevation acute coronary syndrome: An alternative proposal.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Warfarin | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mortality; Neoplasms; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sepsis; Ticagrelor; Ticlopidine | 2015 |
[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty].
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome | 2015 |
Does "smoker's paradox" exist in clopidogrel-treated Turkish patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ROC Curve; Smoking; Ticlopidine; Treatment Outcome; Turkey | 2016 |
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Blood Platelets; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Genotype; Health Care Costs; Heterozygote; Humans; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2015 |
Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.
Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Costs and Cost Analysis; Female; Health Care Costs; Health Services; Humans; Insurance Claim Review; Logistic Models; Male; Markov Chains; Monte Carlo Method; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Retrospective Studies; Ticlopidine | 2015 |
Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Testing; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Phenotype; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Testing; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Reproducibility of Results; Ticlopidine | 2016 |
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Blood Platelets; Chromatography, Liquid; Clopidogrel; Electrodes; Female; Flow Cytometry; Humans; Luminescence; Male; Mass Spectrometry; Middle Aged; Myocardial Infarction; P-Selectin; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Tandem Mass Spectrometry; Ticlopidine | 2015 |
Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Comorbidity; Coronary Artery Bypass; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Stents; Stroke; Surveys and Questionnaires; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a re
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Stable; Asian People; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism.
Topics: Acute Coronary Syndrome; Alleles; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Lab-On-A-Chip Devices; Point-of-Care Systems; Polymorphism, Genetic; Ticlopidine | 2015 |
PHILO -- ensuring trial results are not lost in translation.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Resistance; Female; Humans; Radiography; Ticlopidine; Treatment Outcome; Ultrasonography | 2016 |
Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Bradycardia; Clopidogrel; Comorbidity; Electrocardiography; Female; Germany; Humans; Male; Non-ST Elevated Myocardial Infarction; Prevalence; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Dosage Calculations; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prospective Studies; Saudi Arabia; Sex Factors; Ticlopidine; Treatment Outcome | 2016 |
Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
Topics: Acute Coronary Syndrome; Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Reproducibility of Results; Ticlopidine; Treatment Outcome | 2016 |
Current Antiplatelet Agents in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Acute Coronary Syndromes, Gastrointestinal Protection, and Recommendations Regarding Concomitant Administration of Proton-Pump Inhibitors (Omeprazol/Esomeprazole) and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Diseases; Humans; Male; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome | 2016 |
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Death; Drug-Eluting Stents; Female; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2016 |
Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Clopidogrel; Costs and Cost Analysis; Diabetic Angiopathies; Female; Health Resources; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Peripheral Arterial Disease; Retrospective Studies; Risk Factors; Ticlopidine; United States | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stents; Thrombosis; Ticlopidine; Ultrasonography, Interventional | 2016 |
Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Sex Characteristics; Ticagrelor; Ticlopidine | 2016 |
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiography, Impedance; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Synergism; Europe, Eastern; Genotype; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prevalence; Stroke; Ticlopidine | 2017 |
Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Clopidogrel pharmacokinetics and pharmacodynamics in out-of-hospital cardiac arrest patients with acute coronary syndrome undergoing target temperature management.
Topics: Acute Coronary Syndrome; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Female; Follow-Up Studies; Humans; Hypothermia, Induced; Male; Out-of-Hospital Cardiac Arrest; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Treatment Outcome | 2016 |
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine | 2016 |
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2016 |
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Databases, Factual; Disease Management; Female; Health Resources; Hemorrhage; Hospital Costs; Humans; Length of Stay; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Treatment Outcome | 2016 |
Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Emergencies; Female; Humans; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Preoperative Care; Pyridines; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Greece; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Comparison of Modified Impedance Whole Blood Platelet Aggregation Method Detecting Platelet Function in ACS Patients with Different CYP2C19 Genotypes.
Topics: Acute Coronary Syndrome; Adenosine Triphosphate; Adult; Aged; Automation, Laboratory; Biomarkers; Biotransformation; Blood Platelets; Calcium Chloride; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Monitoring; Electric Impedance; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Pharmacogenetics; Phenotype; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Reproducibility of Results; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angiography; Cause of Death; Clopidogrel; Comorbidity; Drug Substitution; Female; Health Care Surveys; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Risk Factors; Ticagrelor; Ticlopidine | 2016 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort Studies; Coronary Thrombosis; Diabetes Mellitus; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Renal Insufficiency; Risk Assessment; Smoking; Ticlopidine; United States | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1) polymorphism and clopidogrel concentration in acute coronary syndrome: molecular change can explain the observed therapeutic concentration.
Topics: Acute Coronary Syndrome; Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Humans; Polymorphism, Genetic; Ticlopidine | 2016 |
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Tandem Mass Spectrometry; Ticlopidine | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2016 |
Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Prognosis; Retrospective Studies; Risk Assessment; Sex Distribution; Sex Factors; Survival Rate; Ticlopidine; Treatment Outcome; United States | 2017 |
Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Humans; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine | 2016 |
Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Activation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
[THE FIRST RESULTS OF THE PREVALENCE OF CYP2C19 GENEPOLYMORPHISM IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE AKTYUBINSK POPULATION].
Topics: Acute Coronary Syndrome; Adult; Aged; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Association Studies; Humans; Kazakhstan; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; White People | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
[ANMCO/SIC/SICI-GISE/SICCH Consensus document: Clinical approach to pharmacological pretreatment for patients undergoing myocardial revascularization].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fondaparinux; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Myocardial Revascularization; Platelet Aggregation Inhibitors; Polysaccharides; Preoperative Care; Ticlopidine; Treatment Outcome | 2016 |
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2016 |
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ticagrelor; Ticlopidine | 2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine | 2016 |
Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryldialkylphosphatase; Asian People; ATP Binding Cassette Transporter, Subfamily B; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Female; Gene Expression; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Purinergic P2Y12; Ticlopidine | 2016 |
CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2016 |
Optimizing prevention and guideline-concordant care in Montenegro.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Clopidogrel; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Montenegro; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prospective Studies; Ticlopidine | 2016 |
Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe.
Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Clopidogrel; Europe; Female; Follow-Up Studies; Hemorrhage; Humans; Internationality; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Ticlopidine; Treatment Outcome | 2016 |
Treating Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Successful multivessel percutaneous coronary intervention for acute coronary syndrome in a HIV-positive severe haemophiliac.
Topics: Acute Coronary Syndrome; Clopidogrel; Hematuria; Hemophilia A; Hemorrhage; HIV Infections; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Factors; Severity of Illness Index; Ticlopidine | 2016 |
Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Medication Therapy Management; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2016 |
The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Genotyping Techniques; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Polymorphism, Single Nucleotide; Ticlopidine | 2016 |
SNAAP to Replace MONA.
Topics: Acute Coronary Syndrome; Advanced Cardiac Life Support; American Heart Association; Anticoagulants; Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitroglycerin; Oxygen Inhalation Therapy; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; United States; Vasodilator Agents | 2017 |
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longi
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Drug Costs; Female; Health Expenditures; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiveness Research; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticlopidine; Treatment Outcome | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ticlopidine | 2016 |
Time-To-Treatment of Acute Coronary Syndrome and Unit of First Contact in the ERICO Study.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Brazil; Clopidogrel; Educational Status; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Primary Health Care; Prospective Studies; Statistics, Nonparametric; Ticlopidine; Time Factors; Time-to-Treatment | 2016 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Hospitals, Veterans; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Prosthesis Design; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs | 2017 |
ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Carboxylic Acids; Chromatography, Liquid; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; RNA, Messenger; Salicylic Acid; Tandem Mass Spectrometry; Ticlopidine; Up-Regulation | 2017 |
Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Renal Insufficiency, Chronic; Risk Assessment; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occlusion, Vascular; Hemorrhage; Humans; Incidence; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Poland; Prospective Studies; Thrombosis; Ticlopidine | 2016 |
Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Epidemiologic Studies; Female; Humans; Latin America; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; Clopidogrel; Cyclic AMP; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Calcium Channel Blockers; Clopidogrel; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Male; Middle Aged; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proportional Hazards Models; Secondary Prevention; Taiwan; Ticlopidine | 2017 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug Therapy, Combination; Drug Utilization; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Complications; Proportional Hazards Models; Stroke; Survival Rate; Ticlopidine | 2017 |
Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Asian People; Cell Adhesion Molecules; Clopidogrel; Cryopreservation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Vasodilator Agents | 2018 |
Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Asian People; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor | 2018 |
Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Belgium; Cardiologists; Clopidogrel; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS.
Topics: Acute Coronary Syndrome; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carboxylic Ester Hydrolases; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Cross-Sectional Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; ROC Curve; Sensitivity and Specificity | 2017 |
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Black People; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; White People | 2017 |
Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
[Correlation between cytochrome 3A4+894C>T P450 gene polymorphism and outcomes of coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP3A; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Ticlopidine | 2016 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Medication Therapy Management; Patient Discharge; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Survival Analysis; Ticagrelor; Ticlopidine | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Risk Factors; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Risk Factors; Ticlopidine | 2008 |
Benefit of clopidogrel for acute coronary syndrome and percutaneous coronary interventions in doubt due to rebound adverse events.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Warfarin | 2008 |
Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Thrombelastography; Ticlopidine; Tirofiban; Tyrosine | 2008 |
Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Fatal Outcome; Female; Humans; Intracranial Hemorrhages; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticlopidine | 2010 |
[Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Administration Schedule; Drug Resistance; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosis; Ticlopidine; Treatment Failure | 2008 |
Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Comorbidity; Drug-Eluting Stents; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Registries; Retrospective Studies; Stents; Ticlopidine; Treatment Outcome; Victoria | 2008 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Diagnosis, Differential; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Stents; Ticlopidine; Time Factors; Troponin | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Thrombosis; Ticlopidine; Warfarin | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Thrombosis; Ticlopidine; Warfarin | 2008 |
Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Analysis of Variance; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Length of Stay; Logistic Models; Male; Middle Aged; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Predictive Value of Tests; Probability; Reference Values; Reoperation; Retrospective Studies; Risk Assessment; Sex Distribution; Statistics, Nonparametric; Survival Rate; Ticlopidine | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Hospital Mortality; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Ticlopidine; Treatment Outcome | 2009 |
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Female; Genotype; Heterozygote; Humans; Male; Mutation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine | 2009 |
Clopidogrel in acute coronary syndrome: to genotype or not?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Evidence-Based Medicine; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Male; Middle Aged; New South Wales; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Retrospective Studies; Sex Factors; Ticlopidine | 2008 |
Clopidogrel, genetics, and drug responsiveness.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Mutation; Myocardial Infarction; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Predictive Value of Tests; Prognosis; Ticlopidine; Treatment Outcome | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk; Secondary Prevention; Ticlopidine; Treatment Outcome | 2009 |
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Cardiac Catheterization; Clopidogrel; Drug Utilization; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Novel antiplatelet strategies in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Spontaneous coronary artery dissection and severe hypothyroidism.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Eptifibatide; Fatal Outcome; Female; Humans; Hypothyroidism; Neck Pain; Peptides; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Retrospective Studies; Sensitivity and Specificity; Ticlopidine; Troponin T | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Humans; Male; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ticlopidine; Treatment Outcome | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Female; Hemorrhage; Heparin; Humans; Incidence; Inpatients; Logistic Models; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Registries; Risk Factors; Severity of Illness Index; Thrombocytopenia; Ticlopidine | 2009 |
Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Female; Heart; Humans; Male; Middle Aged; Myocardium; Platelet Aggregation; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2009 |
Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Aged, 80 and over; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Hospital Mortality; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Clopidogrel. Bleeding and resistance.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Clopidogrel. Increasing concordance.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Acute coronary syndromes: don't bypass the clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Platelet Aggregation Inhibitors; Preoperative Care; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Impact of combining proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Secondary Prevention; Ticlopidine | 2009 |
Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Secondary Prevention; Ticlopidine; Treatment Outcome | 2009 |
Aprotinin reduces the antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aprotinin; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Female; Hemostatics; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2009 |
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome | 2009 |
Rethinking loading dose clopidogrel in light of increased bleeding complications in bypass patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticlopidine | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Ticlopidine | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Ticlopidine | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Smoking; Ticlopidine | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Ticlopidine | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Homozygote; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prospective Studies; Ticlopidine | 2010 |
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Blood Viscosity; Clopidogrel; Erythrocyte Deformability; Female; Hematocrit; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Microfilament Proteins; Middle Aged; Patient Discharge; Phosphoproteins; Phosphorylation; Pilot Projects; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Assessment; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug Utilization; Emergency Service, Hospital; Female; Guideline Adherence; Health Care Surveys; Health Services Accessibility; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Patient Discharge; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Registries; Retrospective Studies; Ticlopidine; Time Factors; Treatment Outcome; United States | 2009 |
Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticlopidine | 2009 |
Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Acute Disease; Aged; Angioplasty, Balloon, Coronary; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Drug Resistance, Multiple; Female; Gene Frequency; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Risk Assessment; Ticlopidine | 2009 |
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Electrocardiography; Female; Humans; Male; Microfilament Proteins; Middle Aged; Odds Ratio; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Prosthesis Failure; Risk Factors; ROC Curve; Stents; Ticlopidine | 2009 |
[New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Potential unrecognised costs of clopidogrel pretreatment in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; American Heart Association; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Costs and Cost Analysis; Female; Guideline Adherence; Humans; Length of Stay; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Guidelines as Topic; Retrospective Studies; Ticlopidine; Time Factors; United States | 2009 |
Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel.
Topics: Acute Coronary Syndrome; Cardiovascular Surgical Procedures; Clopidogrel; Female; Follow-Up Studies; Health Care Costs; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine | 2009 |
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Drug Utilization; Female; Humans; Logistic Models; Male; Middle Aged; Patient Discharge; Platelet Aggregation Inhibitors; Registries; Smoking; Stents; Stroke; Stroke Volume; Ticlopidine; United States; Warfarin | 2009 |
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB Form; Diabetes Mellitus; Drug Therapy, Combination; Flow Cytometry; Humans; Myocardium; Necrosis; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Up-Regulation | 2010 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Risk and benefit of proton pump inhibitor for patients undergoing anti-platelet therapy including clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Ticlopidine | 2009 |
Glycoprotein IIb/IIIa antagonists: new developments.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Atherectomy; Clinical Trials as Topic; Clopidogrel; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine | 2009 |
Platelet monitoring for PCI: which test is the one to choose?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Electric Impedance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Thromboxane B2; Ticlopidine | 2009 |
Potential Interaction between clopidogrel and proton pump inhibitors.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome | 2009 |
Is it possible to safely administer early a loading dose of clopidogrel before coronary angiography to patients who are candidates for percutaneous coronary intervention?
Topics: Acute Coronary Syndrome; Adult; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Angiography; Coronary Artery Bypass; Feasibility Studies; Female; Humans; Logistic Models; Male; Medical Records; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Predictive Value of Tests; Preoperative Care; Sensitivity and Specificity; Ticlopidine; Treatment Outcome | 2009 |
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Proton Pump Inhibitors; Risk Factors; Ticlopidine; Treatment Outcome | 2009 |
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel versus prasugrel: times are changing, but not for everyone.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
Topics: Acute Coronary Syndrome; Aged; Canada; Clopidogrel; Drug Utilization; Female; Guideline Adherence; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Registries; Retrospective Studies; Ticlopidine | 2009 |
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Health Planning Guidelines; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Societies, Medical; Ticlopidine; Treatment Outcome | 2009 |
Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
The right oral antithrombotics in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prognosis; Ticlopidine; Vitamin K | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
The TRITON versus PLATO trials: differences beyond platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States | 2010 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Ticlopidine; Time Factors | 2008 |
Acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Critical Pathways; Electrocardiography; Emergency Treatment; Guideline Adherence; Humans; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Assessment; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Research Design; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor in ACS: redefining a new standard of care?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Hospital Mortality; Humans; Incidence; Male; Medical Records; Middle Aged; Myocardial Infarction; New York City; Platelet Aggregation Inhibitors; Preoperative Care; Retrospective Studies; Survival Rate; Ticlopidine | 2010 |
Highlights from Transcatheter Cardiovascular Therapeutics 2009: San Francisco, California, September 21 to 25, 2009.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiac Surgical Procedures; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Heart Valve Diseases; Humans; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retreatment; Stents; Ticlopidine; Treatment Outcome | 2010 |
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Humans; Linear Models; Male; Microfilament Proteins; Middle Aged; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-2; Ticlopidine; Treatment Outcome | 2010 |
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Humans; Linear Models; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Predictive Value of Tests; Prospective Studies; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2010 |
[Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Slow response to clopidogrel predicts low response.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Biomarkers, Pharmacological; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Delays of event adjudication in the TRITON trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coagulants; Comorbidity; Coronary Angiography; Dyspnea; Factor VIII; Fatal Outcome; Hemophilia A; Heparin, Low-Molecular-Weight; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Renal Insufficiency; Ticlopidine | 2010 |
Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Clopidogrel; Delivery of Health Care, Integrated; Female; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Survival Analysis; Ticlopidine; United States; Withholding Treatment | 2010 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Cost Sharing; Cost-Benefit Analysis; Female; Follow-Up Studies; Health Benefit Plans, Employee; Health Care Costs; Hospitalization; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prescription Fees; Retrospective Studies; Stents; Ticlopidine; United States | 2010 |
Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Bypass; Drug Monitoring; England; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Stents; Thrombelastography; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
[Recurrent stent thrombosis in a patient with non-ST-segment elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resistance; Electrocardiography; Equipment Failure Analysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Stents; Ticlopidine | 2010 |
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardium; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2010 |
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopidogrel; Emergencies; Fibrinolysis; Forecasting; Humans; Length of Stay; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors | 2010 |
Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Utilization; Evidence-Based Medicine; Guideline Adherence; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Survival Analysis; Ticlopidine; Young Adult | 2010 |
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Melena; Middle Aged; Neoplasms; Patient Selection; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Risk Assessment; Stents; Thrombocytopenia; Ticlopidine; Treatment Outcome | 2010 |
The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diagnostic Tests, Routine; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Practice Guidelines as Topic; Prosthesis Implantation; Ticlopidine | 2010 |
Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Atherectomy; Blood Platelets; Clopidogrel; Diagnostic Tests, Routine; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Practice Guidelines as Topic; Precision Medicine; Reference Standards; Reference Values; Research Design; Thrombosis; Ticlopidine | 2010 |
The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Female; Guideline Adherence; Hospitals; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Outcome and Process Assessment, Health Care; Patient Discharge; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Registries; Risk Assessment; Risk Factors; Taiwan; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
[Standard therapy of acute coronary syndrome becomes easier. Dual platelet inhibition with only 1 tablet].
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Combinations; Germany; Guideline Adherence; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Histamine H2 Antagonists; Humans; Male; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Retrospective Studies; Ticlopidine | 2010 |
[Managing myocardial infarct in general practice].
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical Analysis; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Education, Medical, Continuing; Electroencephalography; Family Practice; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pyrroles; Risk Factors; Switzerland; Ticlopidine | 2010 |
Ad hoc percutaneous coronary intervention after in-laboratory high dose clopidogrel loading for clopidogrel-naive patients: safe for all?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2010 |
Clopidogrel and proton pump inhibitors: between a rock and a hard place.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Humans; Prodrugs; Proton Pump Inhibitors; Risk Factors; Ticlopidine | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Letter by Potter and Le Lorier regarding article, "Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome".
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Pyridines; Selection Bias; Ticlopidine | 2010 |
Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Monitoring, Physiologic; Phosphoproteins; Platelet Activation; Polymerase Chain Reaction; Polymorphism, Genetic; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2010 |
Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Utilization; Electronic Health Records; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Perioperative Period; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Retrospective Studies; Ticlopidine; United States | 2010 |
Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Middle Aged; Mutation; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Republic of Korea; Risk Factors; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine | 2010 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Female; Humans; Inflammation; Male; Pilot Projects; Platelet Activation; Stents; Ticlopidine; Treatment Outcome | 2010 |
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2010 |
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2010 |
Response to antiplatelet treatment: from genes to outcome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2010 |
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2010 |
Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Peptic Ulcer; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Retrospective Studies; Risk; Taiwan; Ticlopidine; Treatment Outcome | 2011 |
Atorvastatin for reduction of myocardial damage during angioplasty trials.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atorvastatin; Clopidogrel; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardium; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2010 |
Acute coronary syndromes: finding meaning in OASIS 7.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2010 |
Fine-tuning therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Ticlopidine | 2010 |
[The PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2010 |
Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Cyclic N-Oxides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Ticagrelor; Ticlopidine | 2010 |
[Clopidogrel resistance in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; C-Reactive Protein; Clopidogrel; Drug Resistance; Electrocardiography; Female; Homozygote; Humans; Interleukin-10; Interleukin-6; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Receptors, Purinergic P2Y12; Ticlopidine | 2010 |
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Diseases; Hemorrhage; Heparin; Hirudins; Hospital Mortality; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; New York City; Odds Ratio; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Propensity Score; Proportional Hazards Models; Recombinant Proteins; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
It is standard practice, but is it really best practice or clinical biocreep?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Combination; Heart Diseases; Hemorrhage; Heparin; Hirudins; Hospital Mortality; Humans; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Odds Ratio; Peptic Ulcer; Platelet Aggregation Inhibitors; Prognosis; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Ticlopidine; Time Factors | 2010 |
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Readmission; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Diabetics with acute coronary syndrome: advances, challenges, and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Diabetic Angiopathies; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Patient Selection; Pharmacogenetics; Platelet Aggregation Inhibitors; Risk; Stents; Ticlopidine | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Follow-Up Studies; Hemorrhage; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Registries; Risk Factors; Smoking; Survival Rate; Ticlopidine; Time Factors | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Antagonism; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Early Diagnosis; Electrocardiography; Female; Heart Conduction System; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Ticlopidine; Treatment Outcome; Troponin T | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; Ticlopidine | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2011 |
Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2011 |
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modality Therapy; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Compliance; Platelet Aggregation Inhibitors; Retrospective Studies; Socioeconomic Factors; Stents; Ticlopidine; United States | 2011 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Approval; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States | 2011 |
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Cause of Death; Clopidogrel; Cohort Studies; Coronary Stenosis; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Reference Values; Renal Insufficiency, Chronic; Risk Assessment; Survival Analysis; Ticlopidine | 2011 |
One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Interactions; Female; Gastrointestinal Hemorrhage; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Patient Readmission; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Inflammation; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine | 2011 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2011 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Humans; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine | 2011 |
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding St
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemorrhage; Humans; Long-Term Care; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Premedication; Prospective Studies; Receptors, Purinergic P2Y12; Stents; Ticlopidine | 2011 |
Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine | 2010 |
CYP2C19 genotype and outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Mutation; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
CYP2C19 genotype and outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Mutation; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2011 |
Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Hyperemia; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticlopidine; Time Factors | 2011 |
Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Canada; Clopidogrel; Female; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Registries; Retrospective Studies; Ticlopidine | 2011 |
Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCI.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Female; Humans; Length of Stay; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prospective Studies; Registries; Retreatment; Stents; Ticlopidine; United Kingdom | 2011 |
CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Variation; Humans; Platelet Aggregation Inhibitors; Precision Medicine; Ticlopidine | 2011 |
Genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Genetic Carrier Screening; Humans; Premedication; Randomized Controlled Trials as Topic; Ticlopidine | 2011 |
Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Blood Vessel Prosthesis Implantation; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Ticlopidine | 2011 |
Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Disease; Drug Interactions; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stents; Thienopyridines; Ticlopidine | 2011 |
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.
Topics: Acute Coronary Syndrome; Adenosine; Bias; Clinical Trials as Topic; Clopidogrel; Europe; Humans; Mortality; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine | 2011 |
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Epidemiologic Research Design; Europe; Humans; Patient Selection; Practice Guidelines as Topic; Statistics as Topic; Survival Analysis; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2011 |
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Clopidogrel; Europe; Genetic Predisposition to Disease; Humans; Research Design; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2011 |
Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Incidence; Insurance Coverage; Insurance, Health; Male; Middle Aged; Platelet Aggregation Inhibitors; Poisson Distribution; Retrospective Studies; Ticlopidine; United States | 2011 |
Influence of updated guidelines on short- and long-term mortality in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Female; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Retrospective Studies; Survival Rate; Ticlopidine; Treatment Outcome | 2012 |
Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2012 |
Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Diabetes Complications; Drug Resistance; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Republic of Korea; Ticlopidine | 2011 |
[Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Age-related differences in antithrombotic therapy, success rate and in-hospital mortality in patients undergoing percutaneous coronary intervention: results of the quality control registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzt
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Comorbidity; Female; Fibrinolytic Agents; Germany; Hospital Mortality; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Registries; Ticlopidine; Treatment Outcome | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Care Units; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Propensity Score; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Stents; Sweden; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
[ACC/AHA warning on effectiveness of clopidogrel].
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Resistance; Genetic Testing; Humans; Purinergic P2Y Receptor Antagonists; Ticlopidine; Treatment Outcome | 2010 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Confidence Intervals; Drug Administration Schedule; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proportional Hazards Models; Randomized Controlled Trials as Topic; Salivary Ducts; Thrombosis; Ticlopidine | 2011 |
Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Databases, Factual; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2011 |
Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; C-Reactive Protein; CD40 Ligand; Clopidogrel; Drug Resistance; Female; Humans; Interleukin-6; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine; Time Factors | 2012 |
Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Risk Factors; ROC Curve; Stents; Ticlopidine | 2011 |
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; Hemorrhage; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Platelet Aggregation Inhibitors; Premedication; Recombinant Proteins; Thrombosis; Ticlopidine | 2011 |
Safety and efficacy of clopidogrel reloading in patients on chronic clopidogrel therapy who present with an acute coronary syndrome and undergo percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2011 |
Unraveling myths of platelet function and genetic testing the road to making tailored antiplatelet therapy a reality.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk Assessment; Risk Factors; Ticlopidine | 2011 |
Non-interventional management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
[Specificities of diabetes in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Hypoglycemic Agents; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2011 |
Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Alleles; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Endpoint Determination; Female; Flow Cytometry; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Prospective Studies; Risk Assessment; Risk Factors; Statistics, Nonparametric; Stents; Ticlopidine; Treatment Outcome | 2011 |
The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Drug Administration Schedule; Female; Flow Cytometry; Humans; Leukocyte Count; Male; Middle Aged; Peptide Fragments; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Malaysia-ACute CORonary syndromes Descriptive study (ACCORD): evaluation of compliance with existing guidelines in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Malaysia; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prospective Studies; Risk Factors; Ticlopidine | 2011 |
Sensitive troponin I assay in patients with suspected acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Creatinine; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Reproducibility of Results; Risk Factors; Ticlopidine; Troponin I | 2011 |
Clinical and prognostic implications of the initial response to aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clopidogrel; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Databases, Factual; Drug Interactions; Esomeprazole; Female; Herb-Drug Interactions; Hospitalization; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Recurrence; Retrospective Studies; Ticlopidine; Treatment Outcome | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Stents; Ticlopidine | 2011 |
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD).
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Death, Sudden, Cardiac; Female; General Practice; Hospitalization; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Registries; Ticlopidine | 2011 |
[Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Electrocardiography; Female; Humans; Male; Nephelometry and Turbidimetry; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticlopidine; Time Factors | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspirin; Cardiac Catheterization; Clopidogrel; Diabetes Mellitus; Female; Fibrinolytic Agents; Heart Failure; Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mechanical Thrombolysis; Middle Aged; Middle East; Myocardial Revascularization; Platelet Aggregation Inhibitors; Registries; Sex Distribution; Shock, Cardiogenic; Smoking; Stroke; Ticlopidine | 2011 |
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Diagnostic Techniques and Procedures; Drug Therapy, Combination; Dyspnea; Emergency Service, Hospital; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Risk; Stents; Stroke; Thrombosis; Ticlopidine | 2011 |
Applying platelet function testing in clinical practice: what are the unmet needs?
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Death; Humans; Myocardial Infarction; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Standard of Care; Stents; Thrombosis; Ticlopidine | 2011 |
Clopidogrel and CYP2C19 testing: ready for clinical prime time?
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Testing; Genotype; Heterozygote; Humans; Polymorphism, Genetic; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2012 |
[Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?].
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Genetic Testing; Genotype; Humans; Male; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Practice Patterns, Physicians'; Predictive Value of Tests; Risk Assessment; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Female; Hip Fractures; Humans; Male; Middle Aged; Morbidity; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Time Factors | 2011 |
Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Base Sequence; Cell Adhesion Molecules; Clopidogrel; DNA Primers; Female; Flow Cytometry; Genotype; Humans; Lipoproteins, HDL; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Cost-effectiveness of prasugrel in a US managed care population.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Managed Care Programs; Middle Aged; Models, Economic; Outcome Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States | 2012 |
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine | 2012 |
No free lunches: balancing bleeding and efficacy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2011 |
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Female; Follow-Up Studies; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Phenotype; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prognosis; Regression Analysis; Ticlopidine | 2012 |
[Acute coronary syndromes in hospitalized patients with diabetes. Data from the RECORD registry].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Protocols; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Electrocardiography; Female; Hospital Mortality; Humans; Male; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Ticlopidine | 2011 |
Managing antiplatelet therapy during ophthalmic procedures: communication is the key.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiology; Clopidogrel; Humans; Interdisciplinary Communication; Ophthalmologic Surgical Procedures; Ophthalmology; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug-Eluting Stents; Electrocardiography; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2012 |
Low mean corpuscular hemoglobin level is a predictor of discontinuation of antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Erythrocyte Indices; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Platelet Aggregation Inhibitors; Risk Factors; Stents; Ticlopidine | 2011 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Testing; Genotype; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Single Nucleotide; Ticlopidine; Time Factors | 2012 |
Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Toward a therapeutic window for antiplatelet therapy in the elderly.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Bare metal stent thrombosis in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Risk Factors; Smoking; Stents; Thrombosis; Ticlopidine | 2012 |
Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Humans; Male; Middle Aged; Patient Readmission; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Risk; Stents; Taiwan; Ticlopidine | 2012 |
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Heparin; Heterozygote; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Risk; Survival Rate; Ticlopidine | 2012 |
Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Hospital Costs; Hospitalization; Humans; Incidence; Length of Stay; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; United States | 2012 |
The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Disclosure; Humans; Informed Consent; Multicenter Studies as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Research Support as Topic; Selection Bias; Ticagrelor; Ticlopidine; Treatment Refusal; United States; United States Food and Drug Administration | 2011 |
Reducing co-administration of clopidogrel and proton pump inhibitors in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Guideline Adherence; Humans; Medical Audit; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prescriptions; Proton Pump Inhibitors; Retrospective Studies; Ticlopidine | 2012 |
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2012 |
Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; New Zealand; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peptic Ulcer; Platelet Aggregation Inhibitors; Precision Medicine; Proton Pump Inhibitors; Ticlopidine | 2012 |
Erratum for Fernandez et al. “Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE Study)” Am J Cardiol
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgical Procedures; Hemorrhage; Humans; Incidence; Platelet Aggregation Inhibitors; Preoperative Care; Risk Factors; Thrombosis; Ticlopidine; United States | 2012 |
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Animals; Clinical Protocols; Clopidogrel; Electrocardiography; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Risk Factors; Ticlopidine | 2012 |
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticagrelor; Ticlopidine | 2012 |
Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogrel; Confidence Intervals; Drug Therapy, Combination; Electrocardiography; Female; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Registries; Switzerland; Ticlopidine; Time Factors; Young Adult | 2012 |
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States | 2012 |
Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell Adhesion Molecules; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Thrombosis; Ticlopidine | 2012 |
Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Greece; Humans; Male; Markov Chains; Models, Economic; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Survival Analysis; Ticlopidine | 2012 |
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
Topics: Acute Coronary Syndrome; Aged; Body Weight; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Female; Flow Cytometry; Glycated Hemoglobin; Humans; Inflammation; Leukocyte Count; Leukocytes; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphorylation; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2012 |
Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Interactions; Female; Follow-Up Studies; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Proton Pump Inhibitors; Regression Analysis; Retrospective Studies; Ticlopidine; Time Factors | 2012 |
Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Female; Hospital Costs; Humans; Length of Stay; Male; Managed Care Programs; Middle Aged; Myocardial Revascularization; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; United States | 2012 |
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Antiplatelet therapy in acute coronary syndromes: beyond aspirin and clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2012 |
Double interruption of antiplatelet therapy and tirofiban "bridging" for lung cancer resection.
Topics: Acute Coronary Syndrome; Aged; Biopsy, Needle; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Substitution; Drug-Eluting Stents; Humans; Lung; Lung Neoplasms; Platelet Aggregation Inhibitors; Retreatment; Ticlopidine; Tirofiban; Tyrosine | 2012 |
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
[Residual platelet activity in patients managed with clopidogrel: clinical implications for the management of patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2012 |
Platelet aggregation at discharge: a useful tool in acute coronary syndromes?
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Longitudinal Studies; Male; Middle Aged; Patient Discharge; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticlopidine | 2012 |
[Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Avena; Chest Pain; Clopidogrel; Coronary Angiography; Coronary Vessels; Female; Humans; Male; Middle Aged; Panax; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine; Tribulus | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; Comorbidity; Denmark; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Registries; Risk Factors; Stroke; Ticlopidine; Vitamin K | 2012 |
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; Imines; Platelet Activation; Platelet Aggregation Inhibitors; Pyridines; Receptors, Thrombin; Ticlopidine | 2012 |
Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Medical Audit; Platelet Aggregation Inhibitors; Risk; Survival Rate; Ticlopidine; Treatment Outcome | 2012 |
Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; Blood Platelets; Chi-Square Distribution; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stents; Thrombelastography; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Diagnosis-Related Groups; Drugs, Generic; Female; Genetic Testing; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Monte Carlo Method; Native Hawaiian or Other Pacific Islander; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Thiophenes; Ticlopidine | 2012 |
Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Humans; Male; Middle Aged; Prospective Studies; Ticlopidine | 2013 |
Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes.
Topics: Acute Coronary Syndrome; Aged; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Period; Prospective Studies; Stents; Ticlopidine; Treatment Outcome | 2012 |
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Thiophenes; Ticlopidine | 2013 |
[Surgery shortly after stent implantation?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Contraindications; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Elective Surgical Procedures; Hernia, Inguinal; Herniorrhaphy; Humans; Male; Postoperative Hemorrhage; Risk Assessment; Ticlopidine | 2012 |
Proton-pump inhibitors could be innocent when used concomitantly with clopidogrel.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Famotidine; Female; Humans; Male; Omeprazole; Platelet Aggregation Inhibitors; Ticlopidine | 2012 |
Clopidogrel and cardiac surgery: enemy or friend?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Occlusion; Female; Humans; Male; Platelet Aggregation; Ticlopidine | 2012 |
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Comorbidity; Decision Support Techniques; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Predictive Value of Tests; Retrospective Studies; Risk Assessment; Risk Factors; Sweden; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Monitoring residual platelet activity among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Reference Values; Ticlopidine | 2014 |
Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Cell Size; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Ticlopidine; Treatment Outcome | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2013 |
Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Expression Regulation; Gene Frequency; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Current status of clopidogrel pharmacogenomics.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight; Cholesterol, LDL; Clopidogrel; Comorbidity; Cost of Illness; Depression; Diabetes Complications; Disease Management; Electrocardiography; Exercise; Exercise Test; Glycated Hemoglobin; Health Behavior; Humans; Hypertension; Life Style; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Physical Examination; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Risk Factors; Risk Reduction Behavior; Smoking Cessation; Ticlopidine | 2012 |
Trilogy: in search of the lost ring.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prognosis; Stroke; Thrombosis; Ticlopidine; Treatment Outcome | 2013 |
Therapeutic momentum: a concept opposite to therapeutic inertia.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cross-Sectional Studies; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Sri Lanka; Ticlopidine; Unnecessary Procedures; Withholding Treatment | 2013 |
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Statistics, Nonparametric; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Clopidogrel has no effect on mortality from hip fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Female; Hip Fractures; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Severity of Illness Index; Stroke; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; Clopidogrel; Coronary Angiography; Female; Hematologic Tests; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sodium Citrate; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Promise and peril of clinical decision support: translating medical evidence to the individual patient.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Comorbidity; Cost-Benefit Analysis; Europe; Humans; Markov Chains; Models, Economic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Turkey | 2013 |
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Establishment of a CYP2C19 genotyping assay for clinical use.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Genome, Human; Genotype; Genotyping Techniques; Humans; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine | 2013 |
[Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization].
Topics: Acute Coronary Syndrome; Age of Onset; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Incidence; Logistic Models; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Factors; Ticlopidine | 2012 |
[Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Ticlopidine | 2012 |
The power of more than one.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2013 |
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Electrocardiography; Female; Germany; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Sex Factors; Ticlopidine | 2007 |
Utilisation review of clopidogrel: are they used under the FDA-approved indications?
Topics: Acute Coronary Syndrome; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Drug Utilization Review; Hospitals, University; Humans; Inpatients; Medical Records; Middle Aged; Outpatients; Platelet Aggregation Inhibitors; Retrospective Studies; Thailand; Ticlopidine; United States; United States Food and Drug Administration | 2007 |
Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Protein Isoforms; Risk Factors; Ticlopidine | 2007 |
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Stents; Ticlopidine; Treatment Outcome | 2008 |
Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Databases, Factual; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Ticlopidine; Treatment Outcome | 2007 |
Of Swiss alchemists and road hazards.
Topics: Acute Coronary Syndrome; Cardiology; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Toxicology | 2007 |
Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Quebec; Retrospective Studies; Risk Factors; Ticlopidine; Warfarin | 2007 |
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Acute Disease; Adenosine Diphosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Ischemia; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation; ROC Curve; Ticlopidine; Treatment Outcome | 2007 |
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Models, Statistical; Platelet Aggregation; Platelet Function Tests; Regression Analysis; Stents; Ticlopidine | 2008 |
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticlopidine | 2007 |
Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atherectomy, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Enoxaparin; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticlopidine | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Europe; Fumarates; Heart Diseases; Heart Failure; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Probucol; Recombinant Proteins; Ticlopidine; Tolvaptan | 2007 |
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Male; Middle Aged; Mixed Function Oxygenases; Pharmacogenetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Ticlopidine | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Clopidogrel; Contraindications; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coronary Stenosis; Drug-Eluting Stents; Electrocardiography; Evidence-Based Medicine; Exercise Test; Humans; Kidney Diseases; Myocardial Infarction; Nomograms; Patient Selection; Platelet Aggregation Inhibitors; Prognosis; Radionuclide Ventriculography; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Stents; Stroke Volume; Thrombolytic Therapy; Ticlopidine | 2008 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Stroke; Thrombosis; Ticlopidine | 2008 |
Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Statistics, Nonparametric; Ticlopidine | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster Analysis; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Poisson Distribution; Proportional Hazards Models; Retrospective Studies; Risk; Ticlopidine; Time Factors; Withholding Treatment | 2008 |
Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Humans; Immunoglobulin Fab Fragments; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome | 2008 |
Antiplatelet therapy in acute coronary syndrome: not as confusing as you think.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Emergency Service, Hospital; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Emergency Service, Hospital; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Preoperative Care; Randomized Controlled Trials as Topic; Ticlopidine; Troponin | 2009 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Effects of continuous administration of clopidogrel before off-pump coronary artery bypass grafting in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemoglobins; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Reoperation; Retrospective Studies; Ticlopidine | 2008 |
Current challenges and directions in antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Alleles; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Resistance; Female; Heterozygote; Humans; Male; Microfilament Proteins; Middle Aged; P-Selectin; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prospective Studies; Ticlopidine | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Ticlopidine; Vascular Diseases | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; Brain Infarction; Brain Ischemia; Clopidogrel; Diabetes Mellitus; Dipyridamole; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticlopidine | 2008 |
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hematemesis; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2008 |
Clopidogrel resistance: more grist for the mill.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatment Outcome | 2008 |
Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Models, Economic; Platelet Aggregation Inhibitors; Terminology as Topic; Ticlopidine | 2008 |
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Arachidonic Acid; Aspirin; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Diabetes Complications; Drug Resistance; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2009 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine | 2008 |
Adverse events associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2008 |
Adverse events associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2008 |